US20130226149A1 - Apparatus and method for separating and concentrating fluids containing multiple components - Google Patents
Apparatus and method for separating and concentrating fluids containing multiple components Download PDFInfo
- Publication number
- US20130226149A1 US20130226149A1 US13/663,637 US201213663637A US2013226149A1 US 20130226149 A1 US20130226149 A1 US 20130226149A1 US 201213663637 A US201213663637 A US 201213663637A US 2013226149 A1 US2013226149 A1 US 2013226149A1
- Authority
- US
- United States
- Prior art keywords
- fraction
- bone marrow
- marrow aspirate
- volume
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 114
- 239000012530 fluid Substances 0.000 title description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 146
- 239000008280 blood Substances 0.000 claims abstract description 145
- 210000001185 bone marrow Anatomy 0.000 claims description 120
- 239000000463 material Substances 0.000 claims description 58
- 210000004027 cell Anatomy 0.000 claims description 42
- 210000003743 erythrocyte Anatomy 0.000 claims description 37
- 238000000605 extraction Methods 0.000 claims description 29
- 210000001519 tissue Anatomy 0.000 claims description 21
- 239000012141 concentrate Substances 0.000 claims description 19
- 230000007547 defect Effects 0.000 claims description 19
- 102000009123 Fibrin Human genes 0.000 claims description 15
- 108010073385 Fibrin Proteins 0.000 claims description 15
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 15
- 229950003499 fibrin Drugs 0.000 claims description 15
- 210000000265 leukocyte Anatomy 0.000 claims description 13
- 238000011068 loading method Methods 0.000 claims description 12
- 210000000130 stem cell Anatomy 0.000 claims description 12
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 10
- 210000002950 fibroblast Anatomy 0.000 claims description 10
- 210000001789 adipocyte Anatomy 0.000 claims description 9
- 210000002889 endothelial cell Anatomy 0.000 claims description 9
- 230000003511 endothelial effect Effects 0.000 claims description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 8
- 210000002805 bone matrix Anatomy 0.000 claims description 7
- 239000000919 ceramic Substances 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229920001222 biopolymer Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 230000005484 gravity Effects 0.000 claims description 5
- 239000012209 synthetic fiber Substances 0.000 claims description 5
- 229920002994 synthetic fiber Polymers 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000008177 pharmaceutical agent Substances 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000008366 buffered solution Substances 0.000 claims 4
- 239000000017 hydrogel Substances 0.000 claims 4
- 210000005259 peripheral blood Anatomy 0.000 claims 4
- 239000011886 peripheral blood Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 238000000926 separation method Methods 0.000 abstract description 20
- 238000005119 centrifugation Methods 0.000 abstract description 13
- 239000000523 sample Substances 0.000 description 126
- 210000002381 plasma Anatomy 0.000 description 88
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 21
- 210000001772 blood platelet Anatomy 0.000 description 18
- 210000000988 bone and bone Anatomy 0.000 description 17
- 230000008569 process Effects 0.000 description 13
- 210000004623 platelet-rich plasma Anatomy 0.000 description 11
- 210000000845 cartilage Anatomy 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 210000003484 anatomy Anatomy 0.000 description 8
- 239000000470 constituent Substances 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 230000006835 compression Effects 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000005499 meniscus Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- -1 bone marrow aspirate Substances 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 101001013272 Homo sapiens Mediator of RNA polymerase II transcription subunit 29 Proteins 0.000 description 2
- 102100029668 Mediator of RNA polymerase II transcription subunit 29 Human genes 0.000 description 2
- 208000013201 Stress fracture Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001306 articular ligament Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229910001610 cryolite Inorganic materials 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/26—Separation of sediment aided by centrifugal force or centripetal force
- B01D21/262—Separation of sediment aided by centrifugal force or centripetal force by using a centrifuge
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/30—Control equipment
- B01D21/307—Passive control mechanisms without external energy, e.g. using a float
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5021—Test tubes specially adapted for centrifugation purposes
- B01L3/50215—Test tubes specially adapted for centrifugation purposes using a float to separate phases
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L1/00—Enclosures; Chambers
- B01L1/52—Transportable laboratories; Field kits
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0409—Moving fluids with specific forces or mechanical means specific forces centrifugal forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0478—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0605—Valves, specific forms thereof check valves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
- B01L9/54—Supports specially adapted for pipettes and burettes
Definitions
- the present teachings relate to a multiple component fluid and a concentrator/separator and, more particularly, relates to a container operable with a centrifuge to separate and/or concentrate various biological components.
- whole blood samples may include a plurality of constituents that may be separated by density in a device such as a centrifuge.
- the whole blood sample may be placed in a test tube, or other similar device, which is then spun in a centrifuge. In the centrifuge the whole blood is separated into different fractions depending upon the density of that fraction. The centrifugal force separates the blood or other sample into different fractions.
- various elements may be added to the test tube to create more than two fractions.
- gels may be used to divide the whole blood into a plurality of different fractions which may include fractions such as platelets, red blood cells, and plasma.
- fractions such as platelets, red blood cells, and plasma.
- Various other biological fluids may be separated as well.
- nucleated cells may be separated and extracted from bone marrow or adipose tissue sample.
- the top fraction of whole blood is plasma, or other blood constituents suspended in plasma.
- the plasma fraction must either be removed for further extracting procedures or spun again to obtain the constituents suspended in this plasma. It is difficult to pierce the top fraction without commingling the sample. Accordingly, obtaining the other fractions is difficult with commonly known systems.
- the present teachings provide an apparatus that separates and concentrates a selected fraction or component of a fluid, such as a biological fluid.
- a fluid such as a biological fluid.
- undifferentiated cells such as mesenchymal stem cells, platelet fraction, buffy coat, or white blood cell fraction can be separated from bone reaming material, whole blood, bone marrow aspirate, and other materials.
- the apparatus when used with a centrifuge, is generally able to create at least two fractions.
- the present teachings also provide for a new method of creating at least three fractions extracting a third fraction from a sample such as, for example, a buffy coat fraction.
- the apparatus includes a container to be placed in a centrifuge after being filled with a sample and the container includes a buoy or fraction separator having a selected density that may be less than one fraction but greater than a second fraction, that is disposed therein.
- a second buoy may be placed in the container with the first.
- the extraction system is connected to the buoy system or to the collection chamber such that the fraction in the container can be collected and drawn outside of the chamber.
- the buoy is forced away from a bottom of the container as the denser fraction collects at the bottom of the container.
- the buoy is generally able to physically separate the denser fraction from another fraction of the sample.
- the fractions can be withdrawn using an extraction system.
- a buoy system in addition to providing a first buoy and/or a second buoy, may be provided.
- the buoy system may separate the sample into at least three fractions. The fractions may be separated and extracted from the container without substantially commingling the various fractions.
- a first buoy and a second buoy operate together to separate the sample into the various fractions and a syringe or tube may then be interconnected with a portion of the buoy system to extract the selected fractions.
- a first buoy may be tuned to a density less than the density of a red blood cell fraction of a whole blood sample, bone marrow aspirate sample, or combinations thereof
- a second buoy may be tuned to a density less than the density of a buffy coat fraction.
- a method of forming an enriched scaffold for application relative to an anatomy may include obtaining a volume of a first whole material and obtaining a volume of a second whole material. A first fraction of the first whole material and a second fraction of the second whole material may be formed. At least one of the first fraction or the second fraction may be applied to the scaffold and at least one fraction for application relative to an anatomy is provided. The method may include obtaining a volume of heterogeneous whole material and separating the material into the desired fraction(s). At least one of the fractions may be applied to the scaffold.
- a method of withdrawing a material directly from a patient and collecting a selected fraction of the material in a container may include forming an access to port to the patient.
- a pressure differential in a collection container may be formed relative to the patient.
- a connection may be made between the patient and the collection container via the port.
- the collection container may be filled with the material and then the material may be separated to form the selected fraction.
- a method for concentrating bone aspirate can include obtaining a volume of bone marrow aspirate from a mammal and loading the volume bone marrow aspirate into a separator, the separator operable to separate the aspirate into three of more fractions. The method also includes centrifuging the separator to create a fraction that is a concentrated bone marrow aspirate and extracting and removing the fraction from the separator.
- a method for concentrating bone marrow aspirate and blood includes collecting bone marrow aspirate and blood from a patient then loading the bone marrow aspirate and blood into a separator that can separate the aspirate and the blood into three or more fractions.
- the method includes centrifuging the separator containing the bone marrow aspirate and the blood creating a fraction that has a concentrated bone marrow aspirate and a concentrated blood.
- a concentration may be referred to as a buffy coat.
- the method also include withdrawing the fraction comprising the concentrate or buffy coat.
- a method for treating a defect in a mammal using a concentrated bone marrow aspirate includes drawing bone marrow aspirate from the mammal and loading the bone marrow aspirate into a separator that can separate the bone marrow aspirate into three or more fractions.
- the method includes centrifuging the separator separating the bone marrow aspirate into fractions and one fraction is concentrated bone marrow aspirate.
- the method also can include the concentrated bone marrow aspirate and applying the bone marrow aspirate to a site of a defect in the mammal.
- a method for treating a defect in a patient includes drawing bone marrow aspirate and whole blood from the patient then adding anticoagulants to the bone marrow aspirate and the blood.
- the method includes the loading of the bone marrow aspirate and the blood into a separator that can separate the bone marrow aspirate and blood into three or more fractions.
- the method also includes centrifuging the separator then withdrawing a fraction comprising at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells, then applying the fraction to the site of the defect in the patient.
- a method of treating a patient with a combination of concentrated bone marrow aspirate and buffy coat includes obtaining blood and bone marrow aspirate from the patient, forming a buffy coat fraction of the whole blood and forming a concentrated bone marrow aspirate fraction, and applying at least one of the buffy coat or concentrated bone marrow aspirates to the patient.
- FIG. 1 is a plan view of a separator including a depth gage affixed to a plunger in a tube according to various embodiments of the present teachings;
- FIG. 2 is a cross-section view taken along line 2 - 2 of FIG. 1 ;
- FIG. 3 is an exploded of the separator apparatus according to various embodiments
- FIG. 4 is a kit including the separator according to an embodiment of the present teachings.
- FIG. 5A is a plan view of the separator, according to various embodiments, being filled
- FIG. 5B is a plan view of a blood sample in the separator after the centrifuge process
- FIG. 5C is a plan view of the plunger plunged into the tube with the depth gage to further separate the blood sample
- FIG. 5D is a plan view of the buffy coat and the plasma fractions being extracted from the separator according to various embodiments
- FIG. 6A is a side plan view of a buoy system according to various embodiments.
- FIG. 6B is a cross-sectional view of the buoy system of FIG. 6 a;
- FIG. 7A is a plan view of a separator, according to various embodiments, being filled
- FIG. 7B is a plan view of a separator, according to various embodiments, after a centrifugation process
- FIG. 7C is a plan view of a separator system, according to various embodiments, being used to extract a selected fraction after the centrifugation process;
- FIG. 7D is a plan view of a second fraction being extracted from the separator according to various embodiments.
- FIG. 8 is a schematic view illustrating an assisted blood withdrawal device according to various embodiments.
- FIG. 9 is a block diagram illustrating a method for applying selected fractions of a fluid.
- a separator 10 also referred to as a concentrator
- the separator 10 generally includes a tube or container 12 that is adapted to hold a fluid sample, such as an anti-coagulated whole blood sample, for further processing.
- a fluid sample such as an anti-coagulated whole blood sample
- the tube 12 may hold other solutions including constituents of more than one density, such as bone marrow or a mixture of whole blood and bone marrow.
- the tube 12 includes a top or open end 12 a , which is closeable, and a bottom or closed end 12 b .
- the bottom 12 b may also be selectively closeable.
- a first piston or buoy 14 that is able to move along a central axis A of the tube 12 .
- the buoy 14 is generally nearer the bottom end 12 b of the tube 12 rather than the open end 12 a .
- the buoy 14 is able to move along a central axis A of tube 12 .
- a second piston or plunger 16 disposed within the tube 12 .
- the plunger 16 is also able to move within the tube 12 generally between a position closer to the open end 12 a to a position closer to the closed end 12 b of the tube 12 .
- a cap 18 substantially mates with the open end 12 a of the tube 12 to close the tube 12 save for ports formed in the cap 18 .
- a plasma valve or port 20 that communicates with an area, described further herein, within the tube 12 defined between the plunger 16 and the cap 18 .
- the plasma port 20 is merely exemplary in nature and simply allows for removal of a selected fraction of a sample such as, for example, plasma from whole blood.
- the cap 18 also includes a depth gage port 19 . Extending from the plunger 16 and through the depth gage port 19 is a first plunger port 22 .
- a depth guide or gage 24 includes a female connector 26 adapted to connect with the first plunger port 22 .
- the depth gage 24 also includes a depth gage housing or cannula 28 .
- the depth gage housing 28 defines a depth gage bore 30 .
- Incorporated in the depth gage housing 28 and extending distal from the end mating with the plunger 16 is a neck 32 .
- the neck 32 includes external neck threads 34 .
- the external neck threads 34 are adapted to engage appropriate internal threads of a mating member.
- the mating member may include a compression nut 36 that mates with the external neck threads 34 to lock a depth gage rod 38 in a predetermined position.
- a split bushing 39 is also provided to substantially seal the depth gage housing 28 when the depth gage rod 38 is locked in place.
- the depth gage rod 38 extends through the depth gage housing 28 and terminates at a rod handle 40 .
- the rod handle 40 may be a form easily manipulated by a human operator.
- the depth gage rod 38 extends coaxially with axis A of the tube 12 .
- the depth gage rod 38 extends through the plunger 16 a predetermined distance and may be locked at that distance with the compression nut 36 .
- the tube 12 is described herein as a cylinder, it will be understood that other shapes may be used, such as polygons.
- the internal portions, such as the cap 18 , buoy 14 , and plunger 16 would also include this alternate shape.
- the tube 12 is formed of a thermal plastic material which is flexible under the forces required to separate blood.
- the tube 12 may be made of a material that includes the properties of both lipid and alcohol resistance. These properties helps increase the separation speed and decrease the amount of material which may cling to the tube wall 42 .
- Cyrolite MED2® produced by Cyro Industries of Rockaway, N.J., may be used to produce the tube 12 .
- the tube 12 has a tube wall 42 with a thickness of between about 0.01 millimeters and about 30.0 millimeters, although the tube wall 42 may be any appropriate thickness.
- the thickness of the tube wall 42 allows the tube wall 42 to flex during the centrifuge process yet be rigid enough for further processing of a blood sample disposed in the tube 12 .
- the tube 12 is closed at the bottom end 12 b with a tube bottom 44 formed of the same material as the tube wall 42 and is formed integrally therewith.
- the tube bottom 44 has a thickness which is substantially rigid under the forces required to separate the sample such that it does not flex.
- the buoy 14 includes an upper or collection face 46 that defines an inverse cone or concave surface.
- the cone has an angle of between about 0.5° to about 45°, and may be about 0.5° to about 90° from a vertical axis, wherein the apex of the cone is within the buoy 14 .
- the collection face 46 forms a depression in the buoy 14 which collects and concentrates material during the separation process.
- the buoy 14 has a bottom face 48 that defines an inverse cone, dome, or covered surface.
- the buoy bottom face 48 includes an apex 50 that engages the tube bottom 44 before a buoy edge 52 engages the tube bottom 44 .
- the buoy 14 includes a material that is a substantially rigid such that the buoy edges 52 never meet the tube bottom 44 . Therefore, there is a gap or free space 54 formed between the buoy edges 52 and the tube bottom 44 along the perimeter of the buoy 14 .
- the separator 10 is generally provided to separate a multi-component fluid that generally includes various components or constituents of varying densities that are commingled or mixed together.
- the separator 10 includes the buoy 14 that is of a selected density depending upon a selected constituent of the multi-constituent liquid.
- the buoy 14 may be tuned or of any selected density, the following example relates to separation of whole blood to various components. Therefore, the buoy 14 will be discussed to include a selected density relative to whole blood separation. It will be understood, however, that the buoy 14 may be of any appropriate density depending upon the multi-component fluid being separated including, for example, the concentrating of bone marrow aspirate.
- the buoy 14 may be formed of any appropriate material that may have a selected density.
- the buoy 14 when the separator 10 is to separate blood, the buoy 14 generally has a density which is greater than that of red blood cells in a whole blood sample, but less than the plasma or non-red blood cell fraction of a whole blood sample.
- the density of the buoy 14 may be between about 1.00 g/cc to about 1.12 g/cc or between about 1.02 g/cc and about 1.09 g/cc.
- the buoy 14 may be formed as a composite or multi-piece construction, including a plurality of materials.
- a first or outside portion 56 defines the upper or collection face 46 and the buoy edges 52 and is formed of the same material as the tube 12 .
- the outside portion 56 defines a cup or void into which a plug or insert 58 is placed.
- the insert 58 has a mass such that the density of the entire buoy 14 is within the selected range, for example, the range described above.
- a high density polyethylene may be used, but the material and size of the insert 58 may be altered to produce the desired density of the buoy 14 .
- the buoy 14 may be formed of a single suitable material that has a density in the selected range. Nevertheless, the buoy 14 formed unitarily or of a single material would still include the other portions described in conjunction with the buoy 14 .
- the outside portion 56 of the buoy 14 also defines the outside circumference of the buoy 14 .
- the outside circumference of the buoy 14 is very close to the internal circumference of the tube 12 . Due to the operation of the buoy 14 , however, described further herein, there is a slight gap between the outside of the buoy 14 and the inside of the tube 12 . Generally, this gap is between about 1 and about 10 thousandths of an inch around the entire circumference of the buoy 14 . Generally, it is desired that the distance between the outside circumference of the buoy 14 and the inside circumference of the tube 12 is great enough to allow a selected material or component to pass. For example, in whole blood the distance is selected so that red blood cells may pass through the gap without being lysed, damaged, or activated.
- the plunger 16 includes a plunger front or collection face 60 and a plunger wall 62 that extends from the plunger front face 60 .
- the plunger wall 62 extends relatively perpendicular to the plunger front face 60 and substantially parallel to the tube wall 42 .
- Extending from the center of the plunger 16 is a sample collection projection 64 .
- Extending from the top of the sample collection projection 64 is the first plunger port 22 .
- the sample collection projection 64 includes a plunger sample collection bore 68 defined therethrough.
- the plunger sample collection bore 68 terminates at a sample collection aperture 70 that is substantially in the center of the plunger front face 60 .
- the plunger front face 60 also defines an inverse cone where the sample collection aperture 70 is the apex of the cone.
- the plunger front face 60 defines a cone with an angle substantially similar or complimentary to the collection face 46 of the buoy 14 . In this way, the plunger front face 60 may mate substantially completely with the collection face 46 for reasons described more fully herein.
- the plunger 16 also includes a back face 72 . Extending from the plunger front face 60 to the back face 72 is a bore 74 .
- a check valve 76 is operably connected to the bore 74 .
- the check valve 76 allows a liquid to move from the plunger front face 60 to the back face 72 while not allowing the liquid to move from the back face 72 to the plunger front face 60 . Therefore, the check valve 76 is substantially a one-way valve which allows a material to move in only one direction.
- the check valve 76 may also operate automatically allowing flow in only one predetermined direction. Alternatively, the check valve 76 may be operated manually and include a portion extending from the check valve 76 requiring manipulation to stop or start a flow through the check valve 76 .
- the plunger 16 may be made out of any appropriate material which does not interfere with the separation of the fractions of the fluid, such as whole blood.
- the plunger 16 is made of a material that is flexible or at least partially deformable.
- a flexible material allows the plunger 16 to have an external circumference defined by the plunger walls 62 that is substantially equal to the internal circumference of the tube 12 . Because of the deformability of the plunger 16 , however, the plunger 16 is still able to move within the tube 12 .
- the plunger 16 is able to move through the tube 12 and also substantially wipe the interior of the tube wall 42 . This creates, generally, a moveable seal within the tube 12 .
- substantially no material escapes the action of the separator 10 when the plunger 16 is plunged into the tube 12 . This also helps concentrate the portion of the sample desired to be collected, described more fully herein.
- the cap 18 provides a structure to substantially close the tube 12 .
- the cap 18 particularly includes a plate 78 that has an external circumference substantially equal to the external circumference of the tube 12 . Extending from the plate 78 and into the tube 12 is a flange 80 . The external circumference of the flange 80 is substantially equal to the internal circumference of the tube 12 . In this way, the cap 18 substantially closes the tube 12 . It will be understood the cap 18 may be in any form so long as the cap 18 substantially closes and/or seals the tube 12 when installed.
- the depth gage port 19 is Formed through the center of the plate 78 .
- the depth gage port 19 is also adapted to receive the sample collection projection 64 .
- the first plunger port 22 extends above the plate 78 through the depth gage port 19 .
- the circumference of the depth gage port 19 is substantially equal to the external circumference of the sample collection projection 64 such that a liquid seal is formed.
- the plate 78 defines a sample face 84 that includes an interior side of the cap 18 .
- the area between the sample face 84 of the cap 18 and the back face 72 of the plunger 16 define a plasma collection area 86 .
- the plasma collection area 86 is exemplary called the plasma collection area, it will be understood that the plasma collection area 86 may also collect any appropriate fraction of the sample that is positioned within a separator 10 .
- the plasma collection area 86 is merely an exemplary name and an example of what material may be collected in the area of the separator 10 .
- the separator 10 may used to separate whole blood into various fractions, therefore, the plasma collection area 86 is used to collect plasma.
- the plasma collection area 86 also allows a space for the check valve 76 to be installed.
- a second bore 88 is formed in the plate 78 . Extending through the second bore 88 is the plasma collection valve 20 . In liquid communication with the plasma collection valve 20 is a plasma collection tube 92 .
- the plasma collection tube 92 has a length such that the plasma collection tube 92 is able to extend from the plasma collection valve 20 to substantially the tube bottom 44 .
- the plasma collection tube 92 is flexible enough such that it may be folded or compressed to fit within the plasma collection area 86 when the plunger 16 is substantially near the open end 12 a of the tube 12 .
- the plasma collection tube 92 may also be connected to a hose barb 93 that includes a plasma collection bore 93 a .
- the plasma collection bore 93 a is substantially level with the plunger back face 72 .
- the plasma collection bore 93 a may be positioned below the plunger back face 72 but in fluid communication with the plasma collection tube 92 .
- the outboard side of the plasma collection valve 20 may include external threads 94 to mate with internal threads of a plasma valve cap 96 . Therefore, the plasma collection valve 20 may be selectively opened and closed via the plasma valve cap 96 . It will be understood, however, that other appropriate means may be used to open and close the plasma collection valve 20 such as a clip or a plug. It will be understood that the plasma collection valve 20 , plasma collection tube 92 , plasma collection bore 23 a may be used to collect any appropriate material or fraction from the separator 10 .
- vent bore 98 Also formed in the plate 78 is a vent bore 98 .
- the vent bore 98 allows air to flow into the plasma collection area 86 as the plunger 16 is being plunged into the tube 12 .
- the vent bore 98 may include a filter 100 such that liquid cannot escape from the tube 12 .
- the filter 100 allows air to enter or escape from the plasma collection area 86 while maintaining the liquid seal of the tube 12 produced by the cap 18 .
- the depth gage 24 is selectiveively attachable to the first plunger port 22 .
- the female connector 26 interconnects the depth gage housing 28 to the first plunger port 22 .
- Internal threads in the female connector 26 mate with an external thread 102 formed on the first plunger port 22 .
- a snap connection rather than a threaded connection between the two may be used.
- the depth gage housing 28 is formed to be substantially rigid. Suitable materials, when sized properly, include polycarbonate and CYRO MED2®. The material preferably is both rigid and does not substantially react with the sample. It is rigid enough to provide a mechanism to plunge the plunger 16 into the tube 12 .
- the external circumference of the depth gage housing 28 is substantially equal to the circumference of the depth gage port 19 in the plate 78 . Therefore, as the plunger 16 is being plunged into the tube 12 with the depth gage 24 , no liquid material is allowed to escape around the depth gage housing 28 and through depth gage port 19 .
- the depth gage rod 38 extends through the plunger sample collection bore 68 of the sample collection projection 64 and protrudes through the sample collection aperture 70 a predetermined length.
- the depth gage rod 38 extends through the sample collection aperture 70 a length such that when an end 104 of the depth gage rod 38 meets the buoy 14 , the volume defined by the collection face 46 and the plunger front face 60 is between about 5% and about 30% of the total volume of the sample that the tube 12 holds.
- the projection of the depth gage rod 38 allows for an easily reproducible collection amount and concentration over several trials.
- the compression nut 36 locks the depth gage rod 38 in the predetermined position. Nevertheless, once the plunger 16 has been plunged to the desired depth in the tube 12 , the compression nut 36 may be loosened so that the depth gage rod 38 may be removed from the plunger 16 and the depth gage housing 28 without moving the plunger 16 . A syringe or other appropriate device may then be affixed to the external neck threads 34 of the depth gage 24 to extract the fraction or phase that is between the plunger front face 60 and the collection face 46 . As described further herein, the fraction or phase that is left between the plunger front face 60 and the collection face 46 may be the buffy coat of a whole blood sample. Nevertheless, it will be understood that the fraction between the plunger front face 60 and the collection face 46 may be any appropriate fraction of the sample that is disposed in the separator 10 .
- the separator 10 may be provided alone or in a kit 200 , as illustrated in FIG. 4 .
- the kit 200 may be placed in a tray 202 which is covered to provide a clean or sterile environment for the contents of the kit 200 .
- the kit 200 may include at least a first separator 10 and a second separator 10 ′.
- a first depth gage 24 and a second depth gage 24 ′ are also provided, one for each separator 10 , 10 ′.
- the kit 200 also generally includes a first syringe 204 , including a needle, to draw a biological sample, such as blood from a patient.
- the first syringe 204 may also be used to place the sample in the first separator 10 .
- a second device or syringe 210 may be used to extract a first fraction of the sample, while a third device or syringe 212 may be used to extract a second fraction of the sample.
- a tourniquet 214 and other medical supplies such as gauze 216 and tape 218 , may be provided to assist the practitioner. It will be understood the elements of the kit 200 are merely exemplary and other appropriate items or elements may be included.
- a method using the separator 10 is illustrated according to various embodiments.
- the following example relates specifically to the taking and separating of a sample of whole blood from a patient.
- another appropriate biological material may be separated and concentrated using the separator 10 .
- bone marrow may be separated and concentrated using the separator 10 .
- the various fractions of the bone marrow are similar to the fractions of whole blood.
- the bone marrow includes a fraction that includes substantially dense material and a second phase that is less dense and has other components suspended therein such as, for example, nucleated cells.
- the bone marrow sample may be positioned in the separator 10 , similarly to the whole blood as described herein, and separated in a substantially similar manner as the whole blood.
- the separator 10 can then be used to remove nucleated cells from the bone marrow sample (which may be referred to as buffy coat), whereas the separator 10 , as described herein, is used to remove the buffy coat from the whole blood which includes platelets and other appropriate materials (which may be referred to as platelet rich plasma (PRP)).
- PRP platelet rich plasma
- a mixture of whole blood and bone marrow may be positioned in the separator 10 for separation and concentration. Similar methods and steps will be used to separate the mixture of whole blood and bone marrow with a main difference being the material that is separated. It will also be understood that various centrifuge times or forces may be altered depending upon the exact material that is being separated with the separator 10 . It will also be understood that the separation of whole blood, bone marrow, or a mixture of whole blood and bone marrow are merely exemplary of the materials that may be separated using the separator 10 .
- a sample of whole blood taken from a patient is placed in the tube 12 with an anticoagulant using the first syringe 204 or other appropriate delivery method.
- the first syringe 204 may be connected to the first plunger port 22 .
- the blood sample is provided to the tube 12 via the sample collection bore 68 and sample collection aperture 70 .
- a cap 220 is then placed over the first plunger port 22 to substantially seal the tube 12 .
- the separator 10 is placed in a centrifuge.
- the second separator 10 ′ substantially identical to the first, is placed opposite the first separator 10 including the sample in a centrifuge.
- the second separator 10 ′ may also include a second sample or may include a blank, such as water, so that the centrifuge is balanced.
- the second separator 10 ′ balances the centrifuge by both weight and dynamics.
- the separator 10 is then spun in the centrifuge in a range between about 1,000 and about 8,000 RPM. This produces a force between about 65 and about 4500 times greater than the force of normal gravity, as generally calculated in the art, on the separator 10 and the blood sample placed in the separator 10 . At this force, the more dense material in a whole blood sample is forced toward the bottom end 12 b of the tube 12 .
- the dense material such as red blood cells or a red blood cell fraction 222 , collects on the tube bottom 44 . Because the buoy 14 has a density that is less than the red blood cell fraction 222 , it is forced in a direction toward the top end 12 a of the tube 12 in the centrifuge. Nevertheless, because the buoy 14 is denser than a plasma fraction 224 , the buoy 14 does not reach the top end 12 a of the tube 12 .
- the forces also affect the tube wall 42 .
- the forces compress the tube 12 linearly along axis A thereby bowing or flexing the tube wall 42 .
- the bottom face 48 defining an inverse cone, helps the initial movement of the buoy 14 . Because the buoy 14 is not substantially flat along its bottom, it does not form a vacuum interaction with the tube bottom 44 . Therefore, the initial movement of the buoy 14 away from the tube bottom 44 is quicker than if the bottom of the buoy 14 was flat.
- the red bloods cells of the red blood cell fraction 222 force the buoy 14 in the direction of the top end 12 a of the tube 12 because the buoy 14 is less dense than the red blood cell fraction 222 .
- the whole blood sample, including the red blood cells is loaded above the buoy 14 , the red blood cells are able to move between the buoy 14 and the tube wall 42 because the circumference of the buoy 14 is less than the internal circumference of the tube 12 .
- the buoy 14 stops at an interface of a plasma fraction 224 and the red blood cell fraction 222 because of the selected or tuned density of the buoy 14 .
- the centrifuge process has been completed and the buoy 14 has moved to the interface of the red blood cell fraction 222 and plasma fraction 224 .
- the tube wall 42 decompresses which helps support the buoy 14 at the interface position. It is also understood that applying an external pressure to the tube 12 via fingers or another apparatus may help stabilize the buoy 14 during the plunging procedure described herein.
- a middle fraction 226 On or near collection face 46 is a middle fraction 226 , including a small, yet concentrated, amount of red blood cells, white blood cells, platelets, and a substantial portion of a buffy coat of the blood sample.
- the plasma is also present near the collection face 46 at this point, the solid portions of the buffy coat are more compressed against the collection face 46 .
- the position of the buoy 14 also helps in this matter. Because the buoy 14 is a single body it defines the interface of the plasma fraction 224 and the red blood cell fraction 222 . Also the density of the buoy 14 assures that it has not passed into the plasma fraction 224 . Therefore, the fractions remain separated after the centrifuge process.
- the buoy 14 is tuned to the density of the red blood cell fraction 222 , it is not affected by variations in the density of the plasma fraction 224 and the buoy's 14 position is always at the interface of the red blood cell fraction 222 and the plasma fraction 224 .
- the depth gage 24 is affixed to the first plunger port 22 of the sample collection projection 64 .
- the plunger 16 is plunged into the tube 12 by pushing on the depth gage 24 .
- the plasma fraction 224 formed and separated above the buoy 14 , is able to flow through the check valve 76 into the plasma collection area 86 . This displacement of the plasma fraction 224 allows the plunger 16 to be plunged into the tube 12 containing the blood sample.
- the plunger 16 is plunged into the tube 12 until the point where the end 104 of the depth gage rod 38 reaches the buoy 14 .
- the volume left in the collection face 46 is the middle fraction 226 and is determined by the depth gage 24 . It may be adjusted by selectively determining the amount that the depth gage rod 38 extends below the plunger front face 60 . By adjusting the depth gage 24 , the concentration of the middle fraction 226 can be adjusted depending upon the desires of the operator.
- the plasma fraction 224 is held in the plasma collection area 86 for later withdrawal. Therefore, the use of the plunger 16 and the buoy 14 creates three distinct fractions that may be removed from the tube 12 after only one spin procedure.
- the fractions include the red blood cell fraction 222 , held between the buoy 14 and the tube bottom 44 .
- the middle or buffy coat fraction 226 is held between the plunger 16 and the buoy 14 .
- the plasma fraction 224 is collected in the plasma collection area 86 .
- the middle fraction 226 may be a platelet rich plasma (PRP) fraction and the plasma fraction 224 may be a platelet poor plasma (PPP) fraction.
- PRP platelet rich plasma
- PPP platelet poor plasma
- the middle fraction 226 may be extracted from the tube 12 first, without commingling the other fractions, through the sample collection bore 68 .
- the depth gage rod 38 may be removed from the depth gage housing 28 . This creates a sample collection cannula which includes the depth gage bore 30 , the sample collection bore 68 , and the sample collection aperture 70 .
- the second syringe 210 may be affixed to the depth gage housing 28 via the external neck threads 34 .
- the second syringe 210 may be substantially similar to the first syringe 204 .
- the separator 10 may be agitated to re-suspend of the platelets and concentrated red blood cells in a portion of the plasma remaining in the collection face 46 . This allows for easier and more complete removal of the middle fraction 226 because it is suspended rather than compressed against the collection face 46 .
- a vacuum is then created in the second syringe 210 by pulling back the plunger 16 to draw the middle fraction 226 into the second syringe 210 .
- the plunger 16 moves toward the buoy 14 . This action is allowed because of the vent bore 98 formed in the cap 18 . Atmospheric air is transferred to the plasma collection area 86 through the vent bore 98 to allow the middle fraction 226 to be removed. This also allows the movement of the plunger 16 toward the buoy 14 . This action also allows the plunger 16 to “wipe” the collection face 46 . As the plunger front face 60 mates with the collection area 46 the middle fraction 226 is pushed into the sample collection aperture 70 . This ensures that substantially the entire middle fraction 226 collected in the collection area 46 is removed into the second syringe 210 . It can also increase the repeatability of the collection volumes.
- the second syringe 210 does not protrude out the sample collection aperture 70 , it does not interfere with the collection of the middle fraction 226 .
- the second syringe 210 is removed from the first plunger port 22 . Also the extraction of the middle fraction 226 leaves the plasma fraction 224 and the red blood cell fractions 222 separated in the tube 12 .
- a third syringe 212 may be affixed to the plasma collection valve 20 .
- the third syringe 212 is connected to the external threads 94 of the plasma collection valve 20 to ensure a liquid tight connection. It will be understood, however, that another connection mechanism such as a snap or compression engagement may be used to connect the third syringe 212 to the plasma collection valve 20 .
- a vacuum is then created in the third syringe 212 to draw the plasma fraction 224 from the plasma collection area 86 through the plasma collection tube 92 .
- the plasma collection tube 92 is connected to the hose barb 93 . Therefore, the plasma flows through the plasma collection bore 93 a through the hose barb 93 , and then through the plasma collection tube 92 .
- the plasma collection tube 92 may alternatively simply rest on the plunger back face 72 to collect the plasma fraction 224 . In this way, the plasma fraction 224 may be removed from the blood separator 10 without commingling it with the red blood cell fraction 222 . After the plasma fraction 224 is removed, the separator 10 may be dismantled to remove the red blood cell fraction 222 . Alternatively, the separator 10 may be discarded in an appropriate manner while retaining the red blood cell fraction 222 .
- the separator 10 allows for the collection of three of a whole blood sample's fractions with only one centrifugation spin.
- the interaction of the buoy 14 and the plunger 16 allows a collection of at least 40% of the available buffy coat in the whole blood sample after a centrifuge processing time of about 5 minutes to about 15 minutes.
- the complimentary geometry of the plunger front face 60 and the collection face 46 help increase the collection efficiency. Although only the cone geometry is discussed herein, it will be understood that various other geometries may be used with similar results.
- the plunger front face 60 being flexible also helps ensure a complete mating with the collection face 46 . This, in turn, helps ensure that substantially the entire volume between the two is evacuated.
- the process first begins with the suction withdrawal of the middle fraction 226 via the second syringe 210 , but is completed with a fluid force action of the middle fraction 226 as the plunger front face 60 mates with the collection face 46 . As the plunger front face 60 mates with the collection face 46 , the fluid force assists in removal of the selected fraction.
- the plunger 16 also substantially wipes the tube wall 42 . Because the plunger 16 is formed of a flexible material it forms a seal with the tube wall 42 which is movable. Therefore, substantially no liquid is able to move between the plunger wall 62 and the tube wall 42 . Material is substantially only able to go past the plunger front face 60 via the check valve 76 .
- the complimentary geometry also helps decrease the collection time of the middle fraction 226 . Therefore, entire time to prepare and remove the middle fraction 226 is generally about 5 to about 40 minutes. This efficiency is also assisted by the fact that the separator 10 allows for the removal of the middle fraction 226 without first removing the plasma fraction 224 , which includes the buffy coat, and re-spinning the plasma fraction 224 . Rather, one spin in the separator 10 with the whole blood sample allows for the separation of the buffy coat for easy extraction through the plunger 16 .
- the separator 10 may be used to separate any appropriate multi-component material.
- a bone marrow sample may be placed in the separator 10 to be centrifuged and separated using the separator 10 .
- the bone marrow sample may include several fractions or components that are similar to whole blood fractions or may differ therefrom. Therefore, the buoy 14 may be altered to include a selected density that is dependent upon a density of a selected fraction of the bone marrow.
- the bone marrow may include a selected fraction that has a different density than another fraction and the buoy 14 may be designed to move to an interface between the two fractions to allow for a physical separation thereof. Similar to the whole blood fraction, the plunger 16 may then be moved to near a collection face 46 of the buoy 14 .
- the middle fraction 226 in the bone marrow sample may include a fraction of undifferentiated or stem cells.
- the middle fraction 226 in a bone marrow sample may include hematopoietic, stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, or endothelial cells.
- the middle fraction 226 is concentrated bone marrow aspirate.
- mixtures of various fluids may be separated in the separator 10 .
- a mixture of whole blood and bone marrow may be positioned in the separator 10 at a single time.
- the buoy 14 may be tuned to move to an interface that will allow for easy removal of both the buffy coat, from the whole blood sample, and the undifferentiated cells, from the bone marrow sample.
- the separator 10 may be used within any appropriate biological material or other material having multiple fractions or components therein. Simply, the buoy 14 may be tuned to the appropriate density and the plunger 16 may be used to cooperate with the buoy 14 to remove a selected fraction.
- the buoy system 300 generally includes a first buoy or fraction separator member 302 and a second buoy member or fraction separator 304 .
- the first buoy 302 and the second buoy 304 may be operably interconnected with a buoy system cylinder or member 306 .
- the buoy system 300 may be placed in a tube, such as the tube 12 .
- the tube 12 may be formed of any appropriate material, such as the Cryolite Med® 2 as discussed above. Nevertheless, the buoy system 300 may be designed to fit in the tube 12 or may be formed to fit in any appropriate member that may be disposed within a selected centrifuging device.
- buoy system 300 may be substantially matched to the size of the tube 12 is merely exemplary. As the buoy 14 may be sized to fit in any appropriate tube, the buoy system 300 may also be sized to fit in any appropriate tube. It will be further understood that the tube 12 may be any appropriate shape. The tube 12 need not only be cylindrical but may also be or include conical portions, polygonal portions, or any other appropriate shapes.
- the first buoy 302 of the buoy system 300 may be generally similar in geometry to the buoy 14 . It will be understood that the first buoy member 302 may be formed in the appropriate manner including shape or size to achieve selected results. Nevertheless, the first buoy member 302 generally includes an exterior diameter that may be slightly smaller than the interior diameter of the tube 12 . Therefore, the first buoy member 302 may be able to move within the tube 12 during the centrifugal process. Also, as discussed above, the tube 12 may flex slightly during the centrifuging process, thus allowing the first buoy member 302 to include an exterior diameter substantially equivalent to the interior diameter of the tube 12 . As discussed further herein, during the centrifugation process, a portion of the fraction of a sample may pass between the exterior wall of the first buoy member 302 and the tube 12 .
- the first buoy member 302 may generally include a density that is substantially equivalent to a first or selected fraction of the sample. If the sample to be separated includes whole blood and is desired to separate the red blood cells from the other portions of the sample, the first buoy member 302 may have a selected density that may be about 1.00 grams per cc (g/cc) to about 1.10 g/cc. It will be understood that the density of the first buoy member 302 may be any appropriate density, depending upon the fraction to be separated, and this range of densities is merely exemplary for separating red blood cells from a whole blood sample.
- the first buoy member 302 includes a collection face or area 308 at a proximal or upper portion of the first buoy member 302 .
- the collection face 308 generally defines a concave area of the first buoy member 302 and may have a selected angle of concavity.
- the buoy assembly 300 defines a central axis D.
- the collection face 308 defines a surface E that is formed at an angle ⁇ to the central axis D of the buoy system 300 .
- the angle ⁇ may be any appropriate angle and may be about 0.5° to about 90°.
- the angle ⁇ may, however, be between about 45° and 89.5°. Nevertheless, it will be understood that the angle ⁇ may be any appropriate angle to assist in collection of a selected fraction or portion of the sample by the first buoy member 302 .
- a bottom or lower surface 310 of the first buoy member 302 may define a bottom face.
- the bottom face 310 may also be formed at an angle D relative to the central axis D.
- the bottom surface 310 defines a surface or plane F that may be formed at an angle ⁇ relative to the central axis D of the buoy system 300 .
- the angle ⁇ may be any appropriate angle and may be about 90° to about 160°.
- the angle ⁇ may be about 15°.
- the bottom surface 310 defines an apex 312 that may first engage the bottom 12 d of the tube 12 , such that most or the majority of the bottom surface 310 does not engage the tube 12 .
- the apex 312 allows for a free space or gap to be formed between the bottom face 310 of the first buoy member 302 and the bottom 12 b of the tube 12 .
- the second buoy member 304 may include an outer diameter substantially equivalent to the outer diameter of the first buoy member 302 . Therefore, the second buoy 304 may move with the first buoy 302 , particularly if the second buoy 304 is interconnected with the first buoy 302 with the buoy central cylinder 306 . Nevertheless, the second buoy member 304 may be allowed to move substantially freely within the tube 12 during the centrifuging process.
- the second buoy member 304 also includes an upper or superior surface 314 that defines a plane G that is formed at an angle relative to the central axis D of the buoy system 300 .
- the angle c of the plane G relative to the central axis D of the buoy system 300 may be any appropriate angle.
- the angle ⁇ may be about 90° to about 150°.
- the angle ⁇ may assist in allowing a selected fraction or a portion of the sample to pass over the top surface 314 and past the second buoy member 304 during the centrifuging process.
- the second buoy member 304 also define a bottom or inferior surface 316 that also defines a plane H that may be formed at an angle K relative to the central axis D of the buoy system 300 .
- the angle K may be any appropriate angle, such as about 90° to about 150°. Nevertheless, the angle K may be substantially complimentary to the angle ⁇ of the collection face 308 of the first buoy member 302 . For example, if the angle ⁇ is about 80°, the angle K may be about 100°, such that substantially 180° or a straight line is formed when the first buoy member 302 engages the second buoy member 304 . This may be for any appropriate reason, such as extraction of a fraction that may be disposed near the collection face 308 of the first buoy member 302 . Nevertheless, the angle K may be any appropriate angle as the angle ⁇ .
- the second buoy member 304 may be formed to include any appropriate density.
- the second buoy member 304 may include a density that is less than the plasma fraction of a whole blood sample. It will be understood that the second buoy member 304 may include any appropriate density and a density that is less than the plasma fraction of a whole blood sample is merely exemplary. Nevertheless, if a whole blood sample is desired to be separated and the plasma sample is to be substantially separated from another fraction, the second buoy member 304 may include a density that is less than the plasma fraction of the whole blood sample. Therefore, the density of the second buoy member 304 may be about 0.01 g/cc to about 1.03 g/cc.
- the buoy system 300 may be substantially positioned near an interface between the red blood cell fraction and the plasma fraction of a whole blood sample. Therefore, as discussed above, and further described herein, the platelet or buffy coat fraction of the whole blood sample may be substantially collected near or in the collection face 308 of the buoy system 300 .
- the buoy post 306 may operably interconnect the first buoy member 302 and the second buoy member 304 .
- the buoy post 306 may be any appropriate connection member.
- the buoy post need not be a single cylindrical portion.
- the buoy post 306 may include one or more members interconnecting the first buoy member 302 and the second buoy member 304 , such as around a perimeter thereof.
- the buoy post 306 may include any appropriate shape or geometry.
- the buoy system post 306 may be rigidly affixed to the first buoy member 302 and the second buoy member 304 , such that the first buoy member 302 may not move relative to the second buoy member 304 and vice versa.
- the buoy post 306 may be slide ably connected to either or both the first buoy member 302 and the second buoy member 304 .
- the buoy post 306 is generally fixedly connected to the first buoy member 302 and slide ably interconnected to the second buoy member 304 .
- the buoy post 306 may include a catch portion or lip 320 that is able to engage a portion of the second buoy member 304 , such that a range of travel of the second buoy member 304 , relative to the first buoy member 302 is limited. Nevertheless, the range of travel of the second buoy member 304 toward the first buoy member 302 may be substantially unlimited until the second buoy member 304 engages the first buoy member 302 .
- the buoy post 306 may also define a central cannula or bore 322 .
- the post bore 322 may include a connection portion 324 substantially defined near an upper or a proximal end of the buoy post 306 . This may allow for interconnection of various components with the buoy post 306 , such that various components may be moved through the bore 322 from an exterior location.
- the buoy post 306 may also define a port or cannula 326 that connects the post cannula 322 with the collection face 308 . Therefore, a substance may travel through the post cannula 322 and through the port 326 . Various substances may then be provided to or removed from the collection face 308 of the first buoy member 302 .
- the buoy system 300 may be used to separate a selected multi component sample, such as a whole blood sample.
- a method of using the buoy system 300 is illustrated and described.
- FIGS. 7A-7D like reference numerals are used to indicate like portions of the tube 12 and the associated mechanisms described in FIGS. 1-3 . Therefore, it will be understood that the buoy system 300 may be used with the tube 12 or any other appropriate tube or container system or apparatus. Nevertheless, for simplicity, the description of a method of use of the buoy system 300 will be described in conjunction with the tube 12 .
- the tube 12 may include the cap 18 that further defines a plasma valve or port 20 . Extending through the cap 18 and interconnecting with a first flexible tube or member 92 , the plasma port 20 may be used to extract a selected fraction of the sample that is positioned above the second buoy member 304 .
- the tube 12 may also define a second port 21 , which may also be referred to as a platelet rich plasma (PRP) port.
- a second flexible member such as a flexible tube 21 a , may interconnect the PRP port 21 and a connection portion 324 of a buoy cylinder 306 .
- the first tube 92 may also be interconnected with a selected portion of the system, such as the top surface 314 of the second buoy member 304 .
- a valve may be positioned and is operably interconnect the tube 92 with the upper surface 314 of the second buoy member 304 . Nevertheless, such a valve is not necessary and it may be provided merely for convenience.
- buoy system 300 may be included in the tube 12 and used with the buoy system 300 . Nevertheless, once the buoy system 300 is interconnected, it may be positioned in the interior of the tube 12 and the syringe 204 used to place a sample into the tube 12 .
- the sample may be expressed from the syringe 204 into the interior of the tube 12 and the sample may be any appropriate sample, such as a whole blood sample. Nevertheless, it will be understood, such as discussed above, various other samples may be used, such as bone marrow samples, a mixture of bone marrow and whole blood or non-biological fluids or materials. It will be understood that two buoys 302 and 304 may generally be near one another when the sample is positioned in the tube 12 , but are illustrated apart for clarity of the present discussion.
- the sample may be placed in the tube 12 according to various embodiments.
- an anticoagulant or other components may be mixed with the whole blood sample, if a whole blood sample is used, before the whole blood sample is positioned within the tube 12 .
- an anticoagulant or other components may be mixed with a bone marrow aspirate sample or a sample of bone marrow aspirate and whole blood, if such samples are used before such sample is positioned within the tube 12 .
- the syringe 204 is connected with the plunger port 22 extending from the cap 18 , although a plunger may not be used in various embodiments.
- a cap may be positioned over the port 22 , such that the sample is not allowed to escape from the tube 12 .
- the tube 12 including the sample and the buoy system 300 may be centrifuged.
- substantially three fractions of the sample may be formed.
- a first fraction 330 may be positioned between the bottom face 310 and the bottom of the tube 44 .
- a middle fraction 332 may be positioned between the collection face 308 and the bottom surface 316 of the second buoy 304 .
- a third fraction 334 may be positioned between the upper surface 314 and the cap 18 of the tube 12 .
- the first fraction 330 , the middle fraction 332 , and the third fraction 334 are substantially physically separated with the buoy system 300 .
- the tube 12 may flex slightly to allow for ease of movement of the buoy system 300 through the tube 12 and the sample.
- the buoy system 300 during the centrifugation process, substantially creates the three fractions 330 , 332 , and 334 without the operation of an operator. Therefore, the formation of at least three fractions may be substantially simultaneous and automatic using the buoy system 300 .
- the buoy system 300 substantially separates the fractions 330 , 332 , and 334 , such that they may be easily removed from the tube 12 .
- a syringe or other instrument 340 may be used to extract the middle fraction 332 by interconnecting a cannula or bored tube 342 with the connection portion 324 of the buoy cylinder 306 .
- a vacuum or upward force is produced within the extraction syringe 340 . This force draws the middle fraction 332 through the ports 326 of the buoy post 306 and through the buoy cannula 322 .
- the middle fraction 332 may be extracted from the tube 12 without substantially commingling the middle fraction 332 with either the first fraction 330 or the third fraction 334 .
- the middle fraction 332 is drawn in the direction of arrow M through the cannula 322 and into the extraction syringe 340 .
- the second tube 21 a may also be used.
- the extraction syringe 340 may be interconnected with the PRP port 21 that is interconnected with the connection portion 324 of the buoy cylinder 306 .
- the buoy cylinder allows access to the middle fraction 332 (platelet rich portion) between the buoy portions.
- the middle fraction 332 platelet rich portion or buffy coat of the sample
- the PRP port 21 would allow for extraction of undifferentiated nucleated cells.
- the PRP port 21 allows for extraction of the buffy coat.
- the post 306 is not provided other portions may be provided to gain access to the middle fraction 332 .
- a valve portion such as a puncture-able valve, may be provided in the second buoy 304 to be punctured with an object. In this way an extraction needle may puncture the valve to gain access to the middle fraction 332 .
- the buoy system 300 may be able to form a plurality of fractions, such as the three fractions 330 , 332 , and 334 and at least the middle fraction 332 may be extracted without substantially commingling the various fractions.
- the second buoy member 304 may move in the direction of arrow M toward the first buoy member 302 .
- the collection face 308 of the first buoy member may include an angle ⁇ that is substantially complementary to the bottom face 316 of the second buoy member 304 . Therefore, if the second buoy member 304 is allowed to move along the buoy cylinder 306 , the bottom face 316 of the second buoy member 304 may be able to substantially mate with the collection face 308 of the first buoy member 302 .
- the second buoy member 304 may be provided with a vent port or valve, such that the extraction of the middle fraction 332 from the collection face 308 may not be hindered by the buildup of undesirable forces. Nevertheless, if the second buoy member 304 may move, the interaction of the bottom face 316 of the second buoy member 304 may assist in substantially removing the entire middle fraction 332 from the tube 12 . As described above, the bottom face 60 of the plunger 16 may also serve a similar purpose when engaging the collection face 46 of the buoy 14 .
- the second buoy member 304 may substantially mate with a portion of the first buoy member 302 .
- the second buoy member 304 may substantially only mate with the first buoy member 302 if the second buoy member 304 is able to substantially move relative to the first buoy member 302 . Therefore, it will be understood that the second buoy member 304 need not necessarily mate with the first buoy member 302 and is merely exemplary of an operation of various embodiments.
- the port 20 may be used in conjunction with a selected instrument, such as a plasma extraction syringe 212 to remove the plasma or the third fraction 334 from the tube 12 using the extraction tube 92 interconnected with the port 20 .
- a selected instrument such as a plasma extraction syringe 212 to remove the plasma or the third fraction 334 from the tube 12 using the extraction tube 92 interconnected with the port 20 .
- the tube 92 allows for extraction of the third fraction 334 from the tube 12 without commingling the third fraction 334 with the remaining first fraction 330 in the tube 12 . Therefore, similar to the separator and extraction system 10 , three fractions may be substantially formed within the tube 12 with the buoy system 300 and may be extracted without substantially commingling the various fractions.
- the buoy system 300 may be removed from the tube 12 , such that the first fraction 330 may be removed from the tube 12 .
- the first fraction 330 may be discarded with the tube 12 and the buoy system 300 as a disposable system.
- the system may be substantially reusable, such that it can be sterilized and may be sterilized for various uses.
- the description of the method of use of the buoy system 300 is exemplary of a method of using a system according to various other embodiments. It will be understood, however, that various specifics may be used from various embodiments to allow for the extraction of selected fractions.
- the centrifugation process may be substantially a single step centrifugation process.
- the buoy system 300 may allow for the formation of three fractions during a single centrifugation process. This centrifugation process may occur at any appropriate speed, such as about 1000 RPM to about 8000 RPM. This speed may produce a selected gravity that may be approximately 4500 times greater than the normal force of gravity. Nevertheless, these specifics are not necessary to the operation of the buoy system 300 according to various embodiments.
- the buoy system 300 may be used to extract a plurality of fractions of a sample after only a single centrifuging process and without substantially commingling the various fractions of the sample.
- the blood collection and separation system that includes the tube 12 may be filled with a multi-component fluid or solution, such as blood from a patient, is illustrated.
- the tube 12 may include any appropriate separation system, such as the separation system 300 .
- any appropriate method may be used to fill the tube 12 . For example, when a solution, including a plurality of components, is placed into the tube 12 it may be collected directly from a source.
- a patient 350 may be provided.
- the patient 350 may be provided for a selected procedure, such as generally an operative procedure or other procedure that requires an intravenous connection 352 , such as a butterfly needle, to be provided in the patient 350 .
- the intravenous connection 352 generally provides a tube 354 extending therefrom.
- the tube 354 may be used to withdraw fluids from the patient 350 or provide materials to the patient 350 , such as medicines or other selected components.
- the intravenous connection 352 is generally provided for various procedures and may be used to fill the tube 12 .
- the tube 354 may interconnect with the plunger port 22 or any appropriate portion of the tube 12 .
- the port 22 may be used to connect with the tube 354 in a similar manner as it would connect with the syringe 204 , if the syringe 204 was provided. Nevertheless, it will be understood that the tube 354 may be provided directly to the tube 12 from the patient 350 . This may reduce the number of steps required to fill the tube 12 and reduce possible cross-contamination from the patient 350 with the various components. Moreover, making a connection directly with the patient 350 may make the withdrawal and collection of blood from the patient 350 more efficient.
- a vacuum system 356 may be provided The vacuum system 356 may include a vacuum inducing portion or member 358 , such as a resilient bulb. The vacuum inducing member 358 may be interconnected with the tube 12 through a selected connecting portion 360 .
- the vacuum connecting portion 360 may interconnect with an orifice 362 .
- the orifice 362 may be interconnected or extend from the cap 18 or provided in any appropriate portion with the tube 12 .
- a first one-way valve 364 may be provided along the connection portion 360 or near the orifice 362 .
- the first one-way valve 364 provides that a flow of a fluid, such as a gas, may pass in a first direction but not in a second.
- a second one-way valve 366 may also be provided downstream from the first one-way valve 364 . In this way, a vacuum may be created with the vacuum inducing member 358 , such that air is drawn out of the tube 12 and removed through the second one-way valve 366 in the direction of arrow V.
- the air is generally withdrawn from the tube 12 without substantially allowing the air to flow back into the tube 12 .
- a vacuum can be created within the tube 12 to assist with removing a selected volume of fluid, such as blood, from the patient 350 .
- the tube 12 may be filled substantially directly from the patient 350 , the collection of the fluid, such as blood, may be provided substantially efficiently to the tube 12 .
- the vacuum system 356 may be provided including the vacuum inducing member 358 .
- Any appropriate vacuum creating device may be used, such as a mechanical pump or the like. Nevertheless, the tube 12 may be filled for use during a selected procedure.
- the tube 12 may be used to separate a selected portion of the blood obtained from the patient 350 substantially intraoperatively. Therefore, the collection or separation of the various components may be substantially autologous and substantially intraoperatively. Moreover, obtaining the fluid directly from the patient 350 may increase the efficiency of the procedure and the efficiency of the intraoperative or the operative procedure.
- the separator 10 may be used to separate any appropriate material.
- the material may be separated for any purpose, such as a surgical procedure.
- a selected fraction of a bone marrow aspirate or a bone marrow portion may be produced with the separator 10 according to various embodiments.
- the selected fraction of the bone marrow aspirate may include various components, such as undifferentiated cells.
- the various undifferentiated cells may be positioned in a selected scaffold or relative to a selected portion of a patient for providing a volume of the undifferentiated cells to the patient.
- a selected portion of the patient may include bone, cartilage, connective tissue, or any other tissue.
- a selected portion of the patient may include a defect in bone, cartilage, connective tissue and/or any other tissue. It will be understood that the method described according to FIG. 9 is merely exemplary of various embodiments that may be used to provide a selected fraction of a bone marrow aspirate or other material to a patient or selected position.
- the selected portion may be placed on the scaffold in any appropriate manner, such as by spraying, dipping, infiltrating, or any appropriate method.
- FIG. 9 A method of selecting or creating a selected fraction of a bone marrow aspirate in a selected scaffold according to a method 400 is illustrated in FIG. 9 .
- the method 400 may start in block 402 in obtaining a bone marrow aspirate volume.
- the bone marrow aspirate (BMA) may be obtained in any selected or generally known manner. For example, a selected region of bone, such as a portion near an operative procedure, may be used to obtain the bone marrow aspirate.
- an accessing device such as a syringe and needle, may be used to access an intramedullary area of a selected bone. The BMA may then be withdrawn into the syringe for various procedures.
- the BMA may be positioned in the separator 10 according to various embodiments in block 404 .
- the BMA may be positioned in any appropriate separator, such as those described above including the separator 10 .
- a selected fraction of the BMA may be separated from the BMA in block 406 .
- BMA is a complex tissue comprised of cellular components (that contribute to bone growth) including red and white blood cells, their precursors and a connective tissue network termed the stroma.
- Bone marrow stromal cells or mesenchymal stem cells have the potential to differentiate into a variety of identifiable cell types including osteoblasts, fibroblasts, endothelial cells, reticulocytes, adipocytes, myoblasts and marrow stroma.
- the selected fraction of the BMA may include undifferentiated cells or any appropriate portion of the BMA.
- the fractionation or separation of various fractions of the BMA may allow for a volume of BMA to be taken from a single location and the separation or concentration of the selected portion may be performed in the separator 10 .
- obtaining a small volume of the selected portion from a plurality of locations may be used to obtain an appropriate volume of BMA or selected fraction of the BMA.
- the separator 10 may allow for separating a selected volume from a single location from which the BMA is obtained. This may reduce the time of a procedure and increase the efficiency of obtaining the selected fraction of the BMA.
- a volume of whole blood may be obtained in block 408 .
- the volume of blood obtained in block 408 may then be positioned in the separator 10 , in block 410 .
- the whole blood may be positioned in any appropriate separator, such as those described above or a separator to separate a selected fraction of the whole blood.
- the whole blood may be separated into an appropriate fraction, such as a fraction including a platelet portion or buffy coat.
- the whole blood may be separated into selected fractions in block 412 . It will be understood that the BMA and the whole blood volume may be obtained substantially simultaneously or consecutively in block 402 and 408 .
- concentrated BMA such as the middle fraction 332 , 226 comprising nucleated cells in separator 10 has a concentration of nucleated cells that is at least 4 times the concentrate of nucleated cells in BMA.
- the selected fractions of the BMA obtained in block 406 and whole blood obtained in block 412 may also be performed substantially sequentially or simultaneously.
- the separator 10 including the volume of the BMA may be positioned in a separating device, such as a centrifuge, substantially opposite, so as to balance, the separator 10 including the volume of the whole blood. Therefore, a single separation, such as centrifuge procedure may be used to separate both the BMA and the whole blood into selected fractions. This again may increase the efficiency of the procedure to provide both a selected fraction of the BMA and a selected fraction of the whole blood substantially simultaneously.
- the selected fractions of the BMA and the whole blood, provided in block 406 and 412 may be harvested in block 414 .
- the selected fractions of the BMA and the whole blood may be harvested in block 414 for appropriate purposes, such as those described herein.
- the separator 10 may be used to obtain the selected fractions of the BMA and the whole blood, through various procedures, such as those described above.
- a plurality of separators 10 may be used to obtain a larger quantity of the selection fractions and such quality of selected fractions may be pooled together.
- the BMA aspirate can be concentrated alone or in combination with whole blood.
- whole blood may be added to the separator 10 , and the resulting buffy coat fraction (middle fraction 332 , 226 ) may not only contain the at least 4 times greater concentration of nucleated cells from bone marrow, and may include at least 5 times greater concentration of white blood cells from the whole blood and at least 8 times greater concentration in platelets from the whole blood.
- circulating stem cells from whole blood may be concentrated with the mature white blood cells in the buffy coat.
- the scaffold in block 416 may be any appropriate scaffold, such as synthetic bone substitutes or allergenic tissue.
- a scaffold include, but are not limited to, bone, cartilage, bone substrates, ceramics, biopolymers, collagens, metal, and the like.
- the scaffolds may be used for appropriate procedures, such as hard or soft tissue grafting, including uses in non-union or chronic wounds.
- the undifferentiated cells of the BMA may allow for a substantial source of cells for use during a substantially natural healing after an operative procedure, for example, the natural healing of a patient may use the supplied undifferentiated cells.
- the undifferentiated cells may be applied to a wound, a defect, a graft site, a bone, cartilage, connective tissue. and the like. Therefore, the scaffold may be positioned in a selected portion of the anatomy and the cells may be allowed to grow and differentiate into selected portions in the implanted position.
- bone marrow contains hematopoietic and mesenchymal stems cells that are precursors for most of the cells found within the body.
- the hematopoietic cells along with angiogeneic growth factors, such as those found in platelets, will promote angiogenesis.
- Angiogenesis is a necessary stage in wound healing of most tissues and treatment of ischemia.
- the mesenchymal stem cells are the cells responsible for the formation of bone, tendon, ligament, articular cartilage, muscle, fat, intervertebral discs, meniscus, skin, and any other structural tissue found in the body.
- a concentration and delivery of these precursor cells will improve therapeutic uses over the native bone marrow.
- the platelets of the whole blood may be positioned on or near the scaffold of block 418 .
- the platelets of the whole blood fraction positioned in the scaffold of block 418 may assist the undifferentiated cells and the anatomy into which the scaffold is positioned to allow for a substantially efficient and complete healing.
- the platelet rich fraction of the whole blood sample may include various healing and growth factors that may assist in providing an efficient and proper healing in the anatomy. Therefore, the undifferentiated cells of the BMA, or other selected fraction obtained from the separation of the BMA, and the selected fraction of the whole blood, obtained from the separator, may be used with the scaffold to provide a substantially efficient implant.
- harvest block 414 may be combined with a growth factors which may include any of the well-known growth factors such as Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF- ⁇ ), Insulin-Like Growth Factor (IGF), Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Bone Morphogenetic Proteins (BMPs), and vectors for gene therapy.
- PDGF Platelet-Derived Growth Factor
- TGF- ⁇ Transforming Growth Factor Beta
- IGF Insulin-Like Growth Factor
- FGF Fibroblast Growth Factor
- EGF Epidermal Growth Factor
- VEGF Vascular Endothelial Growth Factor
- BMPs Bone Morphogenetic Proteins
- harvest block 414 may be combined with cellular solutions, suspensions, and materials including osteoblasts, osteoprogenitor cells, chondroblasts, stem cells, or fibroblasts may also be used, as may solutions or suspensions containing other therapeutic agents such as antibiotics, analgesics, pharmaceutical agents, antithrombinolytics, or chemotherapeutic agents.
- the buffy coat, platelet fraction, and/or undifferentiated cell fraction may be combined with an activator such as thrombin solutions and the like.
- the middle fraction 332 , 226 may be used alone for cartilage repair.
- the platelet rich fraction may be used to fill a cartilage defect with a fibrin matrix, or it may be mixed with other cell sources such as autologous chondrocytes, synovial cells, bone marrow cells, or to mix with the blood clot formed during microfracture.
- the separator 10 or any appropriate separator, such as that described above, may allow for a substantially quick and efficient separation of the BMA and the whole blood into an appropriate fraction for use in the procedure.
- Other examples include pooling whole blood and/or BMA from different sites of the anatomy or from different sources.
- the concentrated bone marrow cells can also be included with a carrier to aide in delivery and to help maintain the cells' location after implantation.
- carriers can include fibrin, concentrated fibrin, demineralized bone matrix, gelatin, collagen, porous calcium based ceramics, porous metal, synthetic fiber matrices, or resorbable matrices.
- carriers can be made from other autogeneic, allogenic, and xenogeneic tissues.
- the scaffold may be implanted in block 420 .
- the scaffold may be implanted in any appropriate position in the block 420 for various procedures. It will be understood that the scaffold may be implanted for any appropriate procedure and may allow for positioning the selected portion of the BMA, such as undifferentiated cells, and the selected portion of the whole blood, such as platelets, relative to a selected portion of the anatomy.
- the scaffold may allow for a bone ingrowth, such as allowed with the undifferentiated cells, to assist in healing of a selected portion of the anatomy.
- concentrated bone marrow aspirate can be used in articular cartilage repair.
- the middle fraction 332 , 226 can be added to a focal defect or to an osteoarthritic defect.
- the defects can be in any joint that contains articular cartilage.
- the middle fraction 332 , 226 can promote the formation of repair tissue.
- these cells can be added to a microfracture technique in order to increase the mesenchymal cells present in the defect and increase the amount and quality of repair tissue that forms.
- the middle fraction 332 , 226 can be delivered in one of the carriers listed above.
- the middle fraction 332 , 226 in an autologous fibrin or concentrated fibrin is activated with an activating solution so that it forms a 3-D gel in situ and holds the middle fraction 332 , 226 within the cartilage defect.
- the concentrated bone marrow can also be used in meniscus repair.
- the concentrated bone marrow can be used to fill a tear with the meniscus, or in can be used to soak a graft used to replace the meniscus after a full or partial meniscectomy.
- concentrated bone marrow aspirate used in combination with platelet rich plasma can also be used for repair of meniscus.
- concentrated bone marrow aspirate can be used to repair bone.
- the middle fraction 332 , 226 can used alone, or mixed with an appropriate carrier such as demineralized bone matrix, calcium based ceramics, fibrin, or concentrated fibrin.
- an appropriate carrier such as demineralized bone matrix, calcium based ceramics, fibrin, or concentrated fibrin.
- the defects in bone could be found in long bones, cranium, sternum, and spine.
- concentrated bone marrow aspirate would be to deliver the undifferentiated cells to a freeze dried demineralized bone product (such as the Bonus DBM product from Biomet Biologics) under vacuum.
- the concentrated bone marrow can infiltrate the graft, and the plasma in the bone marrow may hydrate the bone matrix and create an injectable carrier.
- the undifferentiated cells may have differentiating growth factors included within the demineralized bone to stimulate cartilage and bone formation.
- the concentrated bone marrow can be delivered to the patient with a growth factor that will induce proliferation, chemotaxis, and/or morphogeneis.
- growth factors include PDGF, TGF-b, IGF, VEGF, EGF, CTGF, FGF, and any of the BMPs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Clinical Laboratory Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Ecology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- External Artificial Organs (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.
Description
- This application is a continuation-in-part of U.S. patent application Ser. No. 10/932,882, filed on Sep. 2, 2004, entitled “APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS”, which is a continuation-in-part of U.S. patent application Ser. No. 10/445,381, filed on May 23, 2003, entitled “APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS” that claimed the benefit of U.S. Provisional Application No. 60/383,013, filed on May 24, 2002. The disclosures of the above applications are incorporated herein by reference.
- The present teachings relate to a multiple component fluid and a concentrator/separator and, more particularly, relates to a container operable with a centrifuge to separate and/or concentrate various biological components.
- Various fluids, such as whole blood or various other biological fluids, may be separated into their constituent parts, also referred to as fractions or phases. For example, whole blood samples may include a plurality of constituents that may be separated by density in a device such as a centrifuge. The whole blood sample may be placed in a test tube, or other similar device, which is then spun in a centrifuge. In the centrifuge the whole blood is separated into different fractions depending upon the density of that fraction. The centrifugal force separates the blood or other sample into different fractions. In addition, various elements may be added to the test tube to create more than two fractions. In particular, commonly used gels may be used to divide the whole blood into a plurality of different fractions which may include fractions such as platelets, red blood cells, and plasma. Various other biological fluids may be separated as well. For example, nucleated cells may be separated and extracted from bone marrow or adipose tissue sample.
- Many of these systems, however, do not provide a simple or efficient method to extract any more than one fraction and, especially, a fraction other than the top fraction. The top fraction of whole blood is plasma, or other blood constituents suspended in plasma. Thus, to extract other fractions the plasma fraction must either be removed for further extracting procedures or spun again to obtain the constituents suspended in this plasma. It is difficult to pierce the top fraction without commingling the sample. Accordingly, obtaining the other fractions is difficult with commonly known systems.
- Other systems have attempted to alleviate this problem by providing a float or other device that is disposed within the sample at the interfaces of the different fractions during the centrifuge process. Nevertheless, these systems still do not allow a simple way to remove the different fractions without remixing the sample fractions. In addition, many of the systems do not allow an easy and reproducible method to remove the desired sample fraction.
- Therefore, it is desired to provide a device to allow for the easy and reproducible removal of a particular fraction which does not happen to be the top fraction of a sample. It is desired to remove the required sample without mixing the different fractions during the extraction process. In addition, it is desired to provide a device which allows for a consistent extraction which includes known volumes or concentration of the fraction elements. Moreover, it is desired to separate and concentrate a selected fraction with one centrifugation step.
- The present teachings provide an apparatus that separates and concentrates a selected fraction or component of a fluid, such as a biological fluid. For example, undifferentiated cells, such as mesenchymal stem cells, platelet fraction, buffy coat, or white blood cell fraction can be separated from bone reaming material, whole blood, bone marrow aspirate, and other materials. In various embodiments, the apparatus, when used with a centrifuge, is generally able to create at least two fractions. The present teachings also provide for a new method of creating at least three fractions extracting a third fraction from a sample such as, for example, a buffy coat fraction.
- In various embodiments, the apparatus includes a container to be placed in a centrifuge after being filled with a sample and the container includes a buoy or fraction separator having a selected density that may be less than one fraction but greater than a second fraction, that is disposed therein. In various embodiments, a second buoy may be placed in the container with the first. The extraction system is connected to the buoy system or to the collection chamber such that the fraction in the container can be collected and drawn outside of the chamber. During the centrifuge processing, the buoy is forced away from a bottom of the container as the denser fraction collects at the bottom of the container. The buoy is generally able to physically separate the denser fraction from another fraction of the sample. In various embodiments, the fractions can be withdrawn using an extraction system.
- According to various embodiments, in addition to providing a first buoy and/or a second buoy, a buoy system may be provided. Generally, the buoy system may separate the sample into at least three fractions. The fractions may be separated and extracted from the container without substantially commingling the various fractions. Generally, a first buoy and a second buoy operate together to separate the sample into the various fractions and a syringe or tube may then be interconnected with a portion of the buoy system to extract the selected fractions. For example, a first buoy may be tuned to a density less than the density of a red blood cell fraction of a whole blood sample, bone marrow aspirate sample, or combinations thereof, and a second buoy may be tuned to a density less than the density of a buffy coat fraction.
- According to various embodiments, a method of forming an enriched scaffold for application relative to an anatomy is provided. The method may include obtaining a volume of a first whole material and obtaining a volume of a second whole material. A first fraction of the first whole material and a second fraction of the second whole material may be formed. At least one of the first fraction or the second fraction may be applied to the scaffold and at least one fraction for application relative to an anatomy is provided. The method may include obtaining a volume of heterogeneous whole material and separating the material into the desired fraction(s). At least one of the fractions may be applied to the scaffold.
- According to various embodiments, a method of withdrawing a material directly from a patient and collecting a selected fraction of the material in a container is provided. The method may include forming an access to port to the patient. A pressure differential in a collection container may be formed relative to the patient. A connection may be made between the patient and the collection container via the port. The collection container may be filled with the material and then the material may be separated to form the selected fraction.
- According to various embodiments, a method for concentrating bone aspirate can include obtaining a volume of bone marrow aspirate from a mammal and loading the volume bone marrow aspirate into a separator, the separator operable to separate the aspirate into three of more fractions. The method also includes centrifuging the separator to create a fraction that is a concentrated bone marrow aspirate and extracting and removing the fraction from the separator.
- According to various embodiments, a method for concentrating bone marrow aspirate and blood includes collecting bone marrow aspirate and blood from a patient then loading the bone marrow aspirate and blood into a separator that can separate the aspirate and the blood into three or more fractions. The method includes centrifuging the separator containing the bone marrow aspirate and the blood creating a fraction that has a concentrated bone marrow aspirate and a concentrated blood. In various embodiments, such a concentration may be referred to as a buffy coat. The method also include withdrawing the fraction comprising the concentrate or buffy coat.
- According to various embodiments, a method for treating a defect in a mammal using a concentrated bone marrow aspirate includes drawing bone marrow aspirate from the mammal and loading the bone marrow aspirate into a separator that can separate the bone marrow aspirate into three or more fractions. The method includes centrifuging the separator separating the bone marrow aspirate into fractions and one fraction is concentrated bone marrow aspirate. The method also can include the concentrated bone marrow aspirate and applying the bone marrow aspirate to a site of a defect in the mammal.
- According to various embodiments, a method for treating a defect in a patient includes drawing bone marrow aspirate and whole blood from the patient then adding anticoagulants to the bone marrow aspirate and the blood. The method includes the loading of the bone marrow aspirate and the blood into a separator that can separate the bone marrow aspirate and blood into three or more fractions. The method also includes centrifuging the separator then withdrawing a fraction comprising at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells, then applying the fraction to the site of the defect in the patient.
- According to various embodiments, a method of treating a patient with a combination of concentrated bone marrow aspirate and buffy coat is provided. The method includes obtaining blood and bone marrow aspirate from the patient, forming a buffy coat fraction of the whole blood and forming a concentrated bone marrow aspirate fraction, and applying at least one of the buffy coat or concentrated bone marrow aspirates to the patient.
- Further areas of applicability of the present teachings will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating various embodiment of the teachings, are intended for purposes of illustration only and are not intended to limit the scope of the teachings.
- The present teachings will become more fully understood from the detailed description and the accompanying drawings, wherein:
-
FIG. 1 is a plan view of a separator including a depth gage affixed to a plunger in a tube according to various embodiments of the present teachings; -
FIG. 2 is a cross-section view taken along line 2-2 ofFIG. 1 ; -
FIG. 3 is an exploded of the separator apparatus according to various embodiments; -
FIG. 4 is a kit including the separator according to an embodiment of the present teachings; -
FIG. 5A is a plan view of the separator, according to various embodiments, being filled; -
FIG. 5B is a plan view of a blood sample in the separator after the centrifuge process; -
FIG. 5C is a plan view of the plunger plunged into the tube with the depth gage to further separate the blood sample; -
FIG. 5D is a plan view of the buffy coat and the plasma fractions being extracted from the separator according to various embodiments; -
FIG. 6A is a side plan view of a buoy system according to various embodiments; -
FIG. 6B is a cross-sectional view of the buoy system ofFIG. 6 a; -
FIG. 7A is a plan view of a separator, according to various embodiments, being filled; -
FIG. 7B is a plan view of a separator, according to various embodiments, after a centrifugation process; -
FIG. 7C is a plan view of a separator system, according to various embodiments, being used to extract a selected fraction after the centrifugation process; -
FIG. 7D is a plan view of a second fraction being extracted from the separator according to various embodiments; -
FIG. 8 is a schematic view illustrating an assisted blood withdrawal device according to various embodiments; and -
FIG. 9 is a block diagram illustrating a method for applying selected fractions of a fluid. - The following description of various embodiments is merely exemplary in nature and is in no way intended to limit the teachings, its application, or uses. Although the following description exemplary refers to a bone reaming material, whole blood and/or bone marrow aspirate separation, it will be understood that the present teachings may be used to separate and concentrate any appropriate material. It will be further understood that many multi-component materials containing particles may be separated. The components or fractions are generally intermingled in the whole sample but may be separated with a centrifuge device that causes increased local gravity or gravitational forces.
- With reference to
FIGS. 1-3 , according to various embodiments, aseparator 10, also referred to as a concentrator, is illustrated. Theseparator 10 generally includes a tube orcontainer 12 that is adapted to hold a fluid sample, such as an anti-coagulated whole blood sample, for further processing. It will be understood that thetube 12 may hold other solutions including constituents of more than one density, such as bone marrow or a mixture of whole blood and bone marrow. Thetube 12 includes a top oropen end 12 a, which is closeable, and a bottom orclosed end 12 b. The bottom 12 b may also be selectively closeable. - Disposed within the
tube 12 is a first piston or buoy 14 that is able to move along a central axis A of thetube 12. Thebuoy 14 is generally nearer thebottom end 12 b of thetube 12 rather than theopen end 12 a. Thebuoy 14 is able to move along a central axis A oftube 12. Also disposed within thetube 12 is a second piston orplunger 16. Theplunger 16 is also able to move within thetube 12 generally between a position closer to theopen end 12 a to a position closer to theclosed end 12 b of thetube 12. Acap 18 substantially mates with theopen end 12 a of thetube 12 to close thetube 12 save for ports formed in thecap 18. Extending from thecap 18 is a plasma valve orport 20 that communicates with an area, described further herein, within thetube 12 defined between theplunger 16 and thecap 18. It will be understood that theplasma port 20 is merely exemplary in nature and simply allows for removal of a selected fraction of a sample such as, for example, plasma from whole blood. - The
cap 18 also includes adepth gage port 19. Extending from theplunger 16 and through thedepth gage port 19 is afirst plunger port 22. A depth guide orgage 24 includes afemale connector 26 adapted to connect with thefirst plunger port 22. Thedepth gage 24 also includes a depth gage housing orcannula 28. Thedepth gage housing 28 defines a depth gage bore 30. Incorporated in thedepth gage housing 28 and extending distal from the end mating with theplunger 16 is aneck 32. Theneck 32 includesexternal neck threads 34. Theexternal neck threads 34 are adapted to engage appropriate internal threads of a mating member. - The mating member may include a
compression nut 36 that mates with theexternal neck threads 34 to lock adepth gage rod 38 in a predetermined position. Asplit bushing 39 is also provided to substantially seal thedepth gage housing 28 when thedepth gage rod 38 is locked in place. Thedepth gage rod 38 extends through thedepth gage housing 28 and terminates at arod handle 40. The rod handle 40 may be a form easily manipulated by a human operator. Thedepth gage rod 38 extends coaxially with axis A of thetube 12. Thedepth gage rod 38 extends through the plunger 16 a predetermined distance and may be locked at that distance with thecompression nut 36. - Although the
tube 12 is described herein as a cylinder, it will be understood that other shapes may be used, such as polygons. The internal portions, such as thecap 18,buoy 14, andplunger 16, would also include this alternate shape. Preferably thetube 12 is formed of a thermal plastic material which is flexible under the forces required to separate blood. Thetube 12 may be made of a material that includes the properties of both lipid and alcohol resistance. These properties helps increase the separation speed and decrease the amount of material which may cling to thetube wall 42. For example, Cyrolite MED2® produced by Cyro Industries of Rockaway, N.J., may be used to produce thetube 12. - The
tube 12 has atube wall 42 with a thickness of between about 0.01 millimeters and about 30.0 millimeters, although thetube wall 42 may be any appropriate thickness. The thickness of thetube wall 42 allows thetube wall 42 to flex during the centrifuge process yet be rigid enough for further processing of a blood sample disposed in thetube 12. Thetube 12 is closed at thebottom end 12 b with a tube bottom 44 formed of the same material as thetube wall 42 and is formed integrally therewith. Generally, the tube bottom 44 has a thickness which is substantially rigid under the forces required to separate the sample such that it does not flex. - The
buoy 14 includes an upper or collection face 46 that defines an inverse cone or concave surface. Generally, the cone has an angle of between about 0.5° to about 45°, and may be about 0.5° to about 90° from a vertical axis, wherein the apex of the cone is within thebuoy 14. The collection face 46 forms a depression in thebuoy 14 which collects and concentrates material during the separation process. Additionally, thebuoy 14 has abottom face 48 that defines an inverse cone, dome, or covered surface. Thebuoy bottom face 48 includes an apex 50 that engages the tube bottom 44 before abuoy edge 52 engages thetube bottom 44. Thebuoy 14 includes a material that is a substantially rigid such that the buoy edges 52 never meet thetube bottom 44. Therefore, there is a gap orfree space 54 formed between the buoy edges 52 and the tube bottom 44 along the perimeter of thebuoy 14. - The
separator 10 is generally provided to separate a multi-component fluid that generally includes various components or constituents of varying densities that are commingled or mixed together. Theseparator 10 includes thebuoy 14 that is of a selected density depending upon a selected constituent of the multi-constituent liquid. Although thebuoy 14 may be tuned or of any selected density, the following example relates to separation of whole blood to various components. Therefore, thebuoy 14 will be discussed to include a selected density relative to whole blood separation. It will be understood, however, that thebuoy 14 may be of any appropriate density depending upon the multi-component fluid being separated including, for example, the concentrating of bone marrow aspirate. - The
buoy 14 may be formed of any appropriate material that may have a selected density. For example, when theseparator 10 is to separate blood, thebuoy 14 generally has a density which is greater than that of red blood cells in a whole blood sample, but less than the plasma or non-red blood cell fraction of a whole blood sample. For blood, the density of thebuoy 14 may be between about 1.00 g/cc to about 1.12 g/cc or between about 1.02 g/cc and about 1.09 g/cc. - To achieve the selected density, the
buoy 14 may be formed as a composite or multi-piece construction, including a plurality of materials. Particularly, a first oroutside portion 56 defines the upper orcollection face 46 and the buoy edges 52 and is formed of the same material as thetube 12. Theoutside portion 56 defines a cup or void into which a plug or insert 58 is placed. Theinsert 58 has a mass such that the density of theentire buoy 14 is within the selected range, for example, the range described above. Generally, a high density polyethylene may be used, but the material and size of theinsert 58 may be altered to produce the desired density of thebuoy 14. Alternatively, thebuoy 14 may be formed of a single suitable material that has a density in the selected range. Nevertheless, thebuoy 14 formed unitarily or of a single material would still include the other portions described in conjunction with thebuoy 14. - The
outside portion 56 of thebuoy 14 also defines the outside circumference of thebuoy 14. The outside circumference of thebuoy 14 is very close to the internal circumference of thetube 12. Due to the operation of thebuoy 14, however, described further herein, there is a slight gap between the outside of thebuoy 14 and the inside of thetube 12. Generally, this gap is between about 1 and about 10 thousandths of an inch around the entire circumference of thebuoy 14. Generally, it is desired that the distance between the outside circumference of thebuoy 14 and the inside circumference of thetube 12 is great enough to allow a selected material or component to pass. For example, in whole blood the distance is selected so that red blood cells may pass through the gap without being lysed, damaged, or activated. - The
plunger 16 includes a plunger front orcollection face 60 and aplunger wall 62 that extends from theplunger front face 60. Theplunger wall 62 extends relatively perpendicular to theplunger front face 60 and substantially parallel to thetube wall 42. Extending from the center of theplunger 16 is asample collection projection 64. Extending from the top of thesample collection projection 64 is thefirst plunger port 22. Thesample collection projection 64 includes a plunger sample collection bore 68 defined therethrough. The plunger sample collection bore 68 terminates at asample collection aperture 70 that is substantially in the center of theplunger front face 60. Theplunger front face 60 also defines an inverse cone where thesample collection aperture 70 is the apex of the cone. Theplunger front face 60 defines a cone with an angle substantially similar or complimentary to thecollection face 46 of thebuoy 14. In this way, theplunger front face 60 may mate substantially completely with thecollection face 46 for reasons described more fully herein. - The
plunger 16 also includes aback face 72. Extending from theplunger front face 60 to theback face 72 is abore 74. Acheck valve 76 is operably connected to thebore 74. Thecheck valve 76 allows a liquid to move from theplunger front face 60 to theback face 72 while not allowing the liquid to move from theback face 72 to theplunger front face 60. Therefore, thecheck valve 76 is substantially a one-way valve which allows a material to move in only one direction. Thecheck valve 76 may also operate automatically allowing flow in only one predetermined direction. Alternatively, thecheck valve 76 may be operated manually and include a portion extending from thecheck valve 76 requiring manipulation to stop or start a flow through thecheck valve 76. - The
plunger 16 may be made out of any appropriate material which does not interfere with the separation of the fractions of the fluid, such as whole blood. Theplunger 16, however, is made of a material that is flexible or at least partially deformable. A flexible material allows theplunger 16 to have an external circumference defined by theplunger walls 62 that is substantially equal to the internal circumference of thetube 12. Because of the deformability of theplunger 16, however, theplunger 16 is still able to move within thetube 12. Theplunger 16 is able to move through thetube 12 and also substantially wipe the interior of thetube wall 42. This creates, generally, a moveable seal within thetube 12. Thus, substantially no material escapes the action of theseparator 10 when theplunger 16 is plunged into thetube 12. This also helps concentrate the portion of the sample desired to be collected, described more fully herein. - The
cap 18 provides a structure to substantially close thetube 12. Thecap 18 particularly includes aplate 78 that has an external circumference substantially equal to the external circumference of thetube 12. Extending from theplate 78 and into thetube 12 is aflange 80. The external circumference of theflange 80 is substantially equal to the internal circumference of thetube 12. In this way, thecap 18 substantially closes thetube 12. It will be understood thecap 18 may be in any form so long as thecap 18 substantially closes and/or seals thetube 12 when installed. - Formed through the center of the
plate 78 is thedepth gage port 19. Thedepth gage port 19 is also adapted to receive thesample collection projection 64. Thefirst plunger port 22 extends above theplate 78 through thedepth gage port 19. The circumference of thedepth gage port 19 is substantially equal to the external circumference of thesample collection projection 64 such that a liquid seal is formed. Theplate 78 defines asample face 84 that includes an interior side of thecap 18. The area between thesample face 84 of thecap 18 and theback face 72 of theplunger 16 define aplasma collection area 86. Although theplasma collection area 86 is exemplary called the plasma collection area, it will be understood that theplasma collection area 86 may also collect any appropriate fraction of the sample that is positioned within aseparator 10. Theplasma collection area 86 is merely an exemplary name and an example of what material may be collected in the area of theseparator 10. As discussed herein, theseparator 10 may used to separate whole blood into various fractions, therefore, theplasma collection area 86 is used to collect plasma. Theplasma collection area 86 also allows a space for thecheck valve 76 to be installed. - A second bore 88 is formed in the
plate 78. Extending through the second bore 88 is theplasma collection valve 20. In liquid communication with theplasma collection valve 20 is aplasma collection tube 92. Theplasma collection tube 92 has a length such that theplasma collection tube 92 is able to extend from theplasma collection valve 20 to substantially thetube bottom 44. Theplasma collection tube 92, however, is flexible enough such that it may be folded or compressed to fit within theplasma collection area 86 when theplunger 16 is substantially near theopen end 12 a of thetube 12. Theplasma collection tube 92 may also be connected to ahose barb 93 that includes a plasma collection bore 93 a. The plasma collection bore 93 a is substantially level with the plunger backface 72. Alternatively, the plasma collection bore 93 a may be positioned below the plunger back face 72 but in fluid communication with theplasma collection tube 92. - The outboard side of the
plasma collection valve 20 may include external threads 94 to mate with internal threads of aplasma valve cap 96. Therefore, theplasma collection valve 20 may be selectively opened and closed via theplasma valve cap 96. It will be understood, however, that other appropriate means may be used to open and close theplasma collection valve 20 such as a clip or a plug. It will be understood that theplasma collection valve 20,plasma collection tube 92, plasma collection bore 23 a may be used to collect any appropriate material or fraction from theseparator 10. - Also formed in the
plate 78 is a vent bore 98. The vent bore 98 allows air to flow into theplasma collection area 86 as theplunger 16 is being plunged into thetube 12. The vent bore 98 may include afilter 100 such that liquid cannot escape from thetube 12. Thefilter 100 allows air to enter or escape from theplasma collection area 86 while maintaining the liquid seal of thetube 12 produced by thecap 18. - Selectively attachable to the
first plunger port 22 is thedepth gage 24. Thefemale connector 26 interconnects thedepth gage housing 28 to thefirst plunger port 22. Internal threads in thefemale connector 26 mate with anexternal thread 102 formed on thefirst plunger port 22. It will be understood, however, that other engagement mechanisms between thedepth gage 24 and theplunger 16 may be used. For example, a snap connection rather than a threaded connection between the two may be used. - The
depth gage housing 28 is formed to be substantially rigid. Suitable materials, when sized properly, include polycarbonate and CYRO MED2®. The material preferably is both rigid and does not substantially react with the sample. It is rigid enough to provide a mechanism to plunge theplunger 16 into thetube 12. In addition, the external circumference of thedepth gage housing 28 is substantially equal to the circumference of thedepth gage port 19 in theplate 78. Therefore, as theplunger 16 is being plunged into thetube 12 with thedepth gage 24, no liquid material is allowed to escape around thedepth gage housing 28 and throughdepth gage port 19. - Formed within the
depth gage housing 28 is thebore 30 which receives thedepth gage rod 38. Thedepth gage rod 38 extends through the plunger sample collection bore 68 of thesample collection projection 64 and protrudes through the sample collection aperture 70 a predetermined length. Thedepth gage rod 38 extends through the sample collection aperture 70 a length such that when anend 104 of thedepth gage rod 38 meets thebuoy 14, the volume defined by thecollection face 46 and theplunger front face 60 is between about 5% and about 30% of the total volume of the sample that thetube 12 holds. The projection of thedepth gage rod 38 allows for an easily reproducible collection amount and concentration over several trials. - The
compression nut 36 locks thedepth gage rod 38 in the predetermined position. Nevertheless, once theplunger 16 has been plunged to the desired depth in thetube 12, thecompression nut 36 may be loosened so that thedepth gage rod 38 may be removed from theplunger 16 and thedepth gage housing 28 without moving theplunger 16. A syringe or other appropriate device may then be affixed to theexternal neck threads 34 of thedepth gage 24 to extract the fraction or phase that is between theplunger front face 60 and thecollection face 46. As described further herein, the fraction or phase that is left between theplunger front face 60 and thecollection face 46 may be the buffy coat of a whole blood sample. Nevertheless, it will be understood that the fraction between theplunger front face 60 and thecollection face 46 may be any appropriate fraction of the sample that is disposed in theseparator 10. - The
separator 10 may be provided alone or in akit 200, as illustrated inFIG. 4 . Thekit 200 may be placed in atray 202 which is covered to provide a clean or sterile environment for the contents of thekit 200. Thekit 200 may include at least afirst separator 10 and asecond separator 10′. Afirst depth gage 24 and asecond depth gage 24′ are also provided, one for eachseparator kit 200 also generally includes afirst syringe 204, including a needle, to draw a biological sample, such as blood from a patient. Thefirst syringe 204 may also be used to place the sample in thefirst separator 10. After centrifuging the sample a second device orsyringe 210 may be used to extract a first fraction of the sample, while a third device orsyringe 212 may be used to extract a second fraction of the sample. Also, atourniquet 214 and other medical supplies, such asgauze 216 andtape 218, may be provided to assist the practitioner. It will be understood the elements of thekit 200 are merely exemplary and other appropriate items or elements may be included. - With reference to
FIGS. 5A-5D , a method using theseparator 10 is illustrated according to various embodiments. The following example relates specifically to the taking and separating of a sample of whole blood from a patient. Nevertheless, it will be understood that another appropriate biological material may be separated and concentrated using theseparator 10. For example, bone marrow may be separated and concentrated using theseparator 10. The various fractions of the bone marrow are similar to the fractions of whole blood. Generally, the bone marrow includes a fraction that includes substantially dense material and a second phase that is less dense and has other components suspended therein such as, for example, nucleated cells. The bone marrow sample may be positioned in theseparator 10, similarly to the whole blood as described herein, and separated in a substantially similar manner as the whole blood. Theseparator 10 can then be used to remove nucleated cells from the bone marrow sample (which may be referred to as buffy coat), whereas theseparator 10, as described herein, is used to remove the buffy coat from the whole blood which includes platelets and other appropriate materials (which may be referred to as platelet rich plasma (PRP)). - A mixture of whole blood and bone marrow may be positioned in the
separator 10 for separation and concentration. Similar methods and steps will be used to separate the mixture of whole blood and bone marrow with a main difference being the material that is separated. It will also be understood that various centrifuge times or forces may be altered depending upon the exact material that is being separated with theseparator 10. It will also be understood that the separation of whole blood, bone marrow, or a mixture of whole blood and bone marrow are merely exemplary of the materials that may be separated using theseparator 10. - According to various embodiments, and with reference to
FIGS. 5A-5D and to a whole blood sample, a sample of whole blood taken from a patient is placed in thetube 12 with an anticoagulant using thefirst syringe 204 or other appropriate delivery method. In particular, thefirst syringe 204 may be connected to thefirst plunger port 22. After which the blood sample is provided to thetube 12 via the sample collection bore 68 andsample collection aperture 70. Acap 220 is then placed over thefirst plunger port 22 to substantially seal thetube 12. - After the whole blood sample is delivered to the
tube 12, theseparator 10 is placed in a centrifuge. Thesecond separator 10′, substantially identical to the first, is placed opposite thefirst separator 10 including the sample in a centrifuge. Thesecond separator 10′ may also include a second sample or may include a blank, such as water, so that the centrifuge is balanced. Thesecond separator 10′ balances the centrifuge by both weight and dynamics. - The
separator 10 is then spun in the centrifuge in a range between about 1,000 and about 8,000 RPM. This produces a force between about 65 and about 4500 times greater than the force of normal gravity, as generally calculated in the art, on theseparator 10 and the blood sample placed in theseparator 10. At this force, the more dense material in a whole blood sample is forced toward thebottom end 12 b of thetube 12. The dense material, such as red blood cells or a redblood cell fraction 222, collects on thetube bottom 44. Because thebuoy 14 has a density that is less than the redblood cell fraction 222, it is forced in a direction toward thetop end 12 a of thetube 12 in the centrifuge. Nevertheless, because thebuoy 14 is denser than aplasma fraction 224, thebuoy 14 does not reach thetop end 12 a of thetube 12. - The forces also affect the
tube wall 42. The forces compress thetube 12 linearly along axis A thereby bowing or flexing thetube wall 42. As thetube wall 42 compresses it increases the diameter of thetube 12 making it easier for thebuoy 14 to move in the direction of the top 12 a of thetube 12. In addition, thebottom face 48, defining an inverse cone, helps the initial movement of thebuoy 14. Because thebuoy 14 is not substantially flat along its bottom, it does not form a vacuum interaction with thetube bottom 44. Therefore, the initial movement of thebuoy 14 away from the tube bottom 44 is quicker than if the bottom of thebuoy 14 was flat. - During the centrifuge process, the red bloods cells of the red
blood cell fraction 222 force thebuoy 14 in the direction of thetop end 12 a of thetube 12 because thebuoy 14 is less dense than the redblood cell fraction 222. Although the whole blood sample, including the red blood cells, is loaded above thebuoy 14, the red blood cells are able to move between thebuoy 14 and thetube wall 42 because the circumference of thebuoy 14 is less than the internal circumference of thetube 12. During the centrifuge process, thebuoy 14 stops at an interface of aplasma fraction 224 and the redblood cell fraction 222 because of the selected or tuned density of thebuoy 14. - With particular reference to
FIG. 5B , the centrifuge process has been completed and thebuoy 14 has moved to the interface of the redblood cell fraction 222 andplasma fraction 224. After the centrifuge has slowed or stopped, and before or after thetube 12 has been removed from the centrifuge, thetube wall 42 decompresses which helps support thebuoy 14 at the interface position. It is also understood that applying an external pressure to thetube 12 via fingers or another apparatus may help stabilize thebuoy 14 during the plunging procedure described herein. - On or
near collection face 46 is amiddle fraction 226, including a small, yet concentrated, amount of red blood cells, white blood cells, platelets, and a substantial portion of a buffy coat of the blood sample. Although the plasma is also present near thecollection face 46 at this point, the solid portions of the buffy coat are more compressed against thecollection face 46. The position of thebuoy 14 also helps in this matter. Because thebuoy 14 is a single body it defines the interface of theplasma fraction 224 and the redblood cell fraction 222. Also the density of thebuoy 14 assures that it has not passed into theplasma fraction 224. Therefore, the fractions remain separated after the centrifuge process. In addition because thebuoy 14 is tuned to the density of the redblood cell fraction 222, it is not affected by variations in the density of theplasma fraction 224 and the buoy's 14 position is always at the interface of the redblood cell fraction 222 and theplasma fraction 224. - With particular reference to
FIG. 5C , thedepth gage 24 is affixed to thefirst plunger port 22 of thesample collection projection 64. After connecting thedepth gage 24 to thefirst plunger port 22, theplunger 16 is plunged into thetube 12 by pushing on thedepth gage 24. As this is performed theplasma fraction 224, formed and separated above thebuoy 14, is able to flow through thecheck valve 76 into theplasma collection area 86. This displacement of theplasma fraction 224 allows theplunger 16 to be plunged into thetube 12 containing the blood sample. - The
plunger 16 is plunged into thetube 12 until the point where theend 104 of thedepth gage rod 38 reaches thebuoy 14. The volume left in thecollection face 46 is themiddle fraction 226 and is determined by thedepth gage 24. It may be adjusted by selectively determining the amount that thedepth gage rod 38 extends below theplunger front face 60. By adjusting thedepth gage 24, the concentration of themiddle fraction 226 can be adjusted depending upon the desires of the operator. - The
plasma fraction 224 is held in theplasma collection area 86 for later withdrawal. Therefore, the use of theplunger 16 and thebuoy 14 creates three distinct fractions that may be removed from thetube 12 after only one spin procedure. The fractions include the redblood cell fraction 222, held between thebuoy 14 and thetube bottom 44. The middle orbuffy coat fraction 226 is held between theplunger 16 and thebuoy 14. Finally, theplasma fraction 224 is collected in theplasma collection area 86. In various embodiments, themiddle fraction 226 may be a platelet rich plasma (PRP) fraction and theplasma fraction 224 may be a platelet poor plasma (PPP) fraction. - The
middle fraction 226 may be extracted from thetube 12 first, without commingling the other fractions, through the sample collection bore 68. With particular reference toFIG. 5D , thedepth gage rod 38 may be removed from thedepth gage housing 28. This creates a sample collection cannula which includes the depth gage bore 30, the sample collection bore 68, and thesample collection aperture 70. After thedepth gage rod 38 has been removed, thesecond syringe 210 may be affixed to thedepth gage housing 28 via theexternal neck threads 34. Thesecond syringe 210 may be substantially similar to thefirst syringe 204. - Before attempting to withdraw the
middle fraction 226 theseparator 10 may be agitated to re-suspend of the platelets and concentrated red blood cells in a portion of the plasma remaining in thecollection face 46. This allows for easier and more complete removal of themiddle fraction 226 because it is suspended rather than compressed against thecollection face 46. A vacuum is then created in thesecond syringe 210 by pulling back theplunger 16 to draw themiddle fraction 226 into thesecond syringe 210. - As the
middle fraction 226 is drawn into thesecond syringe 210 theplunger 16 moves toward thebuoy 14. This action is allowed because of the vent bore 98 formed in thecap 18. Atmospheric air is transferred to theplasma collection area 86 through the vent bore 98 to allow themiddle fraction 226 to be removed. This also allows the movement of theplunger 16 toward thebuoy 14. This action also allows theplunger 16 to “wipe” thecollection face 46. As theplunger front face 60 mates with thecollection area 46 themiddle fraction 226 is pushed into thesample collection aperture 70. This ensures that substantially the entiremiddle fraction 226 collected in thecollection area 46 is removed into thesecond syringe 210. It can also increase the repeatability of the collection volumes. In addition, because thesecond syringe 210 does not protrude out thesample collection aperture 70, it does not interfere with the collection of themiddle fraction 226. Once theplunger front face 60 has mated with thecollection face 46 there is substantially no volume between theplunger 16 and thebuoy 14. - Once the
middle fraction 226 is extracted thesecond syringe 210 is removed from thefirst plunger port 22. Also the extraction of themiddle fraction 226 leaves theplasma fraction 224 and the redblood cell fractions 222 separated in thetube 12. At this point, athird syringe 212 may be affixed to theplasma collection valve 20. Thethird syringe 212 is connected to the external threads 94 of theplasma collection valve 20 to ensure a liquid tight connection. It will be understood, however, that another connection mechanism such as a snap or compression engagement may be used to connect thethird syringe 212 to theplasma collection valve 20. - A vacuum is then created in the
third syringe 212 to draw theplasma fraction 224 from theplasma collection area 86 through theplasma collection tube 92. As discussed above, theplasma collection tube 92 is connected to thehose barb 93. Therefore, the plasma flows through the plasma collection bore 93 a through thehose barb 93, and then through theplasma collection tube 92. It will be understood that theplasma collection tube 92 may alternatively simply rest on the plunger back face 72 to collect theplasma fraction 224. In this way, theplasma fraction 224 may be removed from theblood separator 10 without commingling it with the redblood cell fraction 222. After theplasma fraction 224 is removed, theseparator 10 may be dismantled to remove the redblood cell fraction 222. Alternatively, theseparator 10 may be discarded in an appropriate manner while retaining the redblood cell fraction 222. - The
separator 10 allows for the collection of three of a whole blood sample's fractions with only one centrifugation spin. The interaction of thebuoy 14 and theplunger 16 allows a collection of at least 40% of the available buffy coat in the whole blood sample after a centrifuge processing time of about 5 minutes to about 15 minutes. The complimentary geometry of theplunger front face 60 and thecollection face 46 help increase the collection efficiency. Although only the cone geometry is discussed herein, it will be understood that various other geometries may be used with similar results. - The
plunger front face 60 being flexible also helps ensure a complete mating with thecollection face 46. This, in turn, helps ensure that substantially the entire volume between the two is evacuated. The process first begins with the suction withdrawal of themiddle fraction 226 via thesecond syringe 210, but is completed with a fluid force action of themiddle fraction 226 as theplunger front face 60 mates with thecollection face 46. As theplunger front face 60 mates with thecollection face 46, the fluid force assists in removal of the selected fraction. - The
plunger 16 also substantially wipes thetube wall 42. Because theplunger 16 is formed of a flexible material it forms a seal with thetube wall 42 which is movable. Therefore, substantially no liquid is able to move between theplunger wall 62 and thetube wall 42. Material is substantially only able to go past theplunger front face 60 via thecheck valve 76. - The complimentary geometry also helps decrease the collection time of the
middle fraction 226. Therefore, entire time to prepare and remove themiddle fraction 226 is generally about 5 to about 40 minutes. This efficiency is also assisted by the fact that theseparator 10 allows for the removal of themiddle fraction 226 without first removing theplasma fraction 224, which includes the buffy coat, and re-spinning theplasma fraction 224. Rather, one spin in theseparator 10 with the whole blood sample allows for the separation of the buffy coat for easy extraction through theplunger 16. - As discussed above, the
separator 10 may be used to separate any appropriate multi-component material. For example, a bone marrow sample may be placed in theseparator 10 to be centrifuged and separated using theseparator 10. The bone marrow sample may include several fractions or components that are similar to whole blood fractions or may differ therefrom. Therefore, thebuoy 14 may be altered to include a selected density that is dependent upon a density of a selected fraction of the bone marrow. The bone marrow may include a selected fraction that has a different density than another fraction and thebuoy 14 may be designed to move to an interface between the two fractions to allow for a physical separation thereof. Similar to the whole blood fraction, theplunger 16 may then be moved to near acollection face 46 of thebuoy 14. The fraction that is then defined by thecollection face 46 and theplunger 16 may be withdrawn, as described for the removal of the buffy coat from the whole blood sample. For example, themiddle fraction 226 in the bone marrow sample may include a fraction of undifferentiated or stem cells. In various embodiments, themiddle fraction 226 in a bone marrow sample may include hematopoietic, stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, or endothelial cells. In various embodiments, themiddle fraction 226 is concentrated bone marrow aspirate. - It will also be understood that mixtures of various fluids may be separated in the
separator 10. For example, a mixture of whole blood and bone marrow may be positioned in theseparator 10 at a single time. Thebuoy 14 may be tuned to move to an interface that will allow for easy removal of both the buffy coat, from the whole blood sample, and the undifferentiated cells, from the bone marrow sample. Nevertheless, it will be understood that theseparator 10 may be used within any appropriate biological material or other material having multiple fractions or components therein. Simply, thebuoy 14 may be tuned to the appropriate density and theplunger 16 may be used to cooperate with thebuoy 14 to remove a selected fraction. - According to various embodiments and with reference to
FIGS. 6A and 6B , abuoy system 300 is illustrated. Thebuoy system 300 generally includes a first buoy orfraction separator member 302 and a second buoy member orfraction separator 304. Thefirst buoy 302 and thesecond buoy 304 may be operably interconnected with a buoy system cylinder ormember 306. Thebuoy system 300 may be placed in a tube, such as thetube 12. Thetube 12 may be formed of any appropriate material, such as theCryolite Med® 2 as discussed above. Nevertheless, thebuoy system 300 may be designed to fit in thetube 12 or may be formed to fit in any appropriate member that may be disposed within a selected centrifuging device. It will be understood that the following discussion relating to buoysystem 300 to be substantially matched to the size of thetube 12 is merely exemplary. As thebuoy 14 may be sized to fit in any appropriate tube, thebuoy system 300 may also be sized to fit in any appropriate tube. It will be further understood that thetube 12 may be any appropriate shape. Thetube 12 need not only be cylindrical but may also be or include conical portions, polygonal portions, or any other appropriate shapes. - The
first buoy 302 of thebuoy system 300 may be generally similar in geometry to thebuoy 14. It will be understood that thefirst buoy member 302 may be formed in the appropriate manner including shape or size to achieve selected results. Nevertheless, thefirst buoy member 302 generally includes an exterior diameter that may be slightly smaller than the interior diameter of thetube 12. Therefore, thefirst buoy member 302 may be able to move within thetube 12 during the centrifugal process. Also, as discussed above, thetube 12 may flex slightly during the centrifuging process, thus allowing thefirst buoy member 302 to include an exterior diameter substantially equivalent to the interior diameter of thetube 12. As discussed further herein, during the centrifugation process, a portion of the fraction of a sample may pass between the exterior wall of thefirst buoy member 302 and thetube 12. - The
first buoy member 302 may generally include a density that is substantially equivalent to a first or selected fraction of the sample. If the sample to be separated includes whole blood and is desired to separate the red blood cells from the other portions of the sample, thefirst buoy member 302 may have a selected density that may be about 1.00 grams per cc (g/cc) to about 1.10 g/cc. It will be understood that the density of thefirst buoy member 302 may be any appropriate density, depending upon the fraction to be separated, and this range of densities is merely exemplary for separating red blood cells from a whole blood sample. - In addition, the
first buoy member 302 includes a collection face orarea 308 at a proximal or upper portion of thefirst buoy member 302. Thecollection face 308 generally defines a concave area of thefirst buoy member 302 and may have a selected angle of concavity. Thebuoy assembly 300 defines a central axis D. Thecollection face 308 defines a surface E that is formed at an angle γ to the central axis D of thebuoy system 300. The angle γ may be any appropriate angle and may be about 0.5° to about 90°. The angle γ may, however, be between about 45° and 89.5°. Nevertheless, it will be understood that the angle γ may be any appropriate angle to assist in collection of a selected fraction or portion of the sample by thefirst buoy member 302. - A bottom or
lower surface 310 of thefirst buoy member 302 may define a bottom face. Thebottom face 310 may also be formed at an angle D relative to the central axis D. Thebottom surface 310 defines a surface or plane F that may be formed at an angle Δ relative to the central axis D of thebuoy system 300. The angle Δ may be any appropriate angle and may be about 90° to about 160°. For example, the angle Δ may be about 15°. Similarly to thebuoy bottom face 48, thebottom surface 310 defines an apex 312 that may first engage the bottom 12 d of thetube 12, such that most or the majority of thebottom surface 310 does not engage thetube 12. As illustrated further herein, the apex 312 allows for a free space or gap to be formed between thebottom face 310 of thefirst buoy member 302 and the bottom 12 b of thetube 12. - The
second buoy member 304 may include an outer diameter substantially equivalent to the outer diameter of thefirst buoy member 302. Therefore, thesecond buoy 304 may move with thefirst buoy 302, particularly if thesecond buoy 304 is interconnected with thefirst buoy 302 with the buoycentral cylinder 306. Nevertheless, thesecond buoy member 304 may be allowed to move substantially freely within thetube 12 during the centrifuging process. - The
second buoy member 304 also includes an upper orsuperior surface 314 that defines a plane G that is formed at an angle relative to the central axis D of thebuoy system 300. The angle c of the plane G relative to the central axis D of thebuoy system 300 may be any appropriate angle. For example, the angle ε may be about 90° to about 150°. Generally, the angle ε may assist in allowing a selected fraction or a portion of the sample to pass over thetop surface 314 and past thesecond buoy member 304 during the centrifuging process. - The
second buoy member 304 also define a bottom orinferior surface 316 that also defines a plane H that may be formed at an angle K relative to the central axis D of thebuoy system 300. The angle K may be any appropriate angle, such as about 90° to about 150°. Nevertheless, the angle K may be substantially complimentary to the angle γ of thecollection face 308 of thefirst buoy member 302. For example, if the angle γ is about 80°, the angle K may be about 100°, such that substantially 180° or a straight line is formed when thefirst buoy member 302 engages thesecond buoy member 304. This may be for any appropriate reason, such as extraction of a fraction that may be disposed near thecollection face 308 of thefirst buoy member 302. Nevertheless, the angle K may be any appropriate angle as the angle γ. - The
second buoy member 304 may be formed to include any appropriate density. For example, thesecond buoy member 304 may include a density that is less than the plasma fraction of a whole blood sample. It will be understood that thesecond buoy member 304 may include any appropriate density and a density that is less than the plasma fraction of a whole blood sample is merely exemplary. Nevertheless, if a whole blood sample is desired to be separated and the plasma sample is to be substantially separated from another fraction, thesecond buoy member 304 may include a density that is less than the plasma fraction of the whole blood sample. Therefore, the density of thesecond buoy member 304 may be about 0.01 g/cc to about 1.03 g/cc. As described herein, if thesecond buoy member 304 includes a density less than the plasma fraction of a whole blood sample and thefirst buoy member 302 includes a density greater than that of the red blood cells, thebuoy system 300 may be substantially positioned near an interface between the red blood cell fraction and the plasma fraction of a whole blood sample. Therefore, as discussed above, and further described herein, the platelet or buffy coat fraction of the whole blood sample may be substantially collected near or in thecollection face 308 of thebuoy system 300. - The
buoy post 306 may operably interconnect thefirst buoy member 302 and thesecond buoy member 304. Thebuoy post 306 may be any appropriate connection member. The buoy post need not be a single cylindrical portion. For example thebuoy post 306 may include one or more members interconnecting thefirst buoy member 302 and thesecond buoy member 304, such as around a perimeter thereof. In addition, thebuoy post 306 may include any appropriate shape or geometry. - The
buoy system post 306 may be rigidly affixed to thefirst buoy member 302 and thesecond buoy member 304, such that thefirst buoy member 302 may not move relative to thesecond buoy member 304 and vice versa. Alternatively, thebuoy post 306 may be slide ably connected to either or both thefirst buoy member 302 and thesecond buoy member 304. According to various embodiments, thebuoy post 306 is generally fixedly connected to thefirst buoy member 302 and slide ably interconnected to thesecond buoy member 304. Thebuoy post 306 may include a catch portion orlip 320 that is able to engage a portion of thesecond buoy member 304, such that a range of travel of thesecond buoy member 304, relative to thefirst buoy member 302 is limited. Nevertheless, the range of travel of thesecond buoy member 304 toward thefirst buoy member 302 may be substantially unlimited until thesecond buoy member 304 engages thefirst buoy member 302. - In various embodiments, the
buoy post 306 may also define a central cannula or bore 322. The post bore 322 may include aconnection portion 324 substantially defined near an upper or a proximal end of thebuoy post 306. This may allow for interconnection of various components with thebuoy post 306, such that various components may be moved through thebore 322 from an exterior location. Thebuoy post 306 may also define a port orcannula 326 that connects thepost cannula 322 with thecollection face 308. Therefore, a substance may travel through thepost cannula 322 and through theport 326. Various substances may then be provided to or removed from thecollection face 308 of thefirst buoy member 302. - In various embodiments, the
buoy system 300 may be used to separate a selected multi component sample, such as a whole blood sample. With continuing reference toFIGS. 6A and 6B , and reference toFIGS. 7A-7D , a method of using thebuoy system 300, according to various embodiments, is illustrated and described. With reference toFIGS. 7A-7D , like reference numerals are used to indicate like portions of thetube 12 and the associated mechanisms described inFIGS. 1-3 . Therefore, it will be understood that thebuoy system 300 may be used with thetube 12 or any other appropriate tube or container system or apparatus. Nevertheless, for simplicity, the description of a method of use of thebuoy system 300 will be described in conjunction with thetube 12. - The
tube 12 may include thecap 18 that further defines a plasma valve orport 20. Extending through thecap 18 and interconnecting with a first flexible tube ormember 92, theplasma port 20 may be used to extract a selected fraction of the sample that is positioned above thesecond buoy member 304. Thetube 12 may also define a second port 21, which may also be referred to as a platelet rich plasma (PRP) port. As discussed herein, a second flexible member, such as a flexible tube 21 a, may interconnect the PRP port 21 and aconnection portion 324 of abuoy cylinder 306. As illustrated above, thefirst tube 92 may also be interconnected with a selected portion of the system, such as thetop surface 314 of thesecond buoy member 304. As illustrated above, a valve may be positioned and is operably interconnect thetube 92 with theupper surface 314 of thesecond buoy member 304. Nevertheless, such a valve is not necessary and it may be provided merely for convenience. - Other portions of the
blood separator system 20, particularly those portions of thetube 12 and thecap 18 that have various valves connected therewith may be included in thetube 12 and used with thebuoy system 300. Nevertheless, once thebuoy system 300 is interconnected, it may be positioned in the interior of thetube 12 and thesyringe 204 used to place a sample into thetube 12. The sample may be expressed from thesyringe 204 into the interior of thetube 12 and the sample may be any appropriate sample, such as a whole blood sample. Nevertheless, it will be understood, such as discussed above, various other samples may be used, such as bone marrow samples, a mixture of bone marrow and whole blood or non-biological fluids or materials. It will be understood that twobuoys tube 12, but are illustrated apart for clarity of the present discussion. - Also, the sample may be placed in the
tube 12 according to various embodiments. As described above, an anticoagulant or other components may be mixed with the whole blood sample, if a whole blood sample is used, before the whole blood sample is positioned within thetube 12. As is apparent to one skilled in the art, an anticoagulant or other components may be mixed with a bone marrow aspirate sample or a sample of bone marrow aspirate and whole blood, if such samples are used before such sample is positioned within thetube 12. Thesyringe 204 is connected with theplunger port 22 extending from thecap 18, although a plunger may not be used in various embodiments. - After the sample is positioned within the
tube 12, as described above, a cap may be positioned over theport 22, such that the sample is not allowed to escape from thetube 12. After the sample is placed in thetube 12 and the cap placed on theport 22, thetube 12 including the sample and thebuoy system 300 may be centrifuged. - With reference to
FIG. 7B , after a centrifugation of thetube 12, including thebuoy system 300, substantially three fractions of the sample may be formed. Afirst fraction 330 may be positioned between thebottom face 310 and the bottom of thetube 44. Amiddle fraction 332 may be positioned between thecollection face 308 and thebottom surface 316 of thesecond buoy 304. In addition, athird fraction 334 may be positioned between theupper surface 314 and thecap 18 of thetube 12. Generally, thefirst fraction 330, themiddle fraction 332, and thethird fraction 334 are substantially physically separated with thebuoy system 300. During the centrifugation process, thetube 12 may flex slightly to allow for ease of movement of thebuoy system 300 through thetube 12 and the sample. Nevertheless, thebuoy system 300, during the centrifugation process, substantially creates the threefractions buoy system 300. - The
buoy system 300 substantially separates thefractions tube 12. For example, with reference toFIG. 7C , a syringe orother instrument 340 may be used to extract themiddle fraction 332 by interconnecting a cannula orbored tube 342 with theconnection portion 324 of thebuoy cylinder 306. By drawing theplunger 344 into theextraction syringe 340, a vacuum or upward force is produced within theextraction syringe 340. This force draws themiddle fraction 332 through theports 326 of thebuoy post 306 and through thebuoy cannula 322. Therefore, themiddle fraction 332 may be extracted from thetube 12 without substantially commingling themiddle fraction 332 with either thefirst fraction 330 or thethird fraction 334. Themiddle fraction 332 is drawn in the direction of arrow M through thecannula 322 and into theextraction syringe 340. - It will be understood that the second tube 21 a may also be used. The
extraction syringe 340 may be interconnected with the PRP port 21 that is interconnected with theconnection portion 324 of thebuoy cylinder 306. As discussed herein, the buoy cylinder allows access to the middle fraction 332 (platelet rich portion) between the buoy portions. Thus, it will be understood, that access may be obtained and the middle fraction 332 (platelet rich portion or buffy coat of the sample), between the two buoys, may be extracted in a plurality of ways. The illustrations and method described herein is merely exemplary. For example, if bone marrow aspirate is used as the sample, the PRP port 21 would allow for extraction of undifferentiated nucleated cells. In various embodiments, the PRP port 21 allows for extraction of the buffy coat. - Alternatively, if the
post 306 is not provided other portions may be provided to gain access to themiddle fraction 332. For example, if a plurality of members are provided around the perimeter of thefirst buoy 302 and the second buoy 304 a valve portion, such as a puncture-able valve, may be provided in thesecond buoy 304 to be punctured with an object. In this way an extraction needle may puncture the valve to gain access to themiddle fraction 332. Regardless, it will be understood that thebuoy system 300 may be able to form a plurality of fractions, such as the threefractions middle fraction 332 may be extracted without substantially commingling the various fractions. - During the extraction of the
middle fraction 332 through thecannula 322, thesecond buoy member 304 may move in the direction of arrow M toward thefirst buoy member 302. As described above, thecollection face 308 of the first buoy member may include an angle γ that is substantially complementary to thebottom face 316 of thesecond buoy member 304. Therefore, if thesecond buoy member 304 is allowed to move along thebuoy cylinder 306, thebottom face 316 of thesecond buoy member 304 may be able to substantially mate with thecollection face 308 of thefirst buoy member 302. Alternatively, if thesecond buoy member 304 is not allowed to move, the second buoy member may be provided with a vent port or valve, such that the extraction of themiddle fraction 332 from thecollection face 308 may not be hindered by the buildup of undesirable forces. Nevertheless, if thesecond buoy member 304 may move, the interaction of thebottom face 316 of thesecond buoy member 304 may assist in substantially removing the entiremiddle fraction 332 from thetube 12. As described above, thebottom face 60 of theplunger 16 may also serve a similar purpose when engaging thecollection face 46 of thebuoy 14. - With reference to
FIG. 7D , once themiddle fraction 332 has been extracted from thetube 12, thesecond buoy member 304 may substantially mate with a portion of thefirst buoy member 302. As discussed above, thesecond buoy member 304 may substantially only mate with thefirst buoy member 302 if thesecond buoy member 304 is able to substantially move relative to thefirst buoy member 302. Therefore, it will be understood that thesecond buoy member 304 need not necessarily mate with thefirst buoy member 302 and is merely exemplary of an operation of various embodiments. Nevertheless, once themiddle fraction 332 has been extracted from thetube 12, theport 20 may be used in conjunction with a selected instrument, such as aplasma extraction syringe 212 to remove the plasma or thethird fraction 334 from thetube 12 using theextraction tube 92 interconnected with theport 20. - As described above, the
tube 92 allows for extraction of thethird fraction 334 from thetube 12 without commingling thethird fraction 334 with the remainingfirst fraction 330 in thetube 12. Therefore, similar to the separator andextraction system 10, three fractions may be substantially formed within thetube 12 with thebuoy system 300 and may be extracted without substantially commingling the various fractions. Once thethird fraction 334 is extracted from thetube 12, thebuoy system 300 may be removed from thetube 12, such that thefirst fraction 330 may be removed from thetube 12. Alternatively, thefirst fraction 330 may be discarded with thetube 12 and thebuoy system 300 as a disposable system. Alternatively, the system may be substantially reusable, such that it can be sterilized and may be sterilized for various uses. - The description of the method of use of the
buoy system 300 is exemplary of a method of using a system according to various other embodiments. It will be understood, however, that various specifics may be used from various embodiments to allow for the extraction of selected fractions. For example, the centrifugation process may be substantially a single step centrifugation process. Thebuoy system 300, according to various embodiments, may allow for the formation of three fractions during a single centrifugation process. This centrifugation process may occur at any appropriate speed, such as about 1000 RPM to about 8000 RPM. This speed may produce a selected gravity that may be approximately 4500 times greater than the normal force of gravity. Nevertheless, these specifics are not necessary to the operation of thebuoy system 300 according to various embodiments. Thebuoy system 300, according to various embodiments, may be used to extract a plurality of fractions of a sample after only a single centrifuging process and without substantially commingling the various fractions of the sample. - With reference to
FIG. 8 , the blood collection and separation system that includes thetube 12, according to various embodiments, may be filled with a multi-component fluid or solution, such as blood from a patient, is illustrated. Thetube 12 may include any appropriate separation system, such as theseparation system 300. Nevertheless, in addition to filling thetube 12 with a fluid from thesyringe 204 any appropriate method may be used to fill thetube 12. For example, when a solution, including a plurality of components, is placed into thetube 12 it may be collected directly from a source. - For example, a
patient 350 may be provided. Thepatient 350 may be provided for a selected procedure, such as generally an operative procedure or other procedure that requires anintravenous connection 352, such as a butterfly needle, to be provided in thepatient 350. Theintravenous connection 352 generally provides atube 354 extending therefrom. Thetube 354 may be used to withdraw fluids from thepatient 350 or provide materials to thepatient 350, such as medicines or other selected components. Nevertheless, theintravenous connection 352 is generally provided for various procedures and may be used to fill thetube 12. - The
tube 354 may interconnect with theplunger port 22 or any appropriate portion of thetube 12. Theport 22 may be used to connect with thetube 354 in a similar manner as it would connect with thesyringe 204, if thesyringe 204 was provided. Nevertheless, it will be understood that thetube 354 may be provided directly to thetube 12 from thepatient 350. This may reduce the number of steps required to fill thetube 12 and reduce possible cross-contamination from thepatient 350 with the various components. Moreover, making a connection directly with thepatient 350 may make the withdrawal and collection of blood from thepatient 350 more efficient. - Once the
tube 354 is interconnected with thetube 12 the pressure differential between the patient 350, such as the intravenous pressure of the blood, may be used to fill thetube 12 to a selected volume. In addition, avacuum system 356 may be provided Thevacuum system 356 may include a vacuum inducing portion ormember 358, such as a resilient bulb. Thevacuum inducing member 358 may be interconnected with thetube 12 through a selected connectingportion 360. - The
vacuum connecting portion 360 may interconnect with anorifice 362. Theorifice 362 may be interconnected or extend from thecap 18 or provided in any appropriate portion with thetube 12. Nevertheless, a first one-way valve 364 may be provided along theconnection portion 360 or near theorifice 362. The first one-way valve 364 provides that a flow of a fluid, such as a gas, may pass in a first direction but not in a second. A second one-way valve 366 may also be provided downstream from the first one-way valve 364. In this way, a vacuum may be created with thevacuum inducing member 358, such that air is drawn out of thetube 12 and removed through the second one-way valve 366 in the direction of arrow V. Due to the first and second one-way valves 364, 366 the air is generally withdrawn from thetube 12 without substantially allowing the air to flow back into thetube 12. Thus, a vacuum can be created within thetube 12 to assist with removing a selected volume of fluid, such as blood, from thepatient 350. - Because the
tube 12 may be filled substantially directly from thepatient 350, the collection of the fluid, such as blood, may be provided substantially efficiently to thetube 12. Although any appropriate mechanism may be used to assist in withdrawing the blood from thepatient 350 thevacuum system 356 may be provided including thevacuum inducing member 358. Any appropriate vacuum creating device may be used, such as a mechanical pump or the like. Nevertheless, thetube 12 may be filled for use during a selected procedure. - As discussed above, the
tube 12 may be used to separate a selected portion of the blood obtained from thepatient 350 substantially intraoperatively. Therefore, the collection or separation of the various components may be substantially autologous and substantially intraoperatively. Moreover, obtaining the fluid directly from thepatient 350 may increase the efficiency of the procedure and the efficiency of the intraoperative or the operative procedure. - With reference to
FIG. 9 , theseparator 10 may be used to separate any appropriate material. The material may be separated for any purpose, such as a surgical procedure. For example, a selected fraction of a bone marrow aspirate or a bone marrow portion may be produced with theseparator 10 according to various embodiments. The selected fraction of the bone marrow aspirate may include various components, such as undifferentiated cells. The various undifferentiated cells may be positioned in a selected scaffold or relative to a selected portion of a patient for providing a volume of the undifferentiated cells to the patient. As known to those skilled in the art, a selected portion of the patient may include bone, cartilage, connective tissue, or any other tissue. Also as known by those skilled in the art, a selected portion of the patient may include a defect in bone, cartilage, connective tissue and/or any other tissue. It will be understood that the method described according toFIG. 9 is merely exemplary of various embodiments that may be used to provide a selected fraction of a bone marrow aspirate or other material to a patient or selected position. The selected portion may be placed on the scaffold in any appropriate manner, such as by spraying, dipping, infiltrating, or any appropriate method. - A method of selecting or creating a selected fraction of a bone marrow aspirate in a selected scaffold according to a
method 400 is illustrated inFIG. 9 . Generally, themethod 400 may start inblock 402 in obtaining a bone marrow aspirate volume. The bone marrow aspirate (BMA) may be obtained in any selected or generally known manner. For example, a selected region of bone, such as a portion near an operative procedure, may be used to obtain the bone marrow aspirate. Generally, an accessing device, such as a syringe and needle, may be used to access an intramedullary area of a selected bone. The BMA may then be withdrawn into the syringe for various procedures. Once a selected volume of the BMA is obtained inblock 402, the BMA may be positioned in theseparator 10 according to various embodiments inblock 404. The BMA may be positioned in any appropriate separator, such as those described above including theseparator 10. Once the BMA is positioned in theseparator 10, a selected fraction of the BMA may be separated from the BMA inblock 406. - BMA is a complex tissue comprised of cellular components (that contribute to bone growth) including red and white blood cells, their precursors and a connective tissue network termed the stroma. Bone marrow stromal cells or mesenchymal stem cells have the potential to differentiate into a variety of identifiable cell types including osteoblasts, fibroblasts, endothelial cells, reticulocytes, adipocytes, myoblasts and marrow stroma. The selected fraction of the BMA may include undifferentiated cells or any appropriate portion of the BMA. The fractionation or separation of various fractions of the BMA may allow for a volume of BMA to be taken from a single location and the separation or concentration of the selected portion may be performed in the
separator 10. Generally, obtaining a small volume of the selected portion from a plurality of locations may be used to obtain an appropriate volume of BMA or selected fraction of the BMA. Nevertheless, theseparator 10 may allow for separating a selected volume from a single location from which the BMA is obtained. This may reduce the time of a procedure and increase the efficiency of obtaining the selected fraction of the BMA. - In addition to obtaining a volume of the BMA in
block 402, a volume of whole blood may be obtained inblock 408. The volume of blood obtained inblock 408, according to any appropriate procedure, including those described above, may then be positioned in theseparator 10, inblock 410. The whole blood may be positioned in any appropriate separator, such as those described above or a separator to separate a selected fraction of the whole blood. As described above, the whole blood may be separated into an appropriate fraction, such as a fraction including a platelet portion or buffy coat. The whole blood may be separated into selected fractions inblock 412. It will be understood that the BMA and the whole blood volume may be obtained substantially simultaneously or consecutively inblock middle fraction separator 10 has a concentration of nucleated cells that is at least 4 times the concentrate of nucleated cells in BMA. Similarly, the selected fractions of the BMA obtained inblock 406 and whole blood obtained inblock 412 may also be performed substantially sequentially or simultaneously. For example, theseparator 10 including the volume of the BMA may be positioned in a separating device, such as a centrifuge, substantially opposite, so as to balance, theseparator 10 including the volume of the whole blood. Therefore, a single separation, such as centrifuge procedure may be used to separate both the BMA and the whole blood into selected fractions. This again may increase the efficiency of the procedure to provide both a selected fraction of the BMA and a selected fraction of the whole blood substantially simultaneously. - The selected fractions of the BMA and the whole blood, provided in
block block 414. The selected fractions of the BMA and the whole blood, may be harvested inblock 414 for appropriate purposes, such as those described herein. Theseparator 10 may be used to obtain the selected fractions of the BMA and the whole blood, through various procedures, such as those described above. - A plurality of
separators 10 may be used to obtain a larger quantity of the selection fractions and such quality of selected fractions may be pooled together. In various embodiments, the BMA aspirate can be concentrated alone or in combination with whole blood. In various embodiments, whole blood may be added to theseparator 10, and the resulting buffy coat fraction (middle fraction 332, 226) may not only contain the at least 4 times greater concentration of nucleated cells from bone marrow, and may include at least 5 times greater concentration of white blood cells from the whole blood and at least 8 times greater concentration in platelets from the whole blood. In addition, circulating stem cells from whole blood may be concentrated with the mature white blood cells in the buffy coat. - After harvesting the selected fractions of the BMA and the whole blood in
block 414, the selected fraction of the BMA may be positioned on an appropriate scaffold inblock 416. The scaffold inblock 416 may be any appropriate scaffold, such as synthetic bone substitutes or allergenic tissue. Examples of a scaffold include, but are not limited to, bone, cartilage, bone substrates, ceramics, biopolymers, collagens, metal, and the like. The scaffolds may be used for appropriate procedures, such as hard or soft tissue grafting, including uses in non-union or chronic wounds. The undifferentiated cells of the BMA may allow for a substantial source of cells for use during a substantially natural healing after an operative procedure, for example, the natural healing of a patient may use the supplied undifferentiated cells. In such a natural healing of a patient, the undifferentiated cells may be applied to a wound, a defect, a graft site, a bone, cartilage, connective tissue. and the like. Therefore, the scaffold may be positioned in a selected portion of the anatomy and the cells may be allowed to grow and differentiate into selected portions in the implanted position. - It is well known to those skilled in the art that bone marrow contains hematopoietic and mesenchymal stems cells that are precursors for most of the cells found within the body. In general, the hematopoietic cells, along with angiogeneic growth factors, such as those found in platelets, will promote angiogenesis. Angiogenesis is a necessary stage in wound healing of most tissues and treatment of ischemia. The mesenchymal stem cells are the cells responsible for the formation of bone, tendon, ligament, articular cartilage, muscle, fat, intervertebral discs, meniscus, skin, and any other structural tissue found in the body. In various embodiments, a concentration and delivery of these precursor cells, with or without platelet concentrate, will improve therapeutic uses over the native bone marrow.
- In addition to positioning the selected fractioning of the BMA and the scaffold in
block 416, the platelets of the whole blood may be positioned on or near the scaffold ofblock 418. The platelets of the whole blood fraction positioned in the scaffold ofblock 418 may assist the undifferentiated cells and the anatomy into which the scaffold is positioned to allow for a substantially efficient and complete healing. The platelet rich fraction of the whole blood sample may include various healing and growth factors that may assist in providing an efficient and proper healing in the anatomy. Therefore, the undifferentiated cells of the BMA, or other selected fraction obtained from the separation of the BMA, and the selected fraction of the whole blood, obtained from the separator, may be used with the scaffold to provide a substantially efficient implant. - In some embodiments,
harvest block 414 may be combined with a growth factors which may include any of the well-known growth factors such as Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-β), Insulin-Like Growth Factor (IGF), Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), Bone Morphogenetic Proteins (BMPs), and vectors for gene therapy. In various embodiments,harvest block 414 may be combined with cellular solutions, suspensions, and materials including osteoblasts, osteoprogenitor cells, chondroblasts, stem cells, or fibroblasts may also be used, as may solutions or suspensions containing other therapeutic agents such as antibiotics, analgesics, pharmaceutical agents, antithrombinolytics, or chemotherapeutic agents. In various embodiments, the buffy coat, platelet fraction, and/or undifferentiated cell fraction (themiddle fraction 332, 226) may be combined with an activator such as thrombin solutions and the like. In various embodiments themiddle fraction separator 10, or any appropriate separator, such as that described above, may allow for a substantially quick and efficient separation of the BMA and the whole blood into an appropriate fraction for use in the procedure. Other examples include pooling whole blood and/or BMA from different sites of the anatomy or from different sources. - In various embodiments, the concentrated bone marrow cells can also be included with a carrier to aide in delivery and to help maintain the cells' location after implantation. Examples of carriers can include fibrin, concentrated fibrin, demineralized bone matrix, gelatin, collagen, porous calcium based ceramics, porous metal, synthetic fiber matrices, or resorbable matrices. In addition, carriers can be made from other autogeneic, allogenic, and xenogeneic tissues.
- After the selected portion of the BMA and the whole blood are positioned on the scaffold in
blocks block 420. As described above, the scaffold may be implanted in any appropriate position in theblock 420 for various procedures. It will be understood that the scaffold may be implanted for any appropriate procedure and may allow for positioning the selected portion of the BMA, such as undifferentiated cells, and the selected portion of the whole blood, such as platelets, relative to a selected portion of the anatomy. The scaffold may allow for a bone ingrowth, such as allowed with the undifferentiated cells, to assist in healing of a selected portion of the anatomy. In various embodiments, concentrated bone marrow aspirate can be used in articular cartilage repair. Themiddle fraction middle fraction middle fraction middle fraction middle fraction middle fraction - The description of the invention is merely exemplary in nature and, thus, variations that do not depart from the gist of the invention are intended to be within the scope of the invention. Such variations are not to be regarded as a departure from the spirit and scope of the invention.
Claims (34)
1-32. (canceled)
33. A method for concentrating bone marrow aspirate, the method comprising:
obtaining a volume of bone marrow aspirate;
loading the volume of bone marrow aspirate into a separator comprising two buoys and an extraction port, the buoys operable to substantially physically separate the aspirate into three or more fractions and the extraction port operable to allow extraction of a fraction between the buoys without substantially commingling the fraction with the other fractions in the separator;
centrifuging the separator; wherein the buoys separate the bone marrow aspirate creating the fraction between the buoys comprising a bone marrow aspirate concentrate, wherein the bone marrow aspirate concentrate includes red blood cells and white blood cells; and
extracting the fraction between the buoys of the bone marrow aspirate concentrate through the extraction port.
34. The method according to claim 33 wherein the at least one fraction comprises at least one of the group consisting essentially of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
35. The method according to claim 33 wherein an amount of nucleated cells in the bone marrow aspirate concentrate is greater than or equal to 4 times an amount of nucleated cells found in the volume of bone marrow aspirate.
36. The method according to claim 33 further comprising applying the bone marrow aspirate concentrate into a patient.
37. The method according to claim 64 wherein the combined volume comprises at least one of the group consisting essentially of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
38. The method according to claim 64 wherein an amount of nucleated cells in the combined volume is greater than or equal to 4 times an amount of nucleated cells in the volume of bone marrow aspirate and the volume of blood.
39. A method for treating a defect in a mammal using a concentrated bone marrow aspirate, the method comprising:
drawing a volume of bone marrow aspirate from the mammal;
loading the volume of bone marrow aspirate into a separator comprising two buoys, the separator being operable to separate the aspirate into three or more fractions;
centrifuging the separator;
separating the volume of bone marrow aspirate into a plurality of fractions including a fraction comprising a concentrated bone marrow aspirate;
extracting the fraction comprising a concentrated bone marrow aspirate; and
applying the fraction comprising a concentrated bone marrow aspirate to site of the defect.
40. The method according to claim 39 wherein the fraction comprising a concentrated bone marrow aspirate is essentially buffy coat including a plurality of undifferentiated cells.
41. The method according to claim 39 wherein the fraction comprises at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
42. The method according to claim 39 further comprising combining the fraction with a carrier.
43. The method according to claim 42 wherein the carrier is selected from the group consisting essentially of collagen, hydrogel, a bioabsorbable polymer, a biopolymer, water, buffered solution, fibrin, concentrated fibrin, demineralized bone matrix, gelatin, porous calcium based ceramics, porous metal, synthetic fiber matrices, resorbable matrices, autogeneic tissue, allogenic tissue, xenogeneic tissue, and combinations thereof.
44. The method according to claim 39 further comprising combining an activating agent with the fraction.
45. The method according to claim 39 further comprising combining a pharmaceutical agent with the fraction.
46. A method for treating a defect in an animal, the method comprising:
obtaining a volume of bone marrow aspirate and a volume of whole blood from the animal;
loading the volume of bone marrow aspirate into a first separator comprising two buoys, the separator being operable to separate the aspirate into three or more fractions;
loading the volume of whole blood into a second separator comprising two buoys, the separator being operable to separate the aspirate into three or more fractions;
centrifuging the first separator and the second separators, thereby separating the volume of bone marrow aspirate into a plurality of fractions and separating the volume of whole blood into a plurality of fractions;
collecting a fraction of the bone marrow aspirate;
collecting a fraction of the whole blood; and
applying at least one of the fraction of bone marrow aspirate and the fraction of whole blood to site of the defect.
47. The method according to claim 46 wherein the at least one of the fraction of bone marrow aspirate and the fraction of whole blood comprises at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
48. The method according to claim 46 further comprising combining the at least one of the fraction of bone marrow aspirate and the fraction of whole blood with a carrier.
49. The method according to claim 48 wherein the carrier is selected from the group consisting essentially of collagen, hydrogel, a bioabsorbable polymer, a biopolymer, water, buffered solution, fibrin, concentrated fibrin, demineralized bone matrix, gelatin, porous calcium based ceramics, porous metal, synthetic fiber matrices, resorbable matrices, autogeneic tissue, allogenic tissue, xenogeneic tissue, and combinations thereof.
50. The method according to claim 48 further comprising adding an activating agent to the at least one of the fraction of bone marrow aspirate and the fraction of whole blood.
51. The method according to claim 48 further comprising adding a pharmaceutical agent to the at least one of the fraction of bone marrow aspirate and the fraction of whole blood.
52. A method for treating a defect in a patient, the method comprising:
drawing a volume of bone marrow aspirate and a volume of whole blood from the patient;
adding a first anticoagulant to the volume of bone marrow aspirate;
adding a second anticoagulant to the volume of whole blood;
loading the volume of bone marrow aspirate and the volume of whole blood into a separator comprising two buoys, the separator being operable to separate the volume of bone marrow aspirate and the volume of whole blood into three or more fractions;
centrifuging the separator, separating the volume of bone marrow aspirate and the volume of whole blood into a plurality of fractions;
withdrawing a fraction comprising at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells; and
applying the fraction to site of the defect.
53. The method according to claim 52 wherein the fraction is essentially buffy coat including a plurality of undifferentiated cells.
54. The method according to claim 52 further comprising combining the fraction with a carrier.
55. The method according to claim 63 wherein the carrier is selected from the group consisting essentially of collagen, hydrogel, a bioabsorbable polymer, a biopolymer, water, buffered solution, fibrin, concentrated fibrin, demineralized bone matrix, gelatin, porous calcium based ceramics, porous metal, synthetic fiber matrices, resorbable matrices, autogeneic tissue, allogenic tissue, xenogeneic tissue, and combinations thereof.
56. The method according to claim 52 further comprising combining an activating agent with the fraction.
57. The method according to claim 52 further comprising combining a pharmaceutical agent with the fraction.
58. A method of treating a patient with combination of a concentrated bone marrow aspirate and buffy coat, the method comprising:
obtaining a volume of a whole blood from the patient;
obtaining a volume of a bone marrow aspirate from the patient;
forming a buffy coat fraction of the whole blood;
forming a concentrated bone marrow aspirate fraction of the bone marrow aspirate; and
applying at least one of the buffy coat fraction or the concentrated bone marrow aspirate fraction to the patient.
59. The method according to claim 58 , wherein the forming a first fraction of the first whole material and the forming a second fraction of the second whole material includes:
loading the volume of whole blood and the volume of bone marrow aspirate in a container; and
applying a force to the container to form at least three fractions.
60. The method according to claim 58 , wherein the forming a first fraction of the first whole material and the forming a second fraction of the second whole material includes:
loading the volume of whole blood and the volume of bone marrow aspirate in the container having a separating member, the separating member having a specific gravity substantially dependent upon at least one of the at least three fractions; and
centrifuging the container to move the separating member to a selected position relative to the at least one of the volume of whole blood and the volume of bone marrow aspirate to substantially physically separate the at least three fractions.
61. The method according to claim 58 wherein the at least one of the first fraction or the second fraction comprises at least one of the group consisting of hematopoietic stem cells, stromal stem cells, mesenchymal stem cells, endothelial progenitor cells, red blood cells, white blood cells, fibroblasts, reticulacytes, adipose cells, and endothelial cells.
62. The method according to claim 58 further comprising combining the at least one of the first fraction or the second fraction with a carrier.
63. The method according to claim 62 wherein the carrier is selected from the group consisting essentially of collagen, hydrogel, a bioabsorbable polymer, a biopolymer, water, buffered solution, fibrin, concentrated fibrin, demineralized bone matrix, gelatin, porous calcium based ceramics, porous metal, synthetic fiber matrices, resorbable matrices, autogeneic tissue, allogenic tissue, xenogeneic tissue, and combinations thereof.
64. A method for preparing a bone marrow aspirate concentrate and a peripheral blood concentrate, the method comprising:
collecting a volume of bone marrow aspirate and a volume of peripheral blood from a patient to create a combined volume;
loading the combined volume of bone marrow aspirate and blood into a separator comprising two buoys and an extraction port, the buoys being operable to substantially physically separate the combined volume of aspirate and blood into three or more fractions and the extraction port operable to allow extraction of a fraction between the buoys without substantially commingling the fraction with the other fractions in the separator;
centrifuging the separator, wherein the buoys separate the combined volume to create the fraction between the buoys comprising a bone marrow aspirate concentrate and a peripheral blood concentrate fraction comprising red blood cells and white blood cells; and
withdrawing the fraction between the buoys of bone marrow aspirate concentrate and peripheral blood concentrate through the extraction port.
65. The method according to claim 64 further comprising applying the combined volume into a patient.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/663,637 US20130226149A1 (en) | 2002-05-24 | 2012-10-30 | Apparatus and method for separating and concentrating fluids containing multiple components |
US14/510,828 US9897589B2 (en) | 2002-05-24 | 2014-10-09 | Apparatus and method for separating and concentrating fluids containing multiple components |
US15/866,658 US10393728B2 (en) | 2002-05-24 | 2018-01-10 | Apparatus and method for separating and concentrating fluids containing multiple components |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38301302P | 2002-05-24 | 2002-05-24 | |
US10/445,381 US7179391B2 (en) | 2002-05-24 | 2003-05-23 | Apparatus and method for separating and concentrating fluids containing multiple components |
US10/932,882 US7374678B2 (en) | 2002-05-24 | 2004-09-02 | Apparatus and method for separating and concentrating fluids containing multiple components |
US11/442,631 US20060278588A1 (en) | 2002-05-24 | 2006-05-26 | Apparatus and method for separating and concentrating fluids containing multiple components |
US13/663,637 US20130226149A1 (en) | 2002-05-24 | 2012-10-30 | Apparatus and method for separating and concentrating fluids containing multiple components |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/442,631 Continuation US20060278588A1 (en) | 2002-05-24 | 2006-05-26 | Apparatus and method for separating and concentrating fluids containing multiple components |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/510,828 Continuation US9897589B2 (en) | 2002-05-24 | 2014-10-09 | Apparatus and method for separating and concentrating fluids containing multiple components |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130226149A1 true US20130226149A1 (en) | 2013-08-29 |
Family
ID=46324551
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/442,631 Abandoned US20060278588A1 (en) | 2002-05-24 | 2006-05-26 | Apparatus and method for separating and concentrating fluids containing multiple components |
US13/663,637 Abandoned US20130226149A1 (en) | 2002-05-24 | 2012-10-30 | Apparatus and method for separating and concentrating fluids containing multiple components |
US14/510,828 Active 2024-10-24 US9897589B2 (en) | 2002-05-24 | 2014-10-09 | Apparatus and method for separating and concentrating fluids containing multiple components |
US15/866,658 Expired - Lifetime US10393728B2 (en) | 2002-05-24 | 2018-01-10 | Apparatus and method for separating and concentrating fluids containing multiple components |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/442,631 Abandoned US20060278588A1 (en) | 2002-05-24 | 2006-05-26 | Apparatus and method for separating and concentrating fluids containing multiple components |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/510,828 Active 2024-10-24 US9897589B2 (en) | 2002-05-24 | 2014-10-09 | Apparatus and method for separating and concentrating fluids containing multiple components |
US15/866,658 Expired - Lifetime US10393728B2 (en) | 2002-05-24 | 2018-01-10 | Apparatus and method for separating and concentrating fluids containing multiple components |
Country Status (1)
Country | Link |
---|---|
US (4) | US20060278588A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9897589B2 (en) | 2002-05-24 | 2018-02-20 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US10183042B2 (en) | 2002-05-24 | 2019-01-22 | Biomet Manufacturing, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947236B2 (en) | 1999-12-03 | 2011-05-24 | Becton, Dickinson And Company | Device for separating components of a fluid sample |
US7992725B2 (en) * | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US7179391B2 (en) | 2002-05-24 | 2007-02-20 | Biomet Manufacturing Corp. | Apparatus and method for separating and concentrating fluids containing multiple components |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US7731678B2 (en) | 2004-10-13 | 2010-06-08 | Hyprotek, Inc. | Syringe devices and methods for mixing and administering medication |
US7766900B2 (en) | 2005-02-21 | 2010-08-03 | Biomet Manufacturing Corp. | Method and apparatus for application of a fluid |
US8137307B2 (en) | 2005-11-09 | 2012-03-20 | Hyprotek, Inc. | Syringe devices, components of syringe devices, and methods of forming components and syringe devices |
EP2015799A4 (en) * | 2006-04-28 | 2009-12-09 | Harvest Technologies Corp | Injection of anticoagulant into bone marrow space |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US20080193424A1 (en) * | 2007-02-09 | 2008-08-14 | Biomet Biologics, Inc. | Treatment of tissue defects with a therapeutic composition |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
EP2146794B1 (en) | 2007-04-12 | 2016-10-19 | Biomet Biologics, LLC | Buoy suspension fractionation system |
US7901344B2 (en) * | 2007-05-11 | 2011-03-08 | Biomet Biologics, Llc | Methods of reducing surgical complications in cancer patients |
US7846394B2 (en) * | 2007-10-02 | 2010-12-07 | Becton, Dickinson And Company | Apparatus and method for separating particles within a specimen |
US9522097B2 (en) | 2007-10-04 | 2016-12-20 | Hyprotek, Inc. | Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers |
US8002737B2 (en) | 2007-10-04 | 2011-08-23 | Hyprotek, Inc. | Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers |
US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
EP2620139B1 (en) * | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
EP2254991B1 (en) | 2008-02-29 | 2018-08-22 | Biomet Manufacturing, LLC | A system and process for separating a material |
US8518272B2 (en) | 2008-04-04 | 2013-08-27 | Biomet Biologics, Llc | Sterile blood separating system |
US8182769B2 (en) | 2008-04-04 | 2012-05-22 | Biomet Biologics, Llc | Clean transportation system |
CN102149473B (en) | 2008-07-21 | 2014-12-31 | 贝克顿·迪金森公司 | Density phase separation device |
US8309343B2 (en) | 2008-12-01 | 2012-11-13 | Baxter International Inc. | Apparatus and method for processing biological material |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
KR20100116106A (en) * | 2009-04-21 | 2010-10-29 | 에스타 테크날러지스 리미티드 | Assembly, kit and method for preparing platelet-rich plasma (prp) |
JP5638603B2 (en) | 2009-05-15 | 2014-12-10 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | Density phase separation device |
EP2435108B1 (en) | 2009-05-29 | 2016-12-07 | EndoCellutions, Inc. | Apparatus and methods for aspirating and separating components of different densities from a physiological fluid containing cells |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
US8348878B2 (en) * | 2009-11-13 | 2013-01-08 | Ab Holdings, Llc | Device for dispensing cream laden gauze |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
AU2011296356B2 (en) | 2010-09-03 | 2015-07-09 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
CN103384535B (en) * | 2010-11-25 | 2015-02-11 | 可乐丽股份有限公司 | Method for producing implant material |
US20150004702A1 (en) * | 2011-08-29 | 2015-01-01 | Stempeutics Research Private Limited | System for isolating stromal vascular fraction (svf) cells from the adipose tissue and a method thereof |
US9962480B2 (en) * | 2012-01-23 | 2018-05-08 | Estar Technologies Ltd | System and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma (PRP) |
US9937317B2 (en) * | 2012-01-30 | 2018-04-10 | Ipsumpro, S.L. | Modified medical syringe with a flow regulator for the administration of local anaesthetic |
KR101179548B1 (en) * | 2012-03-05 | 2012-09-05 | 김준우 | Dividing device for blood elements or cell fractions |
KR101459109B1 (en) * | 2012-05-21 | 2014-11-12 | 한국과학기술원 | Container for multiple centrifugation and Particle Separation Method Using the Same |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
WO2014120797A1 (en) | 2013-01-29 | 2014-08-07 | Endocellutions, Inc. | Cell concentration devices and methods |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
WO2015021189A1 (en) | 2013-08-06 | 2015-02-12 | Regenerative Sciences, Llc | Bone marrow adipose portion isolation device and methods |
EP3074507B1 (en) | 2013-11-26 | 2022-01-05 | Biomet Biologics, LLC | Methods of mediating macrophage phenotypes |
KR101585857B1 (en) * | 2014-05-23 | 2016-01-15 | 주식회사 라온 | Platelet rich plasma extraction kit |
US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
US9694359B2 (en) | 2014-11-13 | 2017-07-04 | Becton, Dickinson And Company | Mechanical separator for a biological fluid |
US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
JP6812430B2 (en) | 2015-07-31 | 2021-01-13 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | How to Prepare Osteogenic Bone Grafts |
AU2017230806B2 (en) | 2016-03-10 | 2021-06-24 | Arthrex, Inc. | Systems and methods for preparing a thrombin serum |
US10960026B2 (en) * | 2016-03-10 | 2021-03-30 | Arthrex, Inc. | Systems and methods for preparing protein enhanced serums |
US10987672B2 (en) * | 2017-06-08 | 2021-04-27 | Emcyte Corp. | Dual piston centrifuge tube |
CA3089825C (en) | 2018-01-29 | 2022-08-30 | Forever Labs, Inc. | System and method for isolating extracellular vesicles |
JP7244162B2 (en) * | 2018-06-26 | 2023-03-22 | 積水メディカル株式会社 | blood collection container |
EP3784363A4 (en) | 2018-07-09 | 2022-02-16 | Hanuman Pelican, Inc. | Apparatus and methods for separating blood components |
EP3820541A4 (en) | 2018-07-09 | 2022-04-06 | Hanuman Pelican, Inc. | Apparatus and methods for processing blood |
CA3127191A1 (en) | 2019-01-21 | 2020-07-30 | Eclipse Medcorp, Llc | Methods, systems and apparatus for separating components of a biological sample |
EP3890799A4 (en) | 2019-02-06 | 2022-10-26 | Hanuman Pelican, Inc. | Apparatus and methods for concentrating platelet-rich plasma |
EP4052034A4 (en) | 2019-10-31 | 2023-12-20 | Crown Laboratories, Inc. | Systems, methods and apparatus for separating components of a sample |
US20220133962A1 (en) * | 2019-11-11 | 2022-05-05 | Jun Seok Lee | Body fluid component separating device |
KR102323493B1 (en) * | 2019-11-11 | 2021-11-09 | 이준석 | Apparatus for separation of constituents of biofluid |
CN114273091B (en) * | 2021-12-30 | 2022-07-08 | 青岛市中心血站 | Blood rapid centrifugal separation and collection device and control method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030118563A1 (en) * | 1999-09-23 | 2003-06-26 | Loeb Marvin P. | Materials and methods for repair of tissue |
US20060029578A1 (en) * | 2000-06-29 | 2006-02-09 | Ecole Polytechnique | Composition and method for the repair and regeneration of cartilage and other tissues |
Family Cites Families (543)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US280820A (en) * | 1883-07-10 | Milk-can | ||
DE56103C (en) | A. SCHLEE in Altona, Blücherstrafse 24 | Erase roller | ||
US593333A (en) | 1897-11-09 | Device for separating liquids of different | ||
US1468313A (en) | 1920-07-03 | 1923-09-18 | Firm Luftfahrzeugbau Schutte L | Process of producing a cold glue from blood |
GB229644A (en) | 1924-02-19 | 1925-10-08 | Robert Vogel | A method of producing a substance adapted to tampon wounds |
US2722257A (en) | 1953-02-12 | 1955-11-01 | Compule Corp | Sampling tube equipment |
SE169293C1 (en) | 1958-03-13 | 1959-11-10 | ||
US3013557A (en) | 1959-04-13 | 1961-12-19 | Hazleton Lab Inc | Combination syringe, shipping container and centrifuge tube |
US3159159A (en) | 1960-06-01 | 1964-12-01 | Milton J Cohen | Fluid withdrawal device and container |
SE358894B (en) | 1961-10-25 | 1973-08-13 | Pharmacia Ab | |
US3141846A (en) | 1962-04-05 | 1964-07-21 | Western States Machine Co | Load control unit for cyclical centrifugal installation |
DK113248B (en) | 1963-09-02 | 1969-03-03 | Pharmacia Ab | Process for the preparation of dextran substituted by one or more mono- or dihydroxyalkyl groups. |
US3300051A (en) | 1963-09-26 | 1967-01-24 | Internat Equipment Co | Filter tube for use in a centrifuge |
JPS497539B1 (en) | 1966-04-13 | 1974-02-21 | ||
US3469369A (en) | 1966-12-29 | 1969-09-30 | Bell Telephone Labor Inc | Method for preparing and applying a viscous fluid |
US3441143A (en) | 1967-02-10 | 1969-04-29 | Marvel Eng Co | Plural element filter assembly |
US3545671A (en) | 1967-02-14 | 1970-12-08 | Eugene Ross Lab Inc | Apparatus for and method of collecting,storing,separating and dispensing blood and blood components |
US3409165A (en) | 1967-04-03 | 1968-11-05 | Olin Mathieson | Floating deck |
US3508653A (en) * | 1967-11-17 | 1970-04-28 | Charles M Coleman | Method and apparatus for fluid handling and separation |
US3596652A (en) | 1968-10-14 | 1971-08-03 | Bio Science Labor | Fluid separatory device |
US3583627A (en) | 1969-09-04 | 1971-06-08 | Onslow H Wilson | Apparatus for the concentration of macromolecules and subcellular particles from dilute solutions |
US3654925A (en) | 1969-09-23 | 1972-04-11 | Becton Dickinson Co | Plasma separator system |
US3647070A (en) | 1970-06-11 | 1972-03-07 | Technicon Corp | Method and apparatus for the provision of fluid interface barriers |
US3741400A (en) | 1970-06-15 | 1973-06-26 | J Dick | Blood sample container |
US3661265A (en) | 1970-07-27 | 1972-05-09 | Contemporary Research And Dev | Serum separator type container |
USRE32089E (en) | 1970-08-25 | 1986-03-04 | Amicon Corporation | Blood fractionating process and apparatus for carrying out same |
US3723244A (en) | 1971-01-18 | 1973-03-27 | Atomic Energy Commission | Fibrous fibrin sheet and method for producing same |
US3706306A (en) | 1971-03-03 | 1972-12-19 | Harold J Berger | Combination blood sampling vacuum syringe centrifuge container and specimen cup |
US3706305A (en) | 1971-03-03 | 1972-12-19 | Harold J Berger | Combination blood sampling vacuum syringe centrifuge container and specimen cup |
DE2115032C3 (en) | 1971-03-29 | 1975-05-07 | Kernforschungsanlage Juelich Gmbh, 5170 Juelich | Device for separating two phases in liquid-liquid extraction in a centrifuge |
US3814248A (en) * | 1971-09-07 | 1974-06-04 | Corning Glass Works | Method and apparatus for fluid collection and/or partitioning |
US3965889A (en) | 1971-11-26 | 1976-06-29 | Commissariat A L'energie Atomique | Apparatus for the sampling of blood and the separation of plasma under anaerobic conditions |
US3779383A (en) | 1972-04-25 | 1973-12-18 | Becton Dickinson Co | Sealed assembly for separation of blood components and method |
US3849072A (en) | 1972-04-25 | 1974-11-19 | Becton Dickinson Co | Plasma separator |
US3785549A (en) | 1972-07-31 | 1974-01-15 | Haemonetics Corp | Centrifuge chuck for disposable, snap-in centrifuge rotor |
DE7239445U (en) | 1972-10-27 | 1973-08-02 | Merten Utz P | Disposable syringes, especially for taking blood samples |
US4537767A (en) | 1973-01-29 | 1985-08-27 | Pharmacia Aktiebolag | Method for cleansing fluid discharging skin surfaces, wounds and mucous membranes and means for carrying out the method |
SE452109B (en) | 1973-01-29 | 1987-11-16 | Pharmacia Ab | SCIENTIFIC CLEANER EXTENDED SARYTOR |
US3850369A (en) | 1973-03-08 | 1974-11-26 | Coulter Electronics | Centrifuge for preparing platelet rich plasma |
US3879295A (en) * | 1973-08-17 | 1975-04-22 | Eastman Kodak Co | Vacutainer with positive separation barrier |
US4001122A (en) * | 1973-08-22 | 1977-01-04 | Telan Corporation | Method and device for separating blood components |
US3896733A (en) * | 1973-10-18 | 1975-07-29 | Pall Corp | Autotransfusion apparatus |
US3962085A (en) | 1973-12-19 | 1976-06-08 | Abbott Laboratories | Skimmer assembly |
US3931010A (en) | 1974-02-27 | 1976-01-06 | Becton, Dickinson And Company | Serum/plasma separators with centrifugal valves |
US3941699A (en) | 1974-02-27 | 1976-03-02 | Becton, Dickinson And Company | Plasma separator with centrifugal valve |
US3935113A (en) | 1974-02-27 | 1976-01-27 | Becton, Dickinson And Company | Serum/plasma separator with centrifugal valve |
US3897337A (en) | 1974-02-27 | 1975-07-29 | Becton Dickinson Co | Plasma separator assembly having interface-seeking piston with centrifugal valve |
US3945928A (en) | 1974-02-27 | 1976-03-23 | Becton, Dickinson And Company | Serum/plasma separators with centrifugal valves |
US3887466A (en) | 1974-02-27 | 1975-06-03 | Becton Dickinson Co | Serum/plasma separator cannula fluid by-pass type centrifugal valve cannula seal |
US3951801A (en) | 1974-02-27 | 1976-04-20 | Becton, Dickinson And Company | Serum/plasma separator-strut stop type |
US3957654A (en) * | 1974-02-27 | 1976-05-18 | Becton, Dickinson And Company | Plasma separator with barrier to eject sealant |
US3897343A (en) * | 1974-02-27 | 1975-07-29 | Becton Dickinson Co | Plasma separator-hydrostatic pressure type |
US3909419A (en) | 1974-02-27 | 1975-09-30 | Becton Dickinson Co | Plasma separator with squeezed sealant |
US3894952A (en) | 1974-02-27 | 1975-07-15 | Becton Dickinson Co | Serum/plasma separator assembly having interface-seeking piston |
US3929646A (en) | 1974-07-22 | 1975-12-30 | Technicon Instr | Serum separator and fibrin filter |
US3931018A (en) * | 1974-08-09 | 1976-01-06 | Becton, Dickinson And Company | Assembly for collection, separation and filtration of blood |
US4204537A (en) | 1974-08-15 | 1980-05-27 | Haemonetics Corporation | Process for pheresis procedure and disposable plasma |
US4059108A (en) | 1974-08-15 | 1977-11-22 | Haemonetics Corporation | Process for pheresis procedure and disposable pheresis bowl therefor |
DE2444524A1 (en) | 1974-09-18 | 1976-04-08 | Oeser Henning Dr | METHOD AND DEVICE FOR EXPLORATION OF HUMAN BLOOD PLASMA COMPONENTS |
US3982691A (en) | 1974-10-09 | 1976-09-28 | Schlutz Charles A | Centrifuge separation and washing device and method |
US3972812A (en) | 1975-05-08 | 1976-08-03 | Becton, Dickinson And Company | Blood serum separation filter disc |
US4020831A (en) | 1975-12-04 | 1977-05-03 | Technicon Instruments Corporation | Blood collecting syringe |
US4055501A (en) | 1976-01-16 | 1977-10-25 | Sherwood Medical Industries Inc. | Fluid collection device with phase partitioning means |
US4088582A (en) | 1976-01-16 | 1978-05-09 | Sherwood Medical Industries Inc. | Blood phase separation means |
US4027660A (en) * | 1976-04-02 | 1977-06-07 | Wardlaw Stephen C | Material layer volume determination |
CA1074273A (en) * | 1976-05-06 | 1980-03-25 | Sherwood Medical Industries Inc. | Phase separation device |
US4046699A (en) | 1976-11-01 | 1977-09-06 | Corning Glass Works | Access device for centrifugal separation assemblies |
IT1103118B (en) | 1977-01-10 | 1985-10-14 | Levine Robert A | DEVICE AND TECHNIQUE TO IMPROVE THE SEPARATION OF CELL LAYERS IN CENTRIFUGAL BLOOD SAMPLES |
AT381466B (en) | 1977-03-16 | 1986-10-27 | Ballies Uwe | SEPARATING TUBES FOR CENTRIFUGAL SEPARATION |
US4189385A (en) | 1977-05-03 | 1980-02-19 | Greenspan Donald J | Method and apparatus for separating serum or plasma from the formed elements of the blood |
US5217426A (en) | 1977-08-12 | 1993-06-08 | Baxter International Inc. | Combination disposable plastic blood receiving container and blood component centrifuge |
US4146172A (en) | 1977-10-18 | 1979-03-27 | Baxter Travenol Laboratories, Inc. | Centrifugal liquid processing system |
US4187979A (en) * | 1978-09-21 | 1980-02-12 | Baxter Travenol Laboratories, Inc. | Method and system for fractionating a quantity of blood into the components thereof |
US4303193A (en) | 1979-01-22 | 1981-12-01 | Haemonetics Corporation | Apparatus for separating blood into components thereof |
US4229298A (en) | 1979-02-05 | 1980-10-21 | The Western States Machine Company | Method and apparatus for determining the thickness of a charge wall formed in a centrifugal basket |
US4453927A (en) | 1979-02-07 | 1984-06-12 | Gesco International | Method and apparatus for microfiltration of blood |
AT359653B (en) | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
AT359652B (en) | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
US4314823A (en) | 1979-03-05 | 1982-02-09 | Dionex Corporation | Combination apparatus and method for chromatographic separation and quantitative analysis of multiple ionic species |
JPS5917386B2 (en) | 1979-03-23 | 1984-04-20 | テルモ株式会社 | Blood separation method and device |
US4300717A (en) | 1979-04-02 | 1981-11-17 | Haemonetics Corporation | Rotary centrifuge seal |
NO146616C (en) | 1979-10-04 | 1982-11-03 | Ken Heimreid | PROCEDURE AND APPARATUS FOR PREPARATION FOR INVESTIGATION OF UNCOAGULATED BLOOD. |
US4269718A (en) * | 1980-05-05 | 1981-05-26 | The Institutes Of Medical Sciences | Process and device for centrifugal separation of platelets |
DE3165646D1 (en) | 1980-05-08 | 1984-09-27 | Terumo Corp | Apparatus for separating blood |
US4332351A (en) | 1980-09-22 | 1982-06-01 | International Business Machines Corporation | Blood fraction extracting centrifuge |
DE3101752A1 (en) | 1981-01-21 | 1982-08-26 | Behringwerke Ag, 3550 Marburg | "METHOD FOR PURIFYING THE BLOOD COAGINING FACTORS II, VII, IX AND / OR X AND PREPARATIONS PRODUCED THEREFORE" |
DE3101733C2 (en) | 1981-01-21 | 1982-10-14 | Uwe Dr.Med. 2300 Kiel Ballies | Separating element in a separating tube for centrifugal separation |
US4424132A (en) | 1981-02-05 | 1984-01-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Apparatus and method for separating blood components |
DE3105624A1 (en) | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
US4417981A (en) | 1981-05-04 | 1983-11-29 | Becton, Dickinson And Company | Blood phase separator device |
US4322298A (en) * | 1981-06-01 | 1982-03-30 | Advanced Blood Component Technology, Inc. | Centrifugal cell separator, and method of use thereof |
ATE20824T1 (en) | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | ENRICHED PLASMA DERIVES TO SUPPORT WOUND CLOSURE AND HEALING. |
DE3171072D1 (en) | 1981-06-25 | 1985-07-25 | Stroetmann M Serapharm | Enriched plasma derivative for promoting wound sealing and wound covering |
US4442655A (en) | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
US4735726A (en) | 1981-07-22 | 1988-04-05 | E. I. Du Pont De Nemours And Company | Plasmapheresis by reciprocatory pulsatile filtration |
GB2104401B (en) | 1981-08-25 | 1985-03-20 | Krauss Maffei Ag | Support plate for centrifuges |
US4464167A (en) | 1981-09-03 | 1984-08-07 | Haemonetics Corporation | Pheresis apparatus |
US4416654A (en) | 1981-09-03 | 1983-11-22 | Haemonetics Corporation | Pheresis apparatus |
DE3203775A1 (en) | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | FIBRINOGEN PREPARATION, METHOD FOR THEIR PRODUCTION AND THEIR USE |
DE3212412C2 (en) | 1982-04-02 | 1986-01-02 | Dr. Ruhland Nachf. GmbH, 8425 Neustadt | Tissue-bondable collagen wound dressing |
US4511662A (en) * | 1982-06-18 | 1985-04-16 | Bio-Rad Laboratories, Inc. | Simultaneous assay for T and B lymphocyte populations and subpopulations |
US4443345A (en) | 1982-06-28 | 1984-04-17 | Wells John R | Serum preparator |
JPS5928766A (en) | 1982-08-10 | 1984-02-15 | Sony Corp | Delay circuit |
US4445550B1 (en) | 1982-08-20 | 1999-03-09 | Scholle Corp | Flexible walled container having membrane fitment for use with aseptic filling apparatus |
US4680025A (en) | 1982-08-24 | 1987-07-14 | Baxter Travenol Laboratories, Inc. | Blood component collection systems and methods |
DE3378192D1 (en) | 1982-08-24 | 1988-11-17 | Baxter Int | Blood component collection system and method |
US4839058A (en) | 1982-09-13 | 1989-06-13 | Cawley Leo P | On-line plasma modification method |
US4722790A (en) | 1982-09-13 | 1988-02-02 | Cawley Leo P | On-line plasma modification means |
EP0109374A1 (en) | 1982-10-08 | 1984-05-23 | Antoon Soetens | Apparatus for capturing solar energy on a roof or the like |
SE8206767D0 (en) | 1982-11-26 | 1982-11-26 | Seroteknik Hb | SET AND DEVICE FOR BATTERY CENTRIFUGAL SEPARATION OF BLOOD |
US5034135A (en) | 1982-12-13 | 1991-07-23 | William F. McLaughlin | Blood fractionation system and method |
US4755301A (en) | 1983-08-15 | 1988-07-05 | W. R. Grace & Co. | Apparatus and method for centrifugal recovery of retentate |
US4632761A (en) | 1983-08-15 | 1986-12-30 | W. R. Grace & Co. | Centrifugal microconcentrator and methods for its use |
JPS6053845A (en) | 1983-09-05 | 1985-03-27 | Terumo Corp | Blood separating tube |
US4672969A (en) | 1983-10-06 | 1987-06-16 | Sonomo Corporation | Laser healing method |
JPS60250014A (en) | 1984-05-28 | 1985-12-10 | Mitsui Toatsu Chem Inc | Resin for concentration |
CH665565A5 (en) | 1983-10-22 | 1988-05-31 | Mitsui Toatsu Chemicals | METHOD FOR CONTROLLING THE CONCENTRATION OF AN AQUEOUS SOLUTION OR EMULSION CONTAINING A MACROMOLECULAR CONNECTION. |
CA1244774A (en) | 1983-11-09 | 1988-11-15 | Thomas Jefferson University | Medium for storing blood platelets |
DE3410286C2 (en) * | 1984-03-21 | 1986-01-23 | Fresenius AG, 6380 Bad Homburg | Method for separating blood and device for carrying out the method |
AT379311B (en) | 1984-03-29 | 1985-12-27 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE |
US4577514A (en) | 1984-04-09 | 1986-03-25 | Vanderbilt University | Method and apparatus for sampling liquid phase components from a liquid-semisolid fluid |
JPS6144825A (en) | 1984-08-09 | 1986-03-04 | Unitika Ltd | Hemostatic agent |
US4610656A (en) | 1984-08-21 | 1986-09-09 | Mehealus Partnership | Fully portable semi-automatic mechanical heart-lung substitution system and method |
US4776964A (en) | 1984-08-24 | 1988-10-11 | William F. McLaughlin | Closed hemapheresis system and method |
US4928603A (en) | 1984-09-07 | 1990-05-29 | The Trustees Of Columbia University In The City Of New York | Method of preparing a cryoprecipitated suspension and use thereof |
US4627879A (en) | 1984-09-07 | 1986-12-09 | The Trustees Of Columbia University In The City Of New York | Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma |
US5165938A (en) | 1984-11-29 | 1992-11-24 | Regents Of The University Of Minnesota | Wound healing agents derived from platelets |
US5053134A (en) | 1984-12-04 | 1991-10-01 | Becton Dickinson And Company | Lymphocyte collection tube |
US4917801A (en) * | 1984-12-04 | 1990-04-17 | Becton Dickinson And Company | Lymphocyte collection tube |
US4639316A (en) | 1984-12-14 | 1987-01-27 | Becton, Dickinson And Company | Automatic liquid component separator |
US5372945A (en) | 1985-06-06 | 1994-12-13 | Alchas; Paul G. | Device and method for collecting and processing fat tissue and procuring microvessel endothelial cells to produce endothelial cell product |
AT382783B (en) | 1985-06-20 | 1987-04-10 | Immuno Ag | DEVICE FOR APPLICATING A TISSUE ADHESIVE |
SE448323B (en) | 1985-08-27 | 1987-02-09 | Ersson Nils Olof | PROCEDURE AND PROCEDURE TO SEPARATE SERUM OR PLASMA FROM BLOOD |
DE3689903T2 (en) * | 1985-09-10 | 1994-10-20 | Ver Nl Kanker Inst | METHOD AND DEVICE FOR SEPARATING AND ISOLATING BLOOD OR BONE MARBLE COMPONENTS. |
US4724317A (en) | 1985-12-05 | 1988-02-09 | Baxter Travenol Laboratories, Inc. | Optical data collection apparatus and method used with moving members |
US4755300A (en) | 1985-12-23 | 1988-07-05 | Haemonetics Corporation | Couette membrane filtration apparatus for separating suspended components in a fluid medium using high shear |
US4871462A (en) | 1985-12-23 | 1989-10-03 | Haemonetics Corporation | Enhanced separation of blood components |
AU578554B2 (en) | 1986-01-24 | 1988-10-27 | Japanese Red Cross Society | Centrifugal method of separating blood components |
US5112490A (en) | 1986-02-19 | 1992-05-12 | Jon Turpen | Sample filtration, separation and dispensing device |
ES2004281A6 (en) * | 1986-04-04 | 1988-12-16 | Univ Jefferson | Method of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial cell growth, and the surface itself |
SE8601891D0 (en) | 1986-04-24 | 1986-04-24 | Svante Jonsson | PLASMA SWITCH TREATMENT AND TROMBOCYTING MACHINE |
DE3615558A1 (en) | 1986-05-09 | 1987-11-12 | Behringwerke Ag | METHOD FOR PRODUCING A FACTOR V CONCENTRATE |
DE3622642A1 (en) | 1986-07-05 | 1988-01-14 | Behringwerke Ag | ONE-COMPONENT TISSUE ADHESIVE AND METHOD FOR THE PRODUCTION THEREOF |
US4983158A (en) | 1986-07-22 | 1991-01-08 | Haemonetics Corporation | Plasmapheresis centrifuge bowl |
US4943273A (en) | 1986-07-22 | 1990-07-24 | Haemonetics Corporation | Disposable centrifuge bowl for blood processing |
US4714457A (en) | 1986-09-15 | 1987-12-22 | Robert Alterbaum | Method and apparatus for use in preparation of fibrinogen from a patient's blood |
DK475386D0 (en) | 1986-10-03 | 1986-10-03 | Weis Fogh Ulla Sivertsen | METHOD AND APPARATUS FOR MANUFACTURING BIOLOGICAL SUBSTANCES |
US4915847A (en) | 1987-08-04 | 1990-04-10 | Baxter International Inc. | Cryoglobulin separation |
US4929242A (en) * | 1986-11-26 | 1990-05-29 | Baxter International Inc. | Solution and method for maintaining patency of a catheter |
CH673117A5 (en) | 1986-12-10 | 1990-02-15 | Ajinomoto Kk | |
US4933291A (en) | 1986-12-22 | 1990-06-12 | Eastman Kodak Company | Centrifugable pipette tip and pipette therefor |
US5053127A (en) | 1987-01-13 | 1991-10-01 | William F. McLaughlin | Continuous centrifugation system and method for directly deriving intermediate density material from a suspension |
US5370802A (en) | 1987-01-30 | 1994-12-06 | Baxter International Inc. | Enhanced yield platelet collection systems and methods |
US4834890A (en) | 1987-01-30 | 1989-05-30 | Baxter International Inc. | Centrifugation pheresis system |
US5104526A (en) * | 1987-01-30 | 1992-04-14 | Baxter International Inc. | Centrifugation system having an interface detection system |
US5641414A (en) | 1987-01-30 | 1997-06-24 | Baxter International Inc. | Blood processing systems and methods which restrict in flow of whole blood to increase platelet yields |
US4832851A (en) | 1987-02-02 | 1989-05-23 | W. R. Grace & Co. | Centrifugal force-enhanced filtration of fluids |
US4983157A (en) | 1987-03-23 | 1991-01-08 | Ceramics Process Systems Corp. | Centrifugation system using static layer |
US5030341A (en) | 1987-04-03 | 1991-07-09 | Andronic Technologies, Inc. | Apparatus for separating phases of blood |
US5019243A (en) * | 1987-04-03 | 1991-05-28 | Mcewen James A | Apparatus for collecting blood |
IT1203461B (en) | 1987-04-08 | 1989-02-15 | Dideco Spa | BLOOD CENTRIFUGATION CELL |
US4939081A (en) * | 1987-05-27 | 1990-07-03 | The Netherlands Cancer Institute | Cell-separation |
US4846835A (en) | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
US4738655A (en) | 1987-06-17 | 1988-04-19 | Utah Bioresearch, Inc. | Apparatus and method for obtaining a rapid hematocrit |
DE3723092C1 (en) | 1987-07-13 | 1989-01-26 | Westfalia Separator Ag | Continuous centrifuge for the industrial production of proteins from human blood plasma |
US5260420A (en) | 1987-07-30 | 1993-11-09 | Centre Regional De Transfusion Sanguine De Lille | Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof |
DE3726227A1 (en) | 1987-08-07 | 1989-02-16 | Krauss Maffei Ag | DEVICE FOR RESULTS CONTROLLING A FILTER CENTRIFUGE |
US4818386A (en) * | 1987-10-08 | 1989-04-04 | Becton, Dickinson And Company | Device for separating the components of a liquid sample having higher and lower specific gravities |
US4877520A (en) | 1987-10-08 | 1989-10-31 | Becton, Dickinson And Company | Device for separating the components of a liquid sample having higher and lower specific gravities |
US4957638A (en) | 1987-10-23 | 1990-09-18 | Becton Dickinson And Company | Method for separating the cellular components of blood samples |
US4844818A (en) | 1987-10-23 | 1989-07-04 | Becton Dickinson & Company | Method for separating the cellular components of blood samples |
US5290552A (en) | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
ES2064439T3 (en) | 1988-05-02 | 1995-02-01 | Project Hear | SURGICAL ADHESIVE MATERIAL. |
US4957637A (en) | 1988-05-23 | 1990-09-18 | Sherwood Medical Company | Serum separator system for centrifuge with piercable membrane |
AT397203B (en) | 1988-05-31 | 1994-02-25 | Immuno Ag | FABRIC ADHESIVE |
DE68902698C5 (en) | 1988-06-23 | 2005-07-14 | Asahi Medical Co. Ltd. | Method for separating blood into blood components and unit for separating blood components. |
US5024613A (en) * | 1988-07-18 | 1991-06-18 | Pfizer Hospital Products Group, Inc. | Blood recovery system and method |
US4874368A (en) | 1988-07-25 | 1989-10-17 | Micromedics, Inc. | Fibrin glue delivery system |
US4846780A (en) | 1988-08-10 | 1989-07-11 | Exxon Production Research Company | Centrifuge processor and liquid level control system |
US4902281A (en) | 1988-08-16 | 1990-02-20 | Corus Medical Corporation | Fibrinogen dispensing kit |
US4946601A (en) | 1988-08-22 | 1990-08-07 | Sherwood Medical Company | Blood serum separator tube |
JPH02129224A (en) | 1988-11-10 | 1990-05-17 | Terumo Corp | Preparation of fibrin |
US4973168A (en) | 1989-01-13 | 1990-11-27 | Chan Kwan Ho | Vacuum mixing/bone cement cartridge and kit |
DE8900469U1 (en) | 1989-01-17 | 1990-05-23 | Espe Stiftung & Co Produktions- und Vertriebs KG, 8031 Seefeld | Device for mixing and dispensing pasty masses |
US5002571A (en) | 1989-02-06 | 1991-03-26 | Donnell Jr Francis E O | Intraocular lens implant and method of locating and adhering within the posterior chamber |
SE8900586L (en) | 1989-02-21 | 1990-08-22 | Pharmacia Ab | COMPOSITION AND PROCEDURES TO PREVENT ADHESION BETWEEN BODY TISSUE |
CA2011100C (en) | 1989-05-24 | 1996-06-11 | Stephen C. Wardlaw | Centrifuged material layer measurements taken in an evacuated tube |
US5226877A (en) | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
US5000970A (en) | 1989-06-30 | 1991-03-19 | Horizons International Foods, Inc. | Process for preparing reheatable french fried potatoes |
WO1991001383A1 (en) | 1989-07-14 | 1991-02-07 | Michigan State University | Method for diagnosing blood clotting disorders |
US5207638A (en) * | 1989-08-24 | 1993-05-04 | Hemotrans, Inc. | Blood transfer apparatus |
US5316674A (en) | 1989-09-12 | 1994-05-31 | Pall Corporation | Device for processing blood for human transfusion |
US5100564A (en) | 1990-11-06 | 1992-03-31 | Pall Corporation | Blood collection and processing system |
US5258126A (en) | 1989-09-12 | 1993-11-02 | Pall Corporation | Method for obtaining platelets |
US5152905A (en) | 1989-09-12 | 1992-10-06 | Pall Corporation | Method for processing blood for human transfusion |
US5599558A (en) * | 1989-09-15 | 1997-02-04 | Curative Technologies, Inc. | Selecting amounts of platelet releasate for efficacious treatment of tissue |
IL95641A0 (en) | 1989-09-15 | 1991-06-30 | Curative Tech Inc | Preparation of a platelet releasate product |
US5104375A (en) | 1989-10-16 | 1992-04-14 | Johnson & Johnson Medical, Inc. | Locking holder for a pair of syringes and method of use |
US5039401A (en) | 1990-05-16 | 1991-08-13 | Eastman Kodak Company | Blood collection and centrifugal separation device including a valve |
US5318524A (en) | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
US5030215A (en) | 1990-01-03 | 1991-07-09 | Cryolife, Inc. | Preparation of fibrinogen/factor XIII precipitate |
US5219328A (en) | 1990-01-03 | 1993-06-15 | Cryolife, Inc. | Fibrin sealant delivery method |
NL9000090A (en) | 1990-01-15 | 1991-08-01 | Harimex Ligos Bv | METHOD FOR PREPARING A FIBRINOGEN CONCENTRATE FROM BLOOD PLASMA, APPARATUS FOR CARRYING OUT THIS PROCESS AND METHOD FOR PREPARING FIBRINOGEN FROM THE CONCENTRATE |
US5185001A (en) * | 1990-01-18 | 1993-02-09 | The Research Foundation Of State University Of New York | Method of preparing autologous plasma fibrin and application apparatus therefor |
US5047004A (en) | 1990-02-07 | 1991-09-10 | Wells John R | Automatic decanting centrifuge |
US5178602A (en) * | 1990-02-07 | 1993-01-12 | Wells John R | Automatic decanting centrifuge |
US5045048A (en) | 1990-03-29 | 1991-09-03 | Haemonetics Corporation | Rotary centrifuge bowl and seal for blood processing |
US5204537A (en) | 1990-03-30 | 1993-04-20 | Recognition Equipment Incorporated | Thickness sensor comprising a leaf spring means, and a light sensor |
DK119490D0 (en) | 1990-05-14 | 1990-05-14 | Unes As | Apparatus for the preparation of a concentrate of coagulation factors, such as the fibrinogen, from a blood portion |
US5171456A (en) | 1990-06-14 | 1992-12-15 | Baxter International Inc. | Automated blood component separation procedure and apparatus promoting different functional characteristics in multiple blood components |
US5156586A (en) | 1990-07-10 | 1992-10-20 | Bardyne | Orbital separator for orbitally separating a mixture |
FR2665378B1 (en) | 1990-08-03 | 1992-10-09 | Guigan Jean | DEVICE FOR SEPARATING BY CENTRIFUGATION TWO PHASES FROM A SAMPLE OF A HETEROGENEOUS LIQUID, USABLE IN PARTICULAR FOR THE SEPARATION OF TOTAL BLOOD PLASMA. |
US5420250A (en) | 1990-08-06 | 1995-05-30 | Fibrin Corporation | Phase transfer process for producing native plasma protein concentrates |
US5641622A (en) * | 1990-09-13 | 1997-06-24 | Baxter International Inc. | Continuous centrifugation process for the separation of biological components from heterogeneous cell populations |
US5173295A (en) | 1990-10-05 | 1992-12-22 | Advance Biofactures Of Curacao, N.V. | Method of enhancing the regeneration of injured nerves and adhesive pharamaceutical formulation therefor |
US5112484A (en) | 1990-10-11 | 1992-05-12 | Zuk, Inc. | Filtration apparatus |
US5217627A (en) | 1990-11-06 | 1993-06-08 | Pall Corporation | System and method for processing biological fluid |
US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
US5226914A (en) | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
US5955436A (en) | 1990-11-20 | 1999-09-21 | Alcon Laboratories, Inc. | Use of platelet derived growth factor to enhance wound healing |
US6117425A (en) | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5234608A (en) | 1990-12-11 | 1993-08-10 | Baxter International Inc. | Systems and methods for processing cellular rich suspensions |
JPH0774772B2 (en) * | 1990-12-31 | 1995-08-09 | エイ. レビン ロバート | Blood sampling assembly, target cell collection method and target component collection method |
US5137832A (en) | 1991-01-02 | 1992-08-11 | Becton Dickinson & Company | Quantification of fibrinogen in whole blood samples contained in a tube using a float to separate materials |
US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
US5156613A (en) | 1991-02-13 | 1992-10-20 | Interface Biomedical Laboratories Corp. | Collagen welding rod material for use in tissue welding |
US5762798A (en) | 1991-04-12 | 1998-06-09 | Minntech Corporation | Hollow fiber membranes and method of manufacture |
US5236604A (en) | 1991-05-29 | 1993-08-17 | Sherwood Medical Company | Serum separation blood collection tube and the method of using thereof |
US5269927A (en) | 1991-05-29 | 1993-12-14 | Sherwood Medical Company | Separation device for use in blood collection tubes |
US5203825A (en) * | 1991-06-07 | 1993-04-20 | Becton, Dickinson And Company | Capillary tube assembly including a vented cap |
SE9101853D0 (en) | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | IMPROVED TISSUE ASHESIVE |
FR2679251B1 (en) | 1991-07-18 | 1993-11-12 | Nord Assoc Essor Transfusion San | PROCESS FOR THE PREPARATION OF A HUMAN THROMBIN CONCENTRATE FOR THERAPEUTIC USE. |
DE4126341C1 (en) | 1991-08-09 | 1993-01-28 | Fresenius Ag, 6380 Bad Homburg, De | |
US5251786A (en) | 1991-08-16 | 1993-10-12 | Helena Laboratories Corporation | Biological fluid collection and delivery apparatus and method |
BR9103724A (en) | 1991-08-29 | 1993-03-30 | Univ Estadual Paulista Julio D | FIBRINE GLUE DERIVED FROM SNAKE POISON AND PROCESS FOR ITS PREPARATION |
DE69229272T2 (en) | 1991-09-05 | 2000-02-03 | Baxter International Inc., Deerfield | TOPICAL FIBRINOGEN COMPLEX |
DE4129516C2 (en) | 1991-09-06 | 2000-03-09 | Fresenius Ag | Method and device for separating blood into its components |
EP0534178B1 (en) | 1991-09-27 | 2001-04-18 | Omrix Biopharmaceuticals S.A. | Improved tissue glue prepared by using cryoprecipitate |
WO1993007824A1 (en) | 1991-10-18 | 1993-04-29 | Baxter International Inc. | Bone marrow kit |
US5344752A (en) | 1991-10-30 | 1994-09-06 | Thomas Jefferson University | Plasma-based platelet concentrate preparations |
CA2074671A1 (en) | 1991-11-04 | 1993-05-05 | Thomas Bormann | Device and method for separating plasma from a biological fluid |
US5190057A (en) | 1991-12-13 | 1993-03-02 | Faezeh Sarfarazi | Sarfarazi method of closing a corneal incision |
US5833866A (en) | 1991-12-23 | 1998-11-10 | Baxter International Inc. | Blood collection systems and methods which derive instantaneous blood component yield information during blood processing |
US5804079A (en) | 1991-12-23 | 1998-09-08 | Baxter International Inc. | Systems and methods for reducing the number of leukocytes in cellular products like platelets harvested for therapeutic purposes |
DE4202667C1 (en) | 1992-01-29 | 1993-05-13 | Behringwerke Ag, 3550 Marburg, De | |
DE4204012A1 (en) * | 1992-02-12 | 1993-08-19 | Ulrich Prof Dr Zimmermann | MITOGEN-FREE SUBSTANCE, THEIR PRODUCTION AND USE |
AU670075B2 (en) | 1992-02-26 | 1996-07-04 | Allergan, Inc. | Use of platelet derived growth factor in ophthalmic wound healing |
US5298016A (en) | 1992-03-02 | 1994-03-29 | Advanced Haemotechnologies | Apparatus for separating plasma and other wastes from blood |
SE9201413L (en) | 1992-04-30 | 1993-10-31 | Stiftelsen Foer Medicinsk Tekn | Preparation and Methods for Apheresis Preparation of Platelet Concentrate with Significantly Extended Durability |
US5271852A (en) | 1992-05-01 | 1993-12-21 | E. I. Du Pont De Nemours And Company | Centrifugal methods using a phase-separation tube |
US5403272A (en) | 1992-05-29 | 1995-04-04 | Baxter International Inc. | Apparatus and methods for generating leukocyte free platelet concentrate |
US5275585A (en) * | 1992-06-03 | 1994-01-04 | Zimmer Patient Care | Autotransfusion system with portable detachable vacuum source |
FR2691911B1 (en) | 1992-06-05 | 1994-11-25 | Delmas Olivier | Device for obtaining a supernatant of activated thrombocytes, process using the device and obtained supernatant. |
DK83092D0 (en) | 1992-06-24 | 1992-06-24 | Unes As | PROCEDURE FOR THE EXTRACTION OF THROMBIN |
US5443481A (en) | 1992-07-27 | 1995-08-22 | Lee; Benjamin I. | Methods and device for percutaneous sealing of arterial puncture sites |
WO1994006460A1 (en) | 1992-09-21 | 1994-03-31 | Vitaphore Corporation | Embolization plugs for blood vessels |
FR2696095B1 (en) | 1992-09-30 | 1994-11-25 | Inoteb | Biological glue based on proteins coagulable by thrombin, enriched in platelet factors, its preparation and its application. |
US5354483A (en) | 1992-10-01 | 1994-10-11 | Andronic Technologies, Inc. | Double-ended tube for separating phases of blood |
CN1091315A (en) | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | Fibrin sealant compositions and using method thereof |
CN1074709A (en) | 1992-11-26 | 1993-07-28 | 刘高东 | Method for preparing thrombin |
WO1994012223A1 (en) * | 1992-12-01 | 1994-06-09 | Haemonetics Corporation | Red blood cell apheresis apparatus and method |
US5520885A (en) | 1993-01-19 | 1996-05-28 | Thermogenesis Corporation | Fibrinogen processing apparatus, method and container |
US5370221A (en) | 1993-01-29 | 1994-12-06 | Biomet, Inc. | Flexible package for bone cement components |
US5395923A (en) | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
US5290918A (en) | 1993-02-23 | 1994-03-01 | Haemacure Biotech Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation |
US5330974A (en) | 1993-03-01 | 1994-07-19 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
US5614106A (en) * | 1993-03-12 | 1997-03-25 | Baxter International Inc. | Method and apparatus for collection of platelets |
GB9307321D0 (en) | 1993-04-07 | 1993-06-02 | Knight Scient Ltd | Method of separating particles from a filter |
DE69425966T2 (en) * | 1993-04-27 | 2001-03-29 | Haemonetics Corp., Braintree | Apheresis device |
US5409833A (en) | 1993-07-01 | 1995-04-25 | Baxter International Inc. | Microvessel cell isolation apparatus |
US5456885A (en) | 1993-07-12 | 1995-10-10 | Coleman; Charles M. | Fluid collection, separation and dispensing tube |
US6189704B1 (en) | 1993-07-12 | 2001-02-20 | Baxter International Inc. | Inline filter |
JPH07103969A (en) | 1993-08-13 | 1995-04-21 | Niigata Kako Kk | Blood separation member and blood collecting tube for blood separation |
US5571418A (en) | 1993-08-20 | 1996-11-05 | Lee; Patrice A. | Hemofiltration of toxic mediator-related disease |
US5916557A (en) | 1993-11-12 | 1999-06-29 | The Trustees Of Columbia University In The City Of New York | Methods of repairing connective tissues |
CA2131738C (en) | 1993-11-17 | 2001-09-04 | Lonny R. Kelley | Flow enhanced one-pass centrifuge separator |
ZA948564B (en) | 1993-11-19 | 1995-07-26 | Bristol Myers Squibb Co | Liquid separation apparatus and method |
US5411885A (en) | 1993-12-17 | 1995-05-02 | New York Blood Center, Inc. | Methods for tissue embedding and tissue culturing |
US5437598A (en) | 1994-01-21 | 1995-08-01 | Cobe Laboratories, Inc. | Automation of plasma sequestration |
US6245900B1 (en) * | 1994-02-23 | 2001-06-12 | Kyowa Hakko Kogyo Co., Ltd. | Platelet production promoting agent |
US5545339A (en) * | 1994-02-25 | 1996-08-13 | Pall Corporation | Method for processing biological fluid and treating separated component |
WO1995028124A2 (en) * | 1994-04-08 | 1995-10-26 | Atrix Laboratories, Inc. | An adjunctive polymer system for use with medical device |
US5533518A (en) | 1994-04-22 | 1996-07-09 | Becton, Dickinson And Company | Blood collection assembly including mechanical phase separating insert |
US5723331A (en) | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
US5795751A (en) | 1994-06-09 | 1998-08-18 | Lockheed Martin Idaho Technologies Company | Biofilter for removal of nitrogen oxides from contaminated gases under aerobic conditions |
US5501371A (en) | 1994-07-07 | 1996-03-26 | Schwartz-Feldman; Jean | Mixing syringe |
US5577513A (en) | 1994-08-31 | 1996-11-26 | Activated Cell Therapy, Inc. | Centrifugation syringe, system and method |
US5474687A (en) | 1994-08-31 | 1995-12-12 | Activated Cell Therapy, Inc. | Methods for enriching CD34+ human hematopoietic progenitor cells |
US5840502A (en) | 1994-08-31 | 1998-11-24 | Activated Cell Therapy, Inc. | Methods for enriching specific cell-types by density gradient centrifugation |
US5663051A (en) | 1994-08-31 | 1997-09-02 | Activated Cell Therapy, Inc. | Separation apparatus and method |
US5646004A (en) * | 1994-08-31 | 1997-07-08 | Activated Cell Therapy, Inc. | Methods for enriching fetal cells from maternal body fluids |
US5648223A (en) * | 1994-08-31 | 1997-07-15 | Activated Cell Therapy, Inc. | Methods for enriching breast tumor cells |
US5575778A (en) | 1994-09-21 | 1996-11-19 | B. Braun Melsungen Ag | Blood-taking device |
US5588958A (en) | 1994-09-21 | 1996-12-31 | C. R. Bard, Inc. | Closed wound orthopaedic drainage and autotransfusion system |
US5645540A (en) * | 1994-10-11 | 1997-07-08 | Stryker Corporation | Blood conservation system |
US5733253A (en) | 1994-10-13 | 1998-03-31 | Transfusion Technologies Corporation | Fluid separation system |
US5601711A (en) | 1994-10-31 | 1997-02-11 | Gelman Sciences Inc. | Selective separation filter device |
US5733446A (en) | 1994-12-02 | 1998-03-31 | Bristol-Myers Squibb Company | Centrifuge with annular filter |
WO1996016713A1 (en) | 1994-12-02 | 1996-06-06 | E.R. Squibb And Sons, Inc. | Centrifuge reagent delivery system |
CZ164797A3 (en) | 1994-12-02 | 1998-07-15 | Bristol-Myers Sguibb Company | Process of separating fibrin i from blood plasma and apparatus for making the same |
CA2182862C (en) | 1994-12-07 | 2006-10-03 | Richard D. Antanavich | Plasma concentrate and tissue sealant compositions |
US5585007A (en) | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
US5560830A (en) | 1994-12-13 | 1996-10-01 | Coleman; Charles M. | Separator float and tubular body for blood collection and separation and method of use thereof |
NO301562B1 (en) | 1994-12-21 | 1997-11-10 | Exxon Production Research Co | Device for measuring |
US5510102A (en) | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
US7011644B1 (en) | 1995-02-06 | 2006-03-14 | Andrew Mark S | Tissue liquefaction and aspiration for dental treatment |
US6676629B2 (en) | 1995-02-06 | 2004-01-13 | Mark S. Andrew | Tissue liquefaction and aspiration for dental treatment |
US5823986A (en) | 1995-02-08 | 1998-10-20 | Medtronic, Inc. | Perfusion system |
US5733545A (en) | 1995-03-03 | 1998-03-31 | Quantic Biomedical Partners | Platelet glue wound sealant |
US5906934A (en) | 1995-03-14 | 1999-05-25 | Morphogen Pharmaceuticals, Inc. | Mesenchymal stem cells for cartilage repair |
US5900245A (en) | 1996-03-22 | 1999-05-04 | Focal, Inc. | Compliant tissue sealants |
US5716616A (en) * | 1995-03-28 | 1998-02-10 | Thomas Jefferson University | Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects |
US5643192A (en) | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
US6022306A (en) * | 1995-04-18 | 2000-02-08 | Cobe Laboratories, Inc. | Method and apparatus for collecting hyperconcentrated platelets |
US5674173A (en) | 1995-04-18 | 1997-10-07 | Cobe Laboratories, Inc. | Apparatus for separating particles |
US5939319A (en) * | 1995-04-18 | 1999-08-17 | Cobe Laboratories, Inc. | Particle separation method and apparatus |
US6053856A (en) * | 1995-04-18 | 2000-04-25 | Cobe Laboratories | Tubing set apparatus and method for separation of fluid components |
USRE38730E1 (en) | 1995-05-05 | 2005-04-26 | Harvest Technologies Corporation | Automatic multiple-decanting centrifuge and method of treating physiological fluids |
US5707331A (en) | 1995-05-05 | 1998-01-13 | John R. Wells | Automatic multiple-decanting centrifuge |
EP0836487A1 (en) | 1995-06-06 | 1998-04-22 | Quantic Biomedical Partners | Device and method for concentrating plasma |
US5958250A (en) | 1995-06-07 | 1999-09-28 | Baxter International Inc. | Blood processing systems and methods which optically derive the volume of platelets contained in a plasma constituent |
US6544727B1 (en) | 1995-06-07 | 2003-04-08 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
US20020192632A1 (en) | 1995-06-07 | 2002-12-19 | Hei Derek J. | Method and devices for the removal of psoralens from blood products |
US5750025A (en) | 1995-06-07 | 1998-05-12 | Cobe Laboratories, Inc. | Disposable for an apheresis system with a contoured support |
US5738644A (en) * | 1995-06-07 | 1998-04-14 | Cobe Laboratories, Inc. | Extracorporeal blood processing methods and apparatus |
US5837150A (en) | 1995-06-07 | 1998-11-17 | Cobe Laboratories, Inc. | Extracorporeal blood processing methods |
US5632905A (en) * | 1995-08-07 | 1997-05-27 | Haynes; John L. | Method and apparatus for separating formed and unformed components |
US6351659B1 (en) | 1995-09-28 | 2002-02-26 | Brainlab Med. Computersysteme Gmbh | Neuro-navigation system |
WO1997012679A1 (en) | 1995-10-03 | 1997-04-10 | Beckman Instruments, Inc. | Axial spin blood separation system and method |
US5736033A (en) * | 1995-12-13 | 1998-04-07 | Coleman; Charles M. | Separator float for blood collection tubes with water swellable material |
US5643193A (en) | 1995-12-13 | 1997-07-01 | Haemonetics Corporation | Apparatus for collection washing and reinfusion of shed blood |
US6025201A (en) * | 1995-12-28 | 2000-02-15 | Bayer Corporation | Highly sensitive, accurate, and precise automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples |
US5817519A (en) | 1995-12-28 | 1998-10-06 | Bayer Corporation | Automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples |
US6200606B1 (en) * | 1996-01-16 | 2001-03-13 | Depuy Orthopaedics, Inc. | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
US5733466A (en) | 1996-02-06 | 1998-03-31 | International Business Machines Corporation | Electrolytic method of depositing gold connectors on a printed circuit board |
US5865785A (en) | 1996-02-23 | 1999-02-02 | Baxter International Inc. | Systems and methods for on line finishing of cellular blood products like platelets harvested for therapeutic purposes |
US5834418A (en) | 1996-03-20 | 1998-11-10 | Theratechnologies, Inc. | Process for the preparation of platelet growth factors extract |
US5707876A (en) * | 1996-03-25 | 1998-01-13 | Stephen C. Wardlaw | Method and apparatus for harvesting constituent layers from a centrifuged material mixture |
ATE186235T1 (en) | 1996-04-24 | 1999-11-15 | Claude Fell | CELL SEPARATION DEVICE FOR BIOLOGICAL LIQUIDS SUCH AS BLOOD |
WO2000062828A1 (en) | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
DE29723807U1 (en) | 1996-04-30 | 1999-11-04 | Medtronic, Inc., Minneapolis, Minn. | Autologous fibrin hemostatic agent |
US6099493A (en) * | 1997-05-06 | 2000-08-08 | Sherwood Services, Ag | Continuous autotransfusion filtration system |
JP2859845B2 (en) | 1996-05-09 | 1999-02-24 | 照明 伊藤 | Serum collection aid |
US6020196A (en) | 1996-05-09 | 2000-02-01 | Baxter International Inc. | Devices for harvesting and homogenizing adipose tissue containing autologous endothelial cells |
US5811151A (en) | 1996-05-31 | 1998-09-22 | Medtronic, Inc. | Method of modifying the surface of a medical device |
US5824084A (en) | 1996-07-03 | 1998-10-20 | The Cleveland Clinic Foundation | Method of preparing a composite bone graft |
JP3638614B2 (en) | 1996-07-25 | 2005-04-13 | ジェンザイム・コーポレーション | Chondrocyte medium composition and culture method |
WO1998012274A1 (en) | 1996-09-23 | 1998-03-26 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
FR2757770B1 (en) | 1996-12-30 | 1999-02-26 | Inoteb | PROCESS FOR THE PREPARATION OF A BIOLOGICAL GLUE CAPABLE OF COAGULATING BY SIMPLE ADDITION OF CALCIUM IONS |
US5879624A (en) * | 1997-01-15 | 1999-03-09 | Boehringer Laboratories, Inc. | Method and apparatus for collecting and processing blood |
US5961210A (en) | 1997-01-24 | 1999-10-05 | Mccardel; Brian R. | Bone cement preparation device, and methods of constructing and utilizing same |
US5889584A (en) | 1997-03-10 | 1999-03-30 | Robert A. Levine | Assembly for rapid measurement of cell layers |
WO1998043720A1 (en) | 1997-04-03 | 1998-10-08 | Baxter International Inc. | Interface detection and control systems and methods |
US6544162B1 (en) | 1997-04-25 | 2003-04-08 | Washington State University Research Foundation | Semi-continuous, small volume centrifugal blood separator and method of using therefor |
US5860937A (en) | 1997-04-30 | 1999-01-19 | Becton, Dickinson & Company | Evacuated sample collection tube with aqueous additive |
DE19718648A1 (en) | 1997-05-02 | 1998-11-05 | Merck Patent Gmbh | Method and device for producing sterile packed bone cement |
US6063624A (en) | 1997-06-09 | 2000-05-16 | Baxter International Inc. | Platelet suspensions and methods for resuspending platelets |
EP0993311B1 (en) | 1997-06-18 | 2012-11-14 | Angiotech Pharmaceuticals (US), Inc. | Compositions containing thrombin and microfibrillar collagen, and methods for preparation and use thereof |
IT1292410B1 (en) | 1997-06-24 | 1999-02-08 | Roberto Beretta | READY-TO-USE CONTAINER TO OBTAIN AUTOLOGOUS FIBRIN GLUE |
US6979307B2 (en) | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
US5918622A (en) | 1997-07-01 | 1999-07-06 | Bermad | Separation valve |
US6007811A (en) | 1997-07-01 | 1999-12-28 | Sea Run Holdings, Inc. | Method of producing fibrin sealant from clotting factors in fish blood |
CH694074A5 (en) | 1997-08-16 | 2004-07-15 | Orthogen Gentechnologie Gmbh | Process for the preparation of therapeutically active proteins. |
US6200287B1 (en) * | 1997-09-05 | 2001-03-13 | Gambro, Inc. | Extracorporeal blood processing methods and apparatus |
US5938621A (en) | 1997-09-12 | 1999-08-17 | Becton Dickinson And Company | Collection container assembly |
US5955032A (en) | 1997-09-12 | 1999-09-21 | Becton Dickinson And Company | Collection container assembly |
EP1030676B1 (en) | 1997-10-30 | 2005-09-14 | The General Hospital Corporation | Bonding of cartilaginous matrices using isolated chondrocytes |
US5934803A (en) | 1997-10-30 | 1999-08-10 | Physical Systems, Inc. | Apparatus and method for mixing multi-part reaction materials under vacuum |
US7031775B2 (en) | 1997-11-07 | 2006-04-18 | Medtronic, Inc. | Method and system for myocardial infarction repair |
US5951160A (en) | 1997-11-20 | 1999-09-14 | Biomet, Inc. | Method and apparatus for packaging, mixing and delivering bone cement |
US6478808B2 (en) | 1997-12-17 | 2002-11-12 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
US6051146A (en) * | 1998-01-20 | 2000-04-18 | Cobe Laboratories, Inc. | Methods for separation of particles |
WO1999046366A1 (en) * | 1998-03-13 | 1999-09-16 | Osiris Therapeutics, Inc. | Uses for humane non-autologous mesenchymal stem cells |
WO1999047190A1 (en) | 1998-03-16 | 1999-09-23 | Medtronic, Inc. | Hemostatic system and components for extracorporeal circuit |
US5924972A (en) | 1998-03-24 | 1999-07-20 | Turvaville; L. Jackson | Portable D.C. powered centrifuge |
US6835377B2 (en) | 1998-05-13 | 2004-12-28 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration |
CN1307491A (en) * | 1998-06-01 | 2001-08-08 | 丰收技术股份有限公司 | System for withdrawal of blood |
US6327491B1 (en) | 1998-07-06 | 2001-12-04 | Neutar, Llc | Customized surgical fixture |
US6274090B1 (en) | 1998-08-05 | 2001-08-14 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
US5999558A (en) | 1998-08-13 | 1999-12-07 | Ucar Carbon Technology Corporation | Integral spray cooled furnace roof and fume elbow |
US6308747B1 (en) | 1998-10-01 | 2001-10-30 | Barry Farris | Needleless method and apparatus for transferring liquid from a container to an injecting device without ambient air contamination |
US6563953B2 (en) | 1998-11-30 | 2003-05-13 | Microsoft Corporation | Predictive image compression using a single variable length code for both the luminance and chrominance blocks for each macroblock |
US6328765B1 (en) | 1998-12-03 | 2001-12-11 | Gore Enterprise Holdings, Inc. | Methods and articles for regenerating living tissue |
US6406671B1 (en) * | 1998-12-05 | 2002-06-18 | Becton, Dickinson And Company | Device and method for separating components of a fluid sample |
US6479298B1 (en) | 1998-12-05 | 2002-11-12 | Becton, Dickinson And Company | Device and method for separating components of a fluid sample |
US6280400B1 (en) | 1998-12-05 | 2001-08-28 | Becton Dickinson And Company | Device and method for separating component of a liquid sample |
US6516953B1 (en) | 1998-12-05 | 2003-02-11 | Becton, Dickinson And Company | Device for separating components of a fluid sample |
ES2260881T3 (en) | 1998-12-05 | 2006-11-01 | Becton Dickinson And Company | DEVICE AND METHOD FOR SEPARATING COMPONENTS OF A FLUID SAMPLE. |
DE19903876B4 (en) | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Process for the in vitro formation and accumulation of interleukin-1 receptor antagonists |
US6153113A (en) | 1999-02-22 | 2000-11-28 | Cobe Laboratories, Inc. | Method for using ligands in particle separation |
US6294187B1 (en) | 1999-02-23 | 2001-09-25 | Osteotech, Inc. | Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same |
US6322785B1 (en) | 1999-03-02 | 2001-11-27 | Natrex Technologies | Methods and compositions for bone graft implants |
US20030082152A1 (en) | 1999-03-10 | 2003-05-01 | Hedrick Marc H. | Adipose-derived stem cells and lattices |
US20050076396A1 (en) | 1999-03-10 | 2005-04-07 | Katz Adam J. | Adipose-derived stem cells and lattices |
WO2000053795A1 (en) | 1999-03-10 | 2000-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Adipose-derived stem cells and lattices |
US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
US20050153442A1 (en) | 1999-03-10 | 2005-07-14 | Adam Katz | Adipose-derived stem cells and lattices |
US6334842B1 (en) | 1999-03-16 | 2002-01-01 | Gambro, Inc. | Centrifugal separation apparatus and method for separating fluid components |
US6296602B1 (en) | 1999-03-17 | 2001-10-02 | Transfusion Technologies Corporation | Method for collecting platelets and other blood components from whole blood |
US6432119B1 (en) | 1999-03-17 | 2002-08-13 | Angiotrax, Inc. | Apparatus and methods for performing percutaneous myocardial revascularization and stimulating angiogenesis using autologous materials |
WO2000061256A1 (en) | 1999-04-12 | 2000-10-19 | Harvest Technologies Corporation | Method and apparatus for producing platelet rich plasma and/or platelet concentrate |
US6417004B1 (en) | 1999-04-29 | 2002-07-09 | Helena Laboratories Corporation | Enhancing clot detection in activated clotting time and other fibrin endpoint based tests |
EP1057534A1 (en) | 1999-06-03 | 2000-12-06 | Haemonetics Corporation | Centrifugation bowl with filter core |
US6629919B2 (en) | 1999-06-03 | 2003-10-07 | Haemonetics Corporation | Core for blood processing apparatus |
US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
US6316247B1 (en) | 1999-06-15 | 2001-11-13 | University Of Pittsburgh | System and method for refining liposuctioned adipose tissue |
US6716187B1 (en) | 1999-07-08 | 2004-04-06 | Implant Innovations, Inc. | Platelet concentration syringe kit |
AU5918800A (en) | 1999-07-08 | 2001-01-30 | Implant Innovations, Inc. | Platelet concentration syringe kit |
US6758978B1 (en) | 1999-08-06 | 2004-07-06 | Gl&V Management Hungary Kft. | Deep bed thickener/clarifiers with enhanced liquid removal |
US6294094B1 (en) | 1999-09-03 | 2001-09-25 | Baxter International Inc. | Systems and methods for sensing red blood cell hematocrit |
US6284142B1 (en) | 1999-09-03 | 2001-09-04 | Baxter International Inc. | Sensing systems and methods for differentiating between different cellular blood species during extracorporeal blood separation or processing |
US6487992B1 (en) | 1999-11-22 | 2002-12-03 | Robert L. Hollis | Dog behavior monitoring and training apparatus |
US6803022B2 (en) | 1999-12-06 | 2004-10-12 | Becton, Dickinson And Company | Device and method for separating components of a fluid sample |
US6471069B2 (en) | 1999-12-03 | 2002-10-29 | Becton Dickinson And Company | Device for separating components of a fluid sample |
US6409528B1 (en) | 1999-12-06 | 2002-06-25 | Becton, Dickinson And Company | Device and method for collecting, preparation and stabilizing a sample |
ITAL990010U1 (en) | 1999-12-14 | 2001-06-14 | Maria Cristina Sacchi | NEW LABORATORY METHOD FOR PREPARING GEL AND PLATE MEMBRANES OBTAINED FROM THE PLATE CONCENTRATE. |
KR100505445B1 (en) * | 1999-12-28 | 2005-08-04 | 주식회사 하이닉스반도체 | Ferroelectric capacitor and method for forming the same in semiconductor device |
US6286670B1 (en) | 2000-03-14 | 2001-09-11 | Biomet, Inc. | Method and apparatus for mixing a compound utilizing a gas permeable barrier |
US20020104808A1 (en) | 2000-06-30 | 2002-08-08 | Lou Blasetti | Method and apparatus for producing platelet rich plasma and/or platelet concentrate |
JP4128007B2 (en) | 2000-04-28 | 2008-07-30 | ハーベスト・テクノロジーズ・コーポレイション | Blood component separation disk |
US6368498B1 (en) | 2000-08-30 | 2002-04-09 | Paul Guilmette | Liquid separator |
US7411006B2 (en) | 2000-10-23 | 2008-08-12 | Shanbrom Technologies, Llc | Enhanced production of blood clotting factors and fibrin fabric |
KR20030057545A (en) | 2000-11-08 | 2003-07-04 | 옥타파르마 아게 | Process for preparing latent antithrombin III |
US20020090711A1 (en) | 2000-11-20 | 2002-07-11 | Goran Karlsson | Process for preparing latent antithrombin III |
WO2002060925A1 (en) | 2001-01-30 | 2002-08-08 | Genzymes Corporation | Method of producing latent antithrombin iii |
US6911202B2 (en) | 2001-02-06 | 2005-06-28 | Abraham Amir | Cosmetic repair using cartilage producing cells and medical implants coated therewith |
US20030050709A1 (en) * | 2001-02-23 | 2003-03-13 | Ulrich Noth | Trabecular bone-derived human mesenchymal stem cells |
CA2439043A1 (en) | 2001-02-26 | 2002-09-06 | Ben-Ami Ballin | Syringe for use in blood analysis |
US6723131B2 (en) | 2001-02-28 | 2004-04-20 | The Cleveland Clinic Foundation | Composite bone marrow graft material with method and kit |
JP2005098704A (en) | 2001-03-13 | 2005-04-14 | Hajime Ogata | Method for fractionating particulate of different specific gravity |
AU2002256086A1 (en) | 2001-04-09 | 2002-10-21 | Medtronic, Inc. | Methods of isolating blood components using a centrifuge and uses thereof |
CA2448415C (en) | 2001-06-06 | 2013-04-09 | Perfusion Partners & Associates, Inc. | Centrifuge tube assembly |
US6623959B2 (en) | 2001-06-13 | 2003-09-23 | Ethicon, Inc. | Devices and methods for cell harvesting |
US6764531B2 (en) | 2001-07-06 | 2004-07-20 | J. S. Hogan | Method and apparatus for cleaning a gas |
AU2002316696B2 (en) | 2001-07-16 | 2007-08-30 | Depuy Products, Inc. | Cartilage repair and regeneration scaffold and method |
EP1416943B1 (en) | 2001-08-09 | 2012-05-02 | Giuseppe Intini | Tissue implants and methods for making and using same |
US7371409B2 (en) * | 2001-09-06 | 2008-05-13 | Wright Medical Technology, Inc. | Bone graft substitute composition |
US20030054331A1 (en) | 2001-09-14 | 2003-03-20 | Stemsource, Inc. | Preservation of non embryonic cells from non hematopoietic tissues |
US6638503B2 (en) | 2001-11-28 | 2003-10-28 | Maharashtra Association For The Cultivation Of Science | Streptomyces megasporus sd5, process for the isolation thereof, novel fibrinolytic enzyme prepared therefrom, process for the production of said enzyme and method of treatment of thrombolytic disorders using said enzyme |
US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
US7514075B2 (en) | 2001-12-07 | 2009-04-07 | Cytori Therapeutics, Inc. | Systems and methods for separating and concentrating adipose derived stem cells from tissue |
JP4653952B2 (en) | 2001-12-07 | 2011-03-16 | サイトリ セラピューティクス インコーポレイテッド | System and method for treating a patient with treated lipoaspirate cells |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
CN1620306A (en) | 2001-12-20 | 2005-05-25 | 马克罗珀尔公司 | Systems and methods for treating patients with collagen-rich material extracted from adipose tissue |
US8313742B2 (en) | 2002-03-29 | 2012-11-20 | Depuy Acromed, Inc. | Cell-containing bone graft material |
US7608258B2 (en) | 2002-04-13 | 2009-10-27 | Allan Mishra | Method for treatment of tendinosis using platelet rich plasma |
US6811777B2 (en) * | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
US7374678B2 (en) * | 2002-05-24 | 2008-05-20 | Biomet Biologics, Inc. | Apparatus and method for separating and concentrating fluids containing multiple components |
US6905612B2 (en) * | 2003-03-21 | 2005-06-14 | Hanuman Llc | Plasma concentrate apparatus and method |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US7179391B2 (en) * | 2002-05-24 | 2007-02-20 | Biomet Manufacturing Corp. | Apparatus and method for separating and concentrating fluids containing multiple components |
US7992725B2 (en) * | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US20040182795A1 (en) | 2003-03-21 | 2004-09-23 | Randel Dorian | Apparatus and method for concentration of plasma from whole blood |
US7309468B2 (en) | 2002-05-13 | 2007-12-18 | Becton, Dickinson And Company | Protease inhibitor sample collection system |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US7304128B2 (en) | 2002-06-04 | 2007-12-04 | E.I. Du Pont De Nemours And Company | Carbon nanotube binding peptides |
US7176034B2 (en) | 2002-07-03 | 2007-02-13 | St. Joseph's Healthcare | Apparatus and method for filtering biological samples |
AU2003251945A1 (en) | 2002-07-18 | 2004-02-09 | Hanuman Llc | Plasma concentrating apparatus and method |
US7077827B2 (en) | 2002-08-30 | 2006-07-18 | Christian John Greenfield | Syringe for sequential delivery of different fluids |
JP4233525B2 (en) | 2002-09-19 | 2009-03-04 | ハーベスト・テクノロジーズ・コーポレイション | Disposable aseptic processing unit |
US20040120942A1 (en) | 2002-12-23 | 2004-06-24 | Mcginnis Daniel | Device and process for the preparation of autologous thrombin serum |
US20040182394A1 (en) | 2003-03-21 | 2004-09-23 | Alvey Jeffrey Arthur | Powered air purifying respirator system and self contained breathing apparatus |
JP4344528B2 (en) | 2003-04-07 | 2009-10-14 | テルモ株式会社 | Medical container and method for manufacturing medical container |
US7445125B2 (en) | 2003-05-19 | 2008-11-04 | Harvest Technologies Corporation | Method and apparatus for separating fluid components |
WO2004113316A1 (en) | 2003-05-20 | 2004-12-29 | Genentech, Inc. | Benzofuran inhibitors of factor viia |
JP2005013783A (en) | 2003-06-23 | 2005-01-20 | Moriai Seiki Kk | Liquid centrifugal separator |
EP1648478A1 (en) * | 2003-07-09 | 2006-04-26 | SDGI Holdings, Inc. | Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation |
US20050084962A1 (en) * | 2003-08-20 | 2005-04-21 | Bruce Simon | Methods of treatment using electromagnetic field stimulated stem cells |
US7744869B2 (en) * | 2003-08-20 | 2010-06-29 | Ebi, Llc | Methods of treatment using electromagnetic field stimulated mesenchymal stem cells |
EP1670315B1 (en) | 2003-09-17 | 2017-04-19 | Cytori Therapeutics, Inc. | Methods of using adipose derived regenerative cells in the treatment of peripheral vascular disease |
CA2542332C (en) | 2003-10-16 | 2013-03-12 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
US20050145187A1 (en) | 2003-12-29 | 2005-07-07 | Gray James D. | Asset management of livestock in an open range using satellite communications |
US7354515B2 (en) | 2004-02-23 | 2008-04-08 | Millennium Medical Technologies, Inc. | Fluid concentrator |
US20060051865A1 (en) * | 2004-08-31 | 2006-03-09 | Higgins Joel C | Systems and methods for isolating stromal cells from adipose tissue and uses thereof |
SE0402500D0 (en) | 2004-10-14 | 2004-10-14 | Astra Tech Ab | Method and apparatus for autotransfusion |
ITRM20040638A1 (en) | 2004-12-24 | 2005-03-24 | Advance Holdings Ltd | SEMISINTETIC PIASTRINIC GEL AND METHOD FOR ITS PREPARATION. |
WO2006086199A1 (en) | 2005-02-07 | 2006-08-17 | Hanuman Llc | Platelet rich plasma concentrate apparatus and method |
JP4510898B2 (en) | 2005-02-07 | 2010-07-28 | ハヌマン リミテッド ライアビリティ カンパニー | Plasma concentrator |
US7708152B2 (en) | 2005-02-07 | 2010-05-04 | Hanuman Llc | Method and apparatus for preparing platelet rich plasma and concentrates thereof |
US7866485B2 (en) * | 2005-02-07 | 2011-01-11 | Hanuman, Llc | Apparatus and method for preparing platelet rich plasma and concentrates thereof |
US7766900B2 (en) | 2005-02-21 | 2010-08-03 | Biomet Manufacturing Corp. | Method and apparatus for application of a fluid |
US7694828B2 (en) | 2005-04-27 | 2010-04-13 | Biomet Manufacturing Corp. | Method and apparatus for producing autologous clotting components |
US7531355B2 (en) | 2005-07-29 | 2009-05-12 | The Regents Of The University Of California | Methods and compositions for smooth muscle reconstruction |
US8048297B2 (en) | 2005-08-23 | 2011-11-01 | Biomet Biologics, Llc | Method and apparatus for collecting biological materials |
US7771590B2 (en) * | 2005-08-23 | 2010-08-10 | Biomet Manufacturing Corp. | Method and apparatus for collecting biological materials |
FR2890976B1 (en) | 2005-09-20 | 2007-12-14 | Univ La Reunion | KIT FOR PREPARING A COMPOSITION COMPRISING ADIPOCYTE CELLS AND METHOD FOR OBTAINING THE SAME |
DE102006005016A1 (en) | 2006-02-03 | 2007-08-16 | Orthogen Ag | Conditioned blood composition and process for its preparation |
WO2007127834A2 (en) | 2006-04-26 | 2007-11-08 | Medtronic, Inc. | Compositions and methods of preparation thereof |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
TWI311388B (en) | 2006-06-02 | 2009-06-21 | Hon Hai Prec Ind Co Ltd | Printed antenna |
WO2008022651A1 (en) | 2006-08-21 | 2008-02-28 | Antoine Turzi | Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells |
NZ600130A (en) | 2006-09-05 | 2013-11-29 | Maasland Nv | A milking implement |
US20080064626A1 (en) | 2006-09-08 | 2008-03-13 | Zanella John M | Methods of treating tendonitis in a subject by using an anti-cytokine agent |
US7708512B2 (en) | 2006-10-18 | 2010-05-04 | Newfrey Llc | Compression limiter |
JP2008104789A (en) | 2006-10-27 | 2008-05-08 | Nipro Corp | Method and device for separation of platelet rich plasma |
WO2008069975A2 (en) | 2006-12-01 | 2008-06-12 | New York University | Methods of using f-spondin as a biomarker for cartilage degenerative conditions |
US20080164204A1 (en) | 2007-01-08 | 2008-07-10 | Mehdi Hatamian | Valve for facilitating and maintaining separation of fluids and materials |
US20080193424A1 (en) | 2007-02-09 | 2008-08-14 | Biomet Biologics, Inc. | Treatment of tissue defects with a therapeutic composition |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
EP2146794B1 (en) | 2007-04-12 | 2016-10-19 | Biomet Biologics, LLC | Buoy suspension fractionation system |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
US20080258064A1 (en) | 2007-04-23 | 2008-10-23 | Stephen Anthony Cima | Radiation rate meter displaying remaining time parameters |
US20080268064A1 (en) | 2007-04-25 | 2008-10-30 | Biomet Biologics, Inc. | Method for treating cartilage defects |
US20080269762A1 (en) | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
US7901344B2 (en) | 2007-05-11 | 2011-03-08 | Biomet Biologics, Llc | Methods of reducing surgical complications in cancer patients |
FR2917872A1 (en) | 2007-06-25 | 2008-12-26 | France Telecom | METHODS AND DEVICES FOR ENCODING AND DECODING AN IMAGE SEQUENCE REPRESENTED USING MOTION TUBES, COMPUTER PROGRAM PRODUCTS AND CORRESPONDING SIGNAL. |
WO2009021257A1 (en) | 2007-08-13 | 2009-02-19 | Greiner Bio-One Gmbh | Medical separator |
US8672869B2 (en) | 2007-10-30 | 2014-03-18 | Bellco S.R.L. | Kit, system and method of treating myeloma patients |
US20090131827A1 (en) | 2007-11-21 | 2009-05-21 | Stemcor Systems, Inc. | Apparatus and methods for tissue disruption |
CN101952006A (en) | 2007-12-07 | 2011-01-19 | 丰收技术股份有限公司 | Floating disk for separating blood components |
MX2010006823A (en) | 2007-12-20 | 2010-09-30 | Xoma Technology Ltd | Methods for the treatment of gout. |
JP5132303B2 (en) | 2007-12-26 | 2013-01-30 | Meiji Seikaファルマ株式会社 | Stabilized agrochemical solid pharmaceutical composition |
US20090192528A1 (en) * | 2008-01-29 | 2009-07-30 | Biomet Biologics, Inc. | Method and device for hernia repair |
US8753690B2 (en) * | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
EP2620139B1 (en) | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
EP2254991B1 (en) | 2008-02-29 | 2018-08-22 | Biomet Manufacturing, LLC | A system and process for separating a material |
CA2718184A1 (en) | 2008-03-13 | 2009-10-08 | Biotest Ag | Agent for treating disease |
EP2262838B1 (en) | 2008-03-13 | 2016-04-13 | Biotest AG | Agent for treating disease |
CN102027018A (en) | 2008-03-13 | 2011-04-20 | 生物测试股份公司 | Agent for treating disease |
US8518272B2 (en) | 2008-04-04 | 2013-08-27 | Biomet Biologics, Llc | Sterile blood separating system |
US8182769B2 (en) | 2008-04-04 | 2012-05-22 | Biomet Biologics, Llc | Clean transportation system |
US8012077B2 (en) | 2008-05-23 | 2011-09-06 | Biomet Biologics, Llc | Blood separating device |
US9144584B2 (en) | 2008-06-11 | 2015-09-29 | Cell4Vet Corporation | Adipose tissue-derived stem cells for veterinary use |
US7796259B2 (en) | 2008-07-09 | 2010-09-14 | Weifour, Inc. | Rapid acquisition ellipsometry |
US8460227B2 (en) | 2008-11-17 | 2013-06-11 | Arthrex, Inc. | Cytokine concentration system |
US8177072B2 (en) | 2008-12-04 | 2012-05-15 | Thermogenesis Corp. | Apparatus and method for separating and isolating components of a biological fluid |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
EP2416789B1 (en) | 2009-04-07 | 2017-06-21 | Velin-Pharma A/S | Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US20120027746A1 (en) | 2010-07-30 | 2012-02-02 | Biomet Biologics, Llc | Method for generating thrombin |
AU2011296356B2 (en) | 2010-09-03 | 2015-07-09 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
-
2006
- 2006-05-26 US US11/442,631 patent/US20060278588A1/en not_active Abandoned
-
2012
- 2012-10-30 US US13/663,637 patent/US20130226149A1/en not_active Abandoned
-
2014
- 2014-10-09 US US14/510,828 patent/US9897589B2/en active Active
-
2018
- 2018-01-10 US US15/866,658 patent/US10393728B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030118563A1 (en) * | 1999-09-23 | 2003-06-26 | Loeb Marvin P. | Materials and methods for repair of tissue |
US20060029578A1 (en) * | 2000-06-29 | 2006-02-09 | Ecole Polytechnique | Composition and method for the repair and regeneration of cartilage and other tissues |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9897589B2 (en) | 2002-05-24 | 2018-02-20 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US10183042B2 (en) | 2002-05-24 | 2019-01-22 | Biomet Manufacturing, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US10393728B2 (en) | 2002-05-24 | 2019-08-27 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
Also Published As
Publication number | Publication date |
---|---|
US20150023939A1 (en) | 2015-01-22 |
US20180196030A1 (en) | 2018-07-12 |
US10393728B2 (en) | 2019-08-27 |
US9897589B2 (en) | 2018-02-20 |
US20060278588A1 (en) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10393728B2 (en) | Apparatus and method for separating and concentrating fluids containing multiple components | |
US9114334B2 (en) | Apparatus and method for separating and concentrating fluids containing multiple components | |
US7954646B2 (en) | Apparatus and method for separating and concentrating fluids containing multiple components | |
US7374678B2 (en) | Apparatus and method for separating and concentrating fluids containing multiple components | |
US9239276B2 (en) | Apparatus and method for separating and concentrating fluids containing multiple components | |
US10183042B2 (en) | Apparatus and method for separating and concentrating fluids containing multiple components | |
CN112237755B (en) | Preparation method and preparation device of platelet-rich plasma and prepared platelet-rich plasma | |
EP4115918A1 (en) | Syringe system for processing a fluid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOMET BIOLOGICS, LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WOODELL-MAY, JENNIFER E.;REEL/FRAME:031611/0617 Effective date: 20131113 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |